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Telomeres are repetitive sequences of DNA at the ends of chromosomes that become 
progressively shorter during cell division, acting as a form of “biological clock” causing cell 
death once they have reached a certain length. Almost 90% of cancer cells overexpress the 
enzyme telomerase which can lengthen telomeres and confer immortality to the tumour cells. 
Thus, telomerase has become an important target for drug discovery in the oncology area, 
and there is also interest from researchers investigating the aging process. 
During the catalytic cycle of telomerase, a unique DNA/RNA hybrid duplex (DRH) forms that 
is typically between 6-11 base pairs long and is key to extending the telomere. There is interest 
in discovering small drug-like molecules that can recognize and bind to this hybrid duplex to 
inhibit selectively telomerase, either by stabilizing the structure and thereby preventing 
telomerase dissociation (a key step in the catalytic cycle) or by sufficiently distorting the hybrid 
duplex to cause the misalignment of key catalytic groups. 
This project began by using oligonucleotides representing DNA/RNA hybrid duplex (DRH), 
telomeric G-quadruplex and control duplex DNA sequences to screen against the National 
Cancer Institute compound libraries (i.e., Diversity Set II, Mechanistic Set and Natural Product 
Set) using a high throughput Fluorescent Resonance Energy Transfer (FRET)-based DNA 
thermal denaturation assay to determine binding affinity and specificity. Thirteen novel 
chemical scaffold families were identified in the assay, compounds which showed a >5 °C 
selective stabilization of the DNA/RNA hybrid duplex at a 1 μM ligand concentration. Chemical 
modifications were then made to these scaffolds to generate focused libraries of analogues to 
improve selectivity, potency and drug-likeness, and to provide Structure-Activity Relationship 
(SAR) information. 
A total of 49 novel molecules were synthesized and then screened against an expanded range 
of four different nucleic acid constructs including telomeric and DNA/RNA hybrid duplex 
sequences. A number of compounds showed selective DNA/RNA hybrid stabilization potential 
with some compounds also showing notable telomeric G-quadruplex stabilization without 





duplex DNA sequences. The compounds from library-1 provided DNA/RNA hybrid duplex 
stabilization in the 0.5-7.2 C range and telomeric G-quadruplex stabilization in the 0.2-6.5 C 
range at a 1 µM ligand concentration. Molecular modelling and molecular dynamics studies 
confirmed that the methylene spacer between the benzimidazole and phenylene moieties of 
molecules within library-1 is perfectly shaped to fit within the DRH sequence. In addition, it 
was confirmed that minor-groove binding and simultaneous intercalation between the 
nucleobases of a DNA/RNA hybrid duplex requires a linker of specific length (i.e., an eight 
methylene spacer as in compound 3.3). Selected compounds were then studied further using 
a variety of biological techniques to confirm selective telomerase inhibition and cell-based 
assays to utilize their potential as antitumour agents. 
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Chapter 1: Introduction 
1.1 Cancer and General Overview 
In general, cancer is a condition where cells can grow and reproduce uncontrollably in a 
specific part (i.e., cancer proliferation site) of the body. These cancerous cells can invade and 
destroy nearby healthy tissues and organs. Cancer cells usually begin in one part of the body 
and can be implanted into a distant site by metastasis. The metastasis stage only arises when 
malignant cells enter either the bloodstream or lymph system. 
Cancer propagation comprises continuous changing and modifications to the cell genome 
carried out by both internal and external factors. Tumourigenesis is the process that leads to 
cancer cell formation, and an understanding of this process leads to the discovery of mutated 
genes (i.e., oncogenes) and the loss of function of tumour suppressor genes. Tumourigenesis 
involves a multistep process where genetic changes happen at each step that ultimately lead 
to the progressive transformation of healthy cells into tumour cells. Studies confirm that such 
genetic modifications of tumour cells occur at different sites, ranging from point mutations (i.e., 
one DNA base-pair change) to chromosomal translocations.  
This uncontrolled cellular proliferation results in a preliminary heterogenic tumour, and the 
tumour cells ultimately undergo metaplasia, subsequent dysplasia and anaplasia that finally 
results in a malignant phenotype. Such malignancy allows for incursion into the blood 
circulation (metastasis), followed by invasion of a subsequent site for tumourigenesis. As soon 
as the tumour cells come to another resting site, they penetrate the new blood vessel walls to 
undergo further multiplication and ultimately form a clinically detectable tumour. This new 
tumour is known as a metastatic tumour.1 
In 2012, Schroeder and co-workers reported metastasis as a cause of a vast majority of cancer 
related death.2 They described the metastasis process as involving seven steps. At the 
beginning metastatic cells release from the primary tumour (a) and decrease the adhesion to 
adjoining cells, then clear a path for migration into the vasculature-rich stroma (b) and up on 
vasculature formation, cells can freely enter the bloodstream. Intravasation (c) is necessary 
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for continuous vasculature formation, where cells cause either endothelial cell retraction or 
endothelial cell death. In the bloodstream, cancer cell distribution happens due to blood flow 
and interactions between cancer cells and the secondary organs that they colonize (i.e., cells 
can get trapped in narrow capillary beds, such as capillaries in the lung and liver), and can 
also express receptors that bind to metastasis-supporting sites (d) or to platelets (e), which 
help the cancer cells to escape from immune response. After reaching the secondary site, 
cancer cells can exit the bloodstream (f) by inducing endothelial cell retraction or death. To 
proliferate in the secondary site, cancer cells co-opt the local environment by releasing pro-
inflammatory compounds and proteinases that induce their neighbours to release growth 
factors (g). 
 
Figure 1.1: Cancer cells dispersion mechanism (i.e., metastasis). 
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There are around 100 different types of cancer, which vary according to the origin of the cancer 
cells, their growth, the stages of disease propagation and the age of victims, and each of them 
has its own methods for diagnosis and treatment. A most noteworthy point is that not all 
tumours can undergo malignant transformation; some remain at the benign stage and do not 
grow at all.3  
There are four main types of cancer4: 
a. cancers of the organs (Carcinoma), 
b. cancers of the muscles, bone, cartilage, and connective tissue (Sarcoma), 
c. cancers of the lymphatic system (Lymphoma), and 
d. cancers of the blood-making system (Leukaemia) 
 
It is now widely believed that cancer is a result of the accumulation of mutations in the genes 
that directly control cell birth or cell death. The mechanisms through which these genetic 
transformations originate are still the subject of ongoing debate. It is generally said that an 
underlying genetic instability is the key starting point of the multiple mutations and subsequent 
cancer propagation.5, 6 
 
Cancer cells vary according to their patterns of growth and spread throughout the body. The 
American Joint Committee on Cancer defined the stages of cancer growth as follows: 
1. Stage I – Primary tumour only. 
2. Stage II – Primary tumour, but larger than in Stage I. 
3. Stage III – Primary tumour and metastasis to lymph nodes. 
4. Stage IV – Primary tumour and distant metastasis. 
According to the World Cancer Report 2014, cancers are the leading causes of morbidity and 
mortality worldwide, where tobacco is held to cause approximately 70% of global lung cancer 
related deaths and 20% of overall cancer deaths. The WHO also reported that lung, prostate, 
colorectal, stomach and liver cancers are predominant in men and breast, colorectal, lung, 
cervix and stomach cancers are predominant in women. High BMI, low fruit and vegetable 
consumption, lack of physical movement and use of tobacco and alcohol were all highlighted 
in the report as leading behavioural and dietary risk factors for one-third of cancer deaths.7 
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1.2 Hallmarks of Cancer 
According to Hanahan and co-workers, all types of cancer exhibit six common traits that direct 
the transformation of normal cells to cancer cells.8 These traits are well-known as hallmarks 
of cancer, with the six biological capabilities attained during the multistep progression of 
human tumours. The six traits include sustained proliferative signalling, escaping growth 
suppressors, resisting cell death, facilitated replicative immortality, induced angiogenesis and 
activated incursion and metastasis. Two more promising hallmarks were listed by Hanahan 
and colleagues in 20111; reprogramming of energy metabolism and escaping immune 
destruction. They also mentioned genome stability and mutation and tumour promoting 
inflammation as two enabling traits for cancer. 
 
Figure 1.2: Reproduced illustration of the six hallmarks of cancer and two emerging 
hallmarks of cancer, adapted from Hanahan and co-workers. 
1.2.1 Sustaining proliferative signalling 
Cancer cells acquire self-sufficiency in growth signals to reduce their dependence on external 
factors (e.g., biochemical stimulation from cell environment like hormones and other 
molecules). Cancer cells gain some capabilities in a multiple way such as by 
generating autocrine signalling (i.e., by permanently activating the signalling pathways that 
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respond to these signals), by destroying ‘off switches' to prevent excessive growth (i.e., 
negative feedback). Such deregulation in cell division occurs due to the alteration of the 
responsible protein.  
Defects in negative-feedback mechanisms increase proliferative signalling. Usually, this type 
of regulation involves Ras-oncoproteins and oncogenic mutations affecting Ras-genes, which 
compromise Ras GTPase activity. Related negative-feedback mechanisms also function at 
multiple nodes inside the proliferative signalling circuitry like PTEN phosphatase, where 
mutations in PTEN intensify the PI3-Kinase signal. In this way, such mutation can promote 
tumourigenesis, which has been evaluated in a variety of experimental models of cancer.9 
1.2.2 Evading growth suppressors 
Typically, cancer cells are resistant to growth-preventing signals from their neighbours. 
Tumour suppressor genes are responsible for controlling cell division, as they carry a signal 
from the cell to confirm the cell division necessity, and also have capability to halt cell division 
according to their need (e.g., in case of damage DNA). However, in cancer, due to the 
alteration of tumour suppressor proteins, they lose the successive capability to prevent cell 
division, even when the cell has severe abnormalities. Moreover, cancer cells usually lose the 
contact inhibition property (i.e., another way to prevent excess cell division in normal cells, 
where cells stop dividing as soon as they fill up the space within a certain area and touch each 
other), which leads to continuous grow and cell division independent of their neighbourhood. 
Some cancer cells also escape the quiescent state (G0) of the cell cycle, where cells become 
insensitive to extracellular antigrowth signals.  
Transforming growth factor beta (TGF-) is also well known for its anti-proliferative activity, 
but TGF- signalling pathways are redirected away from restraining cell proliferation in many 
late-stage tumours, causing activation of the cellular process known as epithelial-to-
mesenchymal transition that is associated with high-grade malignancy.10 
1.2.3 Evading programmed cell death or apoptosis  
Apoptosis is a mechanism by which cells are programmed to die in the event of cell damage, 
whereas cancer cells have the ability to bypass this mechanism. Moreover, apoptosis is a 
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requirement for organisms to grow and develop properly and to maintain body tissues. It is 
assumed that the cancer cells may acquire some abilities by altering the mechanisms that 
detect the damage or abnormalities within cells. Therefore, evasion of apoptosis is another 
trait for a tumour to expand. 
 
1.2.4 Limitless replicative potential 
Non-cancer cells die after a certain number of divisions, which is an intrinsic program, the 
Hayflick limit (i.e., that limits cells’ multiplication to about 60-70 doublings, at which point cells 
reach a stage of senescence). On the other hand, cancer cells can escape this limit and are 
capable of indefinite growth and division that lead to immortality. Studies confirmed that such 
immortal cells possess damaged chromosomes, primarily at their ends (i.e., telomeres). 
Typically, telomeric DNA shortens with every cell division, until it becomes short enough to 
activate senescence. Cancer cells can overcome this limit by restricting pRB and p53 tumour 
suppressor proteins. Recent studies also confirmed that many cancers (i.e., approximately 
90%) are involved with the upregulation of telomerase enzyme, which is responsible for 
maintaining telomeres length elongation by using the RNA template within the enzyme itself. 
 
1.2.5 Sustained angiogenesis 
Angiogenesis is the process of forming new blood vessels. Cancer cells are able to carry out 
this process, to ensure a continuous supply of oxygen and other nutrients as well as removal 
of waste products. Cancer cells acquire the capacity to produce new vasculature by activating 
the 'angiogenic switch' by controlling non-cancerous cells present in the tumour by reducing 
the production of factors that inhibit blood vessel production, and increasing the production of 
factors that promote blood vessel formation.  
 
1.2.6 Tissue invasion and metastasis 
Cancer cells can disrupt away from their site of origin and can invade surrounding tissue, 
which subsequently can spread to distant body parts. Such metastases processes lead to an 
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untreatable stage for cancer treatment strategies. Approximately 90% of cancer deaths are 
caused by metastasized tumour growth and consecutive diseases. 
In 2011, Hanahan and co-workers postulated further four traits as hallmarks of cancer, which 
were classified as ‘enabling’ and ‘emerging’ characteristics for cancer. The four new traits are 
as follows: 
a. Deregulation of cellular energetics: Most cancer cells utilize atypical metabolic 
pathways to generate excess energy for fast growing cancer cells. Cancer cells gain 
the ability to reprogram their energy production from the normal aerobic metabolism 
of glucose to glycolysis. Additionally, a variety of generated intermediates from 
glycolysis can assist in the biosynthesis of tumour-promoting macromolecules. 
b. Evading immune system: Cancer cells can become invisible to the body defence 
mechanism (i.e., immune system) to bypass destructive consequences. Hanahan 
suggested this as a new evolving characteristic for cancer.  
c. Genome instability and mutation: In general, cancer cells acquire abnormalities in 
chromosomal structure. Such genomic instabilities and mutations can occur due to an 
increase in the rate of mutation caused by sensitivity to mutagenic agents or reduced 
efficiency of genome maintenance systems which includes DNA repair enzymes. 
Somatic mutations can activate downstream pathways in the cancer cell cycle. High-
throughput DNA sequencing studies of cancer cell genomes have shown that 
constitutive initiation of signalling circuits is triggered by the activated growth factor 
receptors due to somatic mutations in human tumours. It is also reported that 
approximately 40% of human malignancies contain stimulated mutations that 
influence the B-Raf protein structure, which causes simultaneous signalling through 
the Raf-protein to mitogen activated protein kinase (MAPK).11 Moreover, mutations in 
the catalytic subunit of phosphoinositide 3-kinase (PI3-kinase) hyper-activate the PI3-
kinase signalling pathway and Akt/PKB signal, which were also observed in a group 
of tumours.9 For this reason, genomic instability and mutation are considered as 
enabling characteristics of cancer. 
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d. Tumour-promoting inflammation: Recent studies demonstrated that the 
inflammation process can promote tumourigenesis by providing growth factors and 
thus facilitate the angiogenesis process.  
 
1.3 Treatment Options for Cancer 
There are number of treatment options available for cancer, where the main approach of any 
treatment is to remove and/or kill cancerous cells to achieve non-recurrence of cancer cell 
development. However, it is challenging to ensure either the complete removal or cure of 
cancer cells as cancer cell proliferation is caused by various cell signalling pathways.  Thus, 
researchers are investing their knowledge to develop a single treatment approach to evade 
cancer. To date, the main treatments for cancer are surgery, radiotherapy and small-molecule 
chemotherapy. 
1.3.1 Chemotherapy 
From the beginning, chemotherapy was accepted as one strategy in combating cancer cells 
and tissues. The fundamental principle of this approach is to kill cancer cells by treating them 
with chemicals that can obstruct susceptible processes related to cell division. Medicines 
(chemotherapeutic agents) treat cancer cells and/or suppress cancer cell proliferation either 
by destroying important proteins involved in cell signalling pathways or by damaging the DNA 
itself.12, 13 The nitrogen mustards were the first chemical agents with low molecular weight, 
which were introduced clinically in the 1940s as chemotherapeutic agents with anti-leukemic 
properties. Promising developments have been observed in the discovery of new anticancer 
drugs during the last few decades when methotrexate and cisplatin came upfront as 
chemotherapeutic agents. However, while chemotherapy drugs are effective against cancer 
cells, they simultaneously affect rapidly proliferating normal cells such as those connected to 
the bone marrow, immune system, gastro-intestinal tract and hair follicles. As a result, 
chemotherapy consistently brings a number of unwanted side effects, for example biliousness, 
alopecia, pain and vomiting. For these shortcomings, researchers are trying to develop small 
molecules that can act as site-specific drugs and interrupt DNA replication, cell division and 
tumour growth in cancer cell-oriented locations. 
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Clinically used chemotherapeutic agents have a wide variety of mechanisms in order to 
interfere with a number of cancer development processes such as tumour cell growth, motility, 
survival, and angiogenesis. However, the DNA interfering small molecules possess the largest 
and most varied ways of anticancer functionalities. There are also other mechanisms involved 
in anticancer treatment strategy. 
1.3.1.1 DNA targeted agents 
Cancer causes different changes to the structure of DNA, causing alteration of normal DNA 
regulation. DNA has been targeted since the invention of chemotherapeutic agents and these 
drugs primarily work by binding to DNA and subsequently inhibiting gene transcription, 
translation and other cellular processes. 
 
Figure 1.3: (a) A timeline for the discovery and evolution of DNA-interactive agents. (b) 
Illustrates the types of modifications that can form on DNA (from left to right, crosslinks, 
intercalation, DNA-strand cleavage and code-reading molecules). The DNA helix is also 
associated with proteins (e.g. topoisomerase II) and secondary DNA structures (e.g. G-
quadruplex). (c) Detailed illustration of the different types of DNA modification. (Adapted 
from DNA and its associated processes as targets for cancer therapy by Laurence H. 
Hurley)14 
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A large proportion of chemotherapeutic anticancer drugs can interact with DNA either directly 
or can prevent the appropriate relaxation of DNA by inhibiting topoisomerases (enzymes that 
regulate the over-winding or under-winding of the DNA helix).  
In cancer treatment, Drug/DNA interactions can be accomplished in two major ways, 
intercalation and/or groove binding. Intercalation involves the placing or stacking of a planar 
molecule between DNA base pairs and causes a decrease in the helical twist that leads to 
broadening of the DNA and, consequently, alteration of the regular helical DNA structure.15 
There is an important free energy involved in making this intercalation cavity, which is 
approximately 4 kcalmol-1 and positive contributions of hydrophobic interactions, ionic 
bonding, hydrogen bonding and van der Waal’s interactions result in association constants of 
105-1011M1.16 Moreover, the intercalation process is usually associated with molecules 
containing fused bi- and/or tri-cyclic ring systems. According to Chaires and co-workers, 
binding does not cause big conformational changes in DNA and can be described according 
to typical lock-and-key models for ligand/macromolecular binding.16 
In contrast, groove binding agents are usually semi-circular shaped molecules that can fit and 
bind to the minor groove of DNA helices (Figure 1.15). Sometimes, such small molecules 
possess both modes of binding efficacy due to them having an intercalating unit along with 
groove-binding side arms in the same molecule. 
A large number of chemotherapeutic agents exert their effect by interacting with DNA. 
Typically, DNA targeted agents interfere with DNA processing (i.e., transcription, translation, 
replication), which lead to cell death through apoptosis. DNA interactive agents can be DNA 
alkylating agents (e.g., dicarbazine, temozolomide, chlorambucil), cross-linkers with two DNA-
alkylating moieties (i.e., interstrand cross-linkers like nitrogen mustard, cisplatin and 
intrastrand cross-linkers like pyrrolobenzodiazepine dimer SJG-136), intercalators (e.g., 
ethidium bromide, doxorubicin and other quadruplex intercalating agents), topoisomerase-I 
inhibitors (e.g., belotecan, topotecan), topoisomerase-II inhibitors (e.g., podophyllotoxin, 
ellipticine), and DNA cleaving agents (e.g., bleomycin). It is to be mentioned that all the DNA 
interactive agents, except intercalators, interfere with the DNA structure either through the 
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minor or major groove of the DNA helix, thus in broad DNA interactive agents are also 
classified as DNA minor groove and major groove binding agents. 
 
 Figure 1.4: Structures of some DNA interacting agents.  
 
Quarfloxin (also known as Itarnafloxin, 1.12) is now in Phase-II clinical trials for the treatment 
of carcinoid and/or neuroendocrine tumours, and is recognised as a G-quadruplex stabilizing 
agent. It acts through inhibiting RNA polymerase (Pol-I)-based transcription by displacing 
nucleolin, a phosphoprotein involved in the synthesis and maturation of the ribosome, from 
the nucleus.17 
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Figure 1.5: The structure of quarfloxin (1.12) and its mechanism of action.18 
1.3.1.2 Antimetabolites 
Antimetabolites are synthetic molecules that can block vital metabolic pathways which are 
required for cell growth. As tumour cells can proliferate at a faster rate than normal cell 
populations (exceptions are observed for bone marrow, hair follicle, GI tract), antimetabolites 
are believed to have antiproliferative properties. Methotrexate is one of the classical examples 
of this class of chemotherapeutic agent. Studies confirmed that the enzyme dihydrofolate 
reductase (DHFR) is responsible for the formation of tetrahydrofolic acid from dihydrofolic acid, 
which is vital for thymine synthesis. Methotrexate, a modified structure of dihydrofolic acid, 
competitively binds to the active site of DHFR and thus blocks the natural activity of dihydrofolic 
acid and subsequently leads to blockage of thymine synthesis.19 
 
Figure 1.6: Structural differences between dihydrofolic acid and methotrexate (circled in red) 
 
Other types of agents in this family include purine antimetabolites (e.g., 6-Mercaptopurine), 
pyrimidine antimetabolites (e.g., 5-fluorouracil20), thymidylate synthase inhibitor (e.g., 
raltitrexed), adenosine deaminase (e.g., pentostatin) and ribonucleotide reductase inhibitors 
(e.g., hydroxycarbamide).21 
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1.3.1.3 Antitubulin Agents 
Microtubules are filamentous intracellular assemblies which are involved in nucleic acid and 
cell division, organization of intracellular structure, and intracellular transport. Typically, 
microtubules are found as polymers of tubulin (i.e., -tubilin and -tubilin) that are integral 
components of the mitotic spindle. Because the functions of microtubules are so critical to the 
existence of eukaryotic cells, agents that disturb this equilibrium (i.e., assembly and 
disassembly) can block mitosis and lead to cell death.22 The Vinca alkaloids (e.g., vincristine 
and vinblastine extracted from Vinca rosea) and taxans (e.g., paclitaxel23) are the most 
common example of this class of chemotherapeutic agents. Vinflunine, a novel fluorinated 
vinca alkaloid, is in Phase II clinical trials which blocks mitosis at the metaphase/anaphase 
transition and leads to apoptosis.24 
 
 
Figure 1.7: Structure of vincristine and paclitaxel. 
1.3.1.4 Molecularly targeted agents 
Generally, in cancer, molecularly targeted therapy means to a mode of medication that block 
the growth and spread of cancer by interfering with specific molecules (i.e., enzyme, regulatory 
protein kinases, macromolecules within tumour cell) that are threatening for tumour 
development. Such a mechanism offers targeted cancer therapy to be equally or even more 
effective than chemotherapy and radiotherapy and less harmful to normal cells. This class of 
drugs are sometimes noted as signal transduction inhibitors or secondary messenger 
inhibitors. Research has shown that numerous cell signalling pathways are responsible for 
intra- and inter-cellular mechanisms like cellular growth, cell death (or apoptosis), and protein 
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synthesis, which are altered within cancer cells due to mutation. Thus inhibition of such 
signalling pathways can stop the formation of further mutated cells or tumourigenic cells, which 
can lead to an anticancer effect.25 Molecularly targeted agents can be as follows according to 
either their targeted signal pathway or inhibition mechanism: 
a. Protein kinase inhibitors: A protein kinase inhibitor is one type of enzyme 
inhibitor that blocks the action of one or more protein kinases, which responsible in 
the addition of a phosphate group to a protein and modulation of protein’s function. 
Such phosphorylation regulates many biological processes, and thus protein kinase 
inhibitors are used to treat diseases related to hyperactivity of protein kinases (e.g., in 
cancer). Few prominent examples are BCR-ABL inhibitor Imatinib, HER2/neu inhibitor 
Trastuzumab, EGFR inhibitor Erlotinib.26 
b. RAS pathway signal inhibitors: The RAS proteins regulate the signalling pathways, 
responsible for some features of normal cell growth and malignant transformation. 
They are abnormal in most human tumours due to mutations in the RAS genes 
themselves or due to changes in upstream or downstream signalling mechanisms. 
Rational therapies targeting the RAS pathways can inhibit tumour growth and 
existence. Several of new therapeutic agents are showing potential in the 
chemotherapeutic drug development area, for example, Tipifarnib, BMS-214662, 
ARRY-142886).27 
c. Cell cycle inhibitors: The cell cycle directs the transition from latency through cell 
growth to proliferation for each cell and the cyclin-dependent kinases (cdks) are the 
key regulators of the cell cycle machinery. In cancer therapy, the cdks can be the 
rational targets due to their expression in cancer cells is abnormal and their inhibition 
can tempt to cell death. Several drugs targeting the cell cycle have already in clinical 
trials. Some examples include flavopiridol, indisulam, AZD5438, SNS-032, bryostatin-
1 and SCH 727965.28 
d. Proteosome inhibitors: Proteasome inhibitors usually block the activity 
of proteasomes, which is responsible for breakdown of unwanted proteins. Though 
there are multiple mechanisms are involved, but inhibiting proteasome may lead to 
prevention of degradation of pro-apoptotic factors (e.g., p53 protein, which is a 
  37|Chapter 1 
 
requirement for programmed cell death). Proteasome inhibitors are being considered 
in the treatment of cancer, and three are approved for use in multiple myeloma, such 
as bortezomib (VelcadeTM)29, Carfilzomib (KyprolisTM) and Ixazomib (NinlaroTM). 
 
To avoid undesirable side effects, molecularly targeted agent development and research is 
ongoing to find less toxic drug candidates. 
1.3.1.5 Hormonal therapy 
Hormones are signalling molecules produced by glands (comprised of the endocrine 
signalling system) in multicellular organisms which are transported to target distant organs by 
the circulatory system. Binding of the hormone to the receptor can result in the activation of 
a signal transduction pathway, which can result in regular cell functioning that includes quick 
non-genomic effects or slower genomic responses. Thus, hormones acting through their 
receptors result in increased specific protein synthesis through the activation of 
gene transcription. Hormone therapy can play a vital in the treatment of hormone dependent 
tissue growth in breast, endometrium, and testes.30 Tamoxifen, a non-steroidal estrogen 
antagonist, is a licenced hormonal therapy used in the UK for breast cancer treatment.31 
Aromatase inhibitors (e.g., aminoglutethimide, formestane, exemestane, letrozole), 
gonadorelin analogues (e.g., busereline, triptoreline, cetrorelix), anti-androgen agents (e.g., 
cyproterone acetate, utamide, bicalutamide), and somatostatin analogues (e.g., octreotide, 
lantreotide) are named treatment options belonging to this class of therapy. Not only 
antagonistic treatment but also agonistic treatment candidates are available for hormone 
therapy as an anticancer strategy, where diethylstilbestrol, gestonorone caproate, 
medroxyprogesterone acetate, and norethoisterone are the named treatment options.32 
One of the greatest challenges in the development and discovery of chemotherapeutic drugs 
is the selectivity between tumour (cancer) cells and healthy tissues. Most of the clinically used 
chemotherapeutic agents are associated with a varied degree of side effects to the healthy 
tissues. To minimize the toxicity, researchers are making efforts to sequence the selective 
anticancer agents’ design and development, wherein targeted DNA sequences are of the most 
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effective type in clinical use that could help in significant increases in the survival of cancer 
patients. 
1.3.2 Antibody-drug conjugates (ADC) for cancer therapy 
Monoclonal antibodies are used as an integral tool in research due to their high specificity and 
affinity for target antigens. Such monoclonal antibodies can impart therapeutic benefit by 
binding and inhibiting the function of target antigens: for example, trastuzumab (Herceptin®) is 
used as a chemotherapeutic agent. However, antibodies against tumour-specific antigens 
often lack therapeutic activity. Such drawbacks can be overcome by conjugating either a 
cytotoxic drug or radionuclide with the antibody and thus expand its utility by improving its 
potency and effectiveness. Such antibodies can then be used as a means to target and deliver 
a toxic payload to the selected diseased tissue.  In the antibody-drug conjugates (ADC) 
system, monoclonal antibodies are conjugated to chemotherapeutic agents, where the 
antibodies used are specific to tumour cell-surface proteins. Thus this treatment is thought to 
be tumour specific. To design an effective ADC for cancer therapy, the pre-requisite 
requirements for selection of a proper target, are a monoclonal antibody against that target, 
potent cytotoxic molecules and conjugation of the monoclonal antibody to the cytotoxic agents. 
Considerable advances in all these features in the past few years have resulted in approval of 
ado-trastuzumab emtansine (Kadcyla®) and brentuximab vedotin (Adcetris®) for clinical use.33 
1.3.3 Radiotherapy 
High-energy particles or waves are used in radiotherapy, which is one of the most common 
treatments used to destroy cancer cells. Radiotherapy utilizes either X-rays or 
radiopharmaceuticals (i.e., radionuclides) as sources of -rays. Theoretically, as tumour cells 
are hypoxic and are less sensitive to damage by irradiation (which works through formation of 
DNA-damaging oxygen free radicals), oxygen is administered to sensitize the tumour cells 
prior to (and during) radiation therapy, A highly focused beam of X-rays is applied locally to 
avoid damaging healthy tissue. In the case of -rays, cobalt-60, gold-198, and iodine-131 are 
used as radionuclides.  
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Sometimes, a chemo-radiotherapy approach is undertaken as a treatment combination of 
chemotherapy agents and radiation. For example, the antibody cetuximab (ErbituxTM) is used 
in combination with radiotherapy for squamous cell cancer of the head and neck. 
1.3.4 Biotherapy or immunotherapy 
In treatment with immunotherapy, certain biological components (e.g., antibody, antibody-drug 
conjugates, interferons, interleukins, enzymes, vaccines) are used to stimulate one’s own 
immune system to attack cancer cells. Some types of immunotherapy are also sometimes 
denoted as biologic therapy or biotherapy. For example, specific tumour antigens are 
produced in breast cancer on their cell surfaces, and monoclonal antibodies specifically target 
these tumours (e.g., Herceptin™) are being used in such types of cancer.34 
1.3.5 Photodynamic therapy (PDT) 
Photodynamic therapy (PDT) is a cancer treatment option where a photosensitizing agent 
(e.g., Photofrin™) is used along with light to kill cancer cells. This photosensitizing agent only 
works upon activation in the presence of certain type of light (i.e., light of a specific and 
appropriate wavelength). In principle, upon decay of the photosensitizing agent to its ground 
state, the available oxygen is transformed into the singlet form (i.e., free radical), which is 
highly cytotoxic and damages the tumour cells. 
1.3.6 Surgery 
A surgical process is usually used to remove a tumour that is small in size and reasonably well 
located. In this process, a well-defined tumour is removed along with some adjacent tissues 
to confirm complete removal of the tumour. However, supplementary treatment by either 
chemotherapy or radiotherapy is provided to eliminate any remainder or metastasized cancer 
cells. Sometimes either radiotherapy or chemotherapy is applied prior to surgery to shrink the 
tumour to expedite its easy removal.  
1.4 DNA Structure 
Deoxyribonucleic acid (DNA) is a macromolecule that contains the genetic information used 
in the development, functioning and reproduction of all living organisms. DNA, together with 
proteins and carbohydrates, constitute the three major and vital macromolecules that are 
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essential for all forms of life. According to the Watson and Crick model, DNA molecules are 
polynucleotides, which are composed of simpler units (nucleotides). The two biopolymer 
strands are coiled around each other running in opposite directions. Each nucleotide is 
composed of nucleobases, either cytosine (C), guanine (G), adenine (A), or thymine (T), along 
with a deoxyribose sugar and a phosphate group. DNA is composed of four 
deoxyribonucleotides, that are classified as either purine (deoxyadenosine, dA and 
deoxyguanosine, dG) or pyrimidine (deoxythymidine, dT and deoxycytidine, dC) nucleotides, 
as well as the deoxyribose sugars and a phosphate backbone. The sugar carbons are denoted 
as C1, C2, C3, C4, C5, starting with the carbon at the glycosidic bond that attaches the 
base to the sugar, to make them distinguishable from the carbons of the nucleobases (Figure 
1.8). The deoxynucleotides of DNA lack an O2 oxygen, which distinguishes them from 
ribonucleotides (RNA). The nucleotides are connected to one another in a sequential manner 
by covalent bonding between the sugar of one nucleotide and the phosphate of the following 
nucleotide and form an alternating sugar-phosphate backbone. It has been well-established 
that adenine binds with thymine, and cytosine binds with guanine through hydrogen bonding 
between the two separate polynucleotide strands that make up a double-stranded DNA 
helix.35, 36 
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Figure 1.8: Components of DNA; the four common deoxyribonucleotides connected by 
phosphodiester bonds to form a single-strand (5→3). 
 
In general, the DNA sequence is assembled through a condensation reaction to form a 
phosphodiester link that bridges the O3 and O5 oxygens of sequential nucleotides (Figure 
1.8). It is common in the primary structure of a DNA strand that the link starts from the free 
O5 oxygen (5-end) and proceeds to the free O3 oxygen (3-end). In double stranded DNA, 
two corresponding strands are joined together in a sequence-specific style to form an 
antiparallel duplex sequence, where one strand is in the 5 to 3 direction and the counterpart 
3 to 5. 
DNA molecules are polymorphic and can adopt more than one form. About 60 years ago, x-
ray diffraction studies carried out by Franklin and Wilkins discovered the A-form diffraction 
pattern produced by the dried DNA fibre; the same fibre produced a different, B-pattern when 
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moist. The B-form DNA structure is the familiar double helical DNA structure in which the axis 
of the helix runs through the Watson-Crick base pairs.37 
Nucleic acid structures are also found to exist in triple-stranded and quadruple-stranded forms 
as well as left-handed forms. Quadruplex structures based on G-quartets are reported to form 
at the guanine-rich sequence of both the telomere and centromere regions whereas their 
complementary cytosine-rich strands are found to fold into an intercalated tetramer called the 
i-motif.38 
Additionally, other DNA sequences have also been reported that can adopt a variety of 
unusual conformations; for example, polypurine-polypyrimidine rich sequences can form a 
triple-stranded structure known as H-DNA that is found abundantly in the eukaryotic genome, 
although their role has not been confirmed to date.39 
1.4.1 Double Helical DNA 
James D. Watson and Francis Crick first published the double-helix model of DNA structure 
(Figure 1.9 a) in 1953.36 DNA, a long chain made from repeating units known as nucleotides, 
is 22–26 Å wide where each nucleotide is 3.3 Å long.40 In a double helix, the strands are anti-
parallel and the asymmetric ends of the strands are termed the 5′ end (with a terminal primary 
–OH group) and 3′ end (with a terminal secondary –OH group). The four nucleobases present 
in DNA, adenine (dA), cytosine (dC), guanine (dG) and thymine (dT), are joined to the sugar 
and phosphate and complete the nucleotide (Figure 1.9 b). The DNA double helix structure is 
stabilized through both hydrogen bonding between the nucleotides and base-stacking 
interactions between the aromatic nucleobases.41 
The most accepted parameters for DNA duplex strands are the helical repeat (i.e., the number 
of base pairs in one whole turn) and the helical rise (i.e., the distance between nucleotides, 
measured along the helical axis). The repeat outlines the angle involving each base pair with 
the helical axis, where the helical twist is 360° per repeat that allows the repeat and rise (i.e., 
the distance between one whole turn) of the DNA. Thus such parameters limit the DNA 
geometries. On the basis of varied geometric measures of the duplex DNA strand, three major 
types of duplex orientation are observed; A-DNA, B-DNA and Z-DNA. 
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Figure 1.9: (a) Complementary base pairs in the DNA double helix, and (b) double stranded 
DNA helical structure.39, 42 
1.4.1.1 A-DNA 
Duplex DNA can adopt an A-form helical structure, a right-handed double helix similar to the 
more common form of DNA, B-DNA. It has been confirmed that if the deoxyribose sugar adopts 
a C3-endo conformation with an approximate 6 Å phosphate-to-phosphate distance, this 
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results in a structure with a helical twist of around 31° that can accommodate a helical repeat 
of 11-12 base pairs, leading to a shorter, more compact helical structure known as A-DNA. 
Rosalind Franklin discovered the changes in conformation and also showed that under 
dehydrating conditions (i.e., during crystal formation), regular DNA transforms into A-form 
DNA. 
 
Figure 1.10: The three major types of DNA double helix, (a) A-DNA, (b) B-DNA and (c) Z-
DNA.39, 43-45 
1.4.1.2 B-DNA 
James D. Watson and Francis Crick described the B-form DNA, which is believed to be in the 
majority of cells’ nucleosome core.46 In general, B-DNA is approximately 23.7 Å wide and can 
extend the helix by 34 Å per 10 base pairs of sequence. In solution, the double helix makes 
one whole turn around its axis for every 10.4-10.5 base pairs. It occurs in living cells at high 
levels of hydration. 
1.4.1.3 Z-DNA 
In 1979, a different type of double helical structure was discovered during the investigation of 
the DNA hexamer crystal structure of d(CGCGCG). The two strands were found to be joined 
by Watson-Crick base pairing in an antiparallel arrangement however, the helix was left 
handed.44 Due to the unusual zigzag backbone of the structure, it was labelled as Z-DNA 
(Figure 1.10). The base pairs were flipped upside down because of the rotating cytidine 
moieties, introducing a criss-cross shape in the backbone leading to the conversion of B-DNA 
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to Z-DNA. Additionally, the guanine residues rotated to the syn-form from an anti-conformation 
(Figure 1.11); in contrast, the mononucleotide repeat observed in the B-DNA had a 
dinucleotide repeat as the nucleobases alternate in syn- and anti-conformations when moved 
along the Z-DNA sugar-phosphate chains. Alternate purine and pyrimidine moieties with d(CG) 
sequences readily form Z-DNA because the pyrimidine’s preferred anti-conformation47 
requires less energy to form Z-DNA. 
 
Figure 1.11: The helical axis of A-, B-, and Z-DNA. 
 
Table 1.1: Geometric comparison of A-DNA43, B-DNA45 and Z-DNA44 
Geometry attribute A-form B-form Z-form 
Helix sense right-handed right-handed left-handed 
Repeating unit 1 bp 1 bp 2 bp 
Rotation/bp 32.7° 34.3° 60°/2 
Mean bp/turn 11 10.5 12 
Inclination of bp to axis +19° −1.2° −9° 
Rise/bp along axis 2.6 Å (0.26 nm) 3.4 Å (0.34 nm) 3.7 Å (0.37 nm) 
Rise/turn of helix 28.6 Å (2.86 nm) 35.7 Å (3.57 nm) 45.6 Å (4.56 nm) 
Mean propeller twist +18° +16° 0° 
Glycosyl angle Anti Anti pyrimidine: anti, 
purine: syn 
Nucleotide phosphate 
to phosphate distance 
5.9 Å 7.0 Å dC: 5.7 Å, 
dG: 6.1 Å 
Sugar pucker C3'-endo C2'-endo dC: C2'-endo, 
dG: C3'-endo 
Diameter 23 Å (2.3 nm) 20 Å (2.0 nm) 18 Å (1.8 nm) 
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1.4.2 Triplex DNA 
Intermolecular triple helical DNA structures were first reported about 56 years ago48-51 and 
were found to form at polypurine (R)-polypyrimidine (Y) tracts (Figure 1.12). A triplex DNA 
usually forms when a third strand binds to the major groove and binds to the purine rich strand 
of the underlying duplex DNA sequence by creating Hoogsteen and/or reversed Hoogsteen 
hydrogen bonds. There are two main scenarios for the triplex formation; when DNA with 
adjacent segments of homopurine and homopyrimidine runs can melt and refold to form 
intermolecular triplexes and binding of an oligonucleotide specifically to a DNA duplex.52 
 
Figure 1.12: Diagram of DNA triplex structure. 
 
Two basic forms of triplexes, R-R-Y and Y-R-Y, are formed depending on the type of 
nucleobases in the third strand which can be either purine (R) rich or pyrimidine (Y) rich. 
Reaction conditions also assist in the formation of these triplexes, as for example acidic pH 
allows the generation of Y-R-Y triplexes while neutral pH and divalent metal cations are the 
requirement of R-R-Y triplex formation in normal physiological conditions.53 Triplex formation 
is mostly affected by the site of formation because of its structure, charge and rigid nature. 
Moreover, DNA sequence is another significant factor in triplex formation that needs to be 
either mirror repeats for intramolecular triplex, but for intermolecular triplexes the main 
requirement is that it should be a homopurine-homopyrimidine sequence.54 The triple helical 
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DNA can be targeted selectively to control gene expression in vivo which presents the 
prospect of developing therapeutic agents like anti-cancer and anti-viral drugs. Triplex forming 
oligonucleotides (TFOs) also can be used to control gene expression, which can bind in the 
major groove of duplex DNA with high specificity and affinity. Because of these features of 
TFOs, it has been proposed as homing devices for genetic manipulation in vivo.55 
 
1.4.3 Quadruplex DNA 
Gellert and co-workers suggested quadruplex DNA by studying the X-ray diffraction 
configurations of gels produced by guanosine monophosphate (GMP) where four guanine 
residues formed a cyclic structure by forming hydrogen bonds in the centre.37 This quadruple 
helical form of DNA is known as G-quadruplex (Figure 1.13), which forms from certain 
guanine-rich sequences. In 1958, four-stranded nucleic acid structures were first discovered 
during the study of the polyinosinic acid fiber. The X-ray diffraction pattern indicated the 
presence of parallel three- or four-fold polynucleotide strands,56 which later on was proved to 
be quadruple-stranded.48, 57 
The G-quadruplex structure is formed either by repetitive folding of the single polynucleotide 
molecule or by association of two or four guanine molecules. The structure consists of stacked 
G-quartets, which are square, co-planar arrangements of four guanine bases (Figure 1.13). 
G-quadruplex structures can be formed due to the addition of 1-, 2- or 4- guanine-rich DNA 
strands with different topologies (Figure 1.13 c), where the topology adopted by single-strands 
is possibly most significant for guanine-rich sequences at the 3′-ends of chromosomes(for 
example, telomeric G-quadruplex).58 
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Figure 1.13: (a) G-quartet with central stabilizing cation, (b) Potential topologies for G-
quadruplex structures, topologies constructed from four parallel strands (i), from two strands 
that are non-crossing (ii), cross-over (iii) and from a single strand (iv).18  
The tetrad structure is stabilized through Hoogsteen hydrogen bond formation between the 
four guanine bases. These structures are reported to be found in telomeric regions along with 
the promoters of certain genes like c-Myc, c-Kit and Bcl-2 with individual structures. For 
example, telomeric DNA structures form parallel or antiparallel/parallel mixed-type structures 
in the presence of K+ while antiparallel structures are formed in the presence of Na+. On the 
other hand, c-Myc promoters form four-looped parallel structures, while in c-Kit promoters four 
connecting loops are found in three stacked G-quadruplex.59 In 1989, Williamson and co-
workers first reported the importance of monovalent cations (K+, Na+) in the formation and 
stabilization of the G-quadruplex structures and suggested that cations placed themselves in 
the cavity generated by the guanines of each quadruplex.60 
A number of bioinformatic experiments have identified about 375,000 possible G-tetrad 
forming sequences in the human genome, though their existence has yet to be proved in 
vivo.61 However, many indirect confirmations indicate the presence of G-quadruplex structures 
at several places in the human genome and they are suggested to be involved in various 
cellular activities. These quadruplex structures are found to control the expression of some 
genes that are involved in the progression of carcinogenesis and in the maintenance of 
telomere organization.62 Their ability to stop telomeric elongation by inhibiting the telomerase 
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enzyme (which is found to be overexpressed in malignant cells) has prompted fantastic 
research interest.18 
1.4.4 i-Motif 
The i-motif is a tertiary DNA structure generated by intercalating two parallel duplex structures 
in a head-to-tail fashion where the strands are attached together through hemi-protonated C-
C+ pairs (Figure 1.14). This structure can be generated by the association of one, two or four 
strands containing four, two or one cytidine repeats, respectively. The centromeric and 
telomeric C-rich repeats can fold to form an intramolecular i-motif structure.63, 64 
 
Figure 1.14: (a) Hemi-protonated C-C+ pairs (note, hydrogen bonds are not of an 
appropriate length) (b) Intermolecular i-motif pattern. 
 
Slightly acidic pH favours and guides the interconversion of the C-rich ss-DNA into an i-motif 
and forms an antiparallel structure.63 Moreover, the pH-dependent structure is found to be 
significantly affected by the cytosine base numbers, environmental conditions and the length 
of the loops.65 It is well known that >40% of all genes contain C-rich sequences in or near the 
regulatory regions, including the oncogenes.66 
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1.5 DNA Major and Minor Grooves 
The DNA double helix is a reasonably rigid and viscid molecule of huge length and small 
diameter, which has spaces, or grooves (Figure 1.15), between the strands. Together with 
the base pairs, these empty spaces are possible binding pockets or sites for proteins or drugs. 
Such grooves are unequally sized and classified into two types, the major groove which is 22 
Å in width and the minor groove which is 12 Å wide. The major groove is deep and wide, 
whereas the minor groove is narrow and shallow.67 The major and minor grooves are reverse 
to each other, and each runs constantly along with the full length of the DNA molecule; usually 
such grooves form due to the antiparallel double strand arrangement. It has been established 
that these grooves play a vital role by providing space for a protein to bind for cell cycle 
processes like transcription and DNA replication. Hydrogen bonding, van der Waal’s 
interactions and electrostatic interactions play key roles in protein-DNA binding. Thus it is 
hypothesised and proven in many cases that small molecules can also bind to the major as 
well as minor grooves, resulting in a distorted DNA structure or interruption of protein-DNA 
binding, followed by a targeted beneficial effect (for example, anticancer agents, HIV 
treatment). 
 
Figure 1.15: (a) Major and minor groove formation at a dC-dG base pair and (b) major and 
minor groove formation at a dT-dA base pair. 
The widths of the major and minor grooves are defined by the distance of the phosphate-to-
phosphate backbone through two strands in a direction perpendicular to the helical axis of the 
strands. In general conformation, a wide major groove is observed in B-DNA, while a narrow 
major groove is present in A-DNA that leads to a wider minor groove in A-DNA.39, 68 
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1.6 Telomeric DNA 
The idea of telomeres originated in the late 1930s. Muller and McClintock autonomously 
observed that regular chromosome ends have special properties to protect them from end-to-
end fusion using cytogenetic tactics. After extensive study in the past few years, it has been 
confirmed that highly preserved telomere structures at the ends of linear chromosomes with 
tandem repeats of DNA sequences and associated proteins are the key components for 
conserving DNA structure. 
The telomere is responsible for some vital biological functions (Figure 1.16), for example, 
protecting chromosomes from recombination, end-to-end fusion and recognition as damaged 
DNA; providing resources for complete replication of chromosomes; contributing to 
chromosomal organization within the nucleus; participating in gene expression regulation; and 
also serves as a molecular clock by controlling the replicative ability of human cells and their 
entry into senescence. 
 
Figure 1.16: The consequences that arise from telomere function and dysfunction.69 
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Replication of chromosome ends presents a distinct problem for cells. Where DNA replication 
by polymerase proceeds in a 5 → 3 direction, Watson and Olovnikov individually postulated 
that DNA is gradually lost from the ends of chromosomes during each instance of cell division, 
as the conventional DNA polymerase cannot fully replicate the 3-end of the lagging strand. 
This is known as the end replication problem. The newly synthesized leading strand cannot 
generate overhangs; however, the lagging strand loses its extreme 3-end after RNA primers 
are removed. (Figure 1.17). 
 
Figure 1.17: Schematic representation of the end replication problem. 
Such telomere shortening is detected with progressive cell division in vitro and enlarged in 
vivo.70-72 In general, regular mammalian somatic cells multiply a limited number of times in 
vitro, where the maximum number of cell proliferation cycles is referred to as the Hayflick 
limit73, which acts as a molecular clock. At the Hayflick limit, one or more critically shortened 
telomeres initiate a permanent growth arrest known as replicative senescence or mortality 
stage 1 (M1).74, 75 If cells can escape M1 due to inactivation of critical cell cycle checkpoint 
genes (such as p53) then those cells continue to divide and suffer more telomere loss until 
reaching the second proliferative block, crisis, or mortality stage (M2)76-78, which is categorised 
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by massive cell death caused by critically short and dysfunctional telomeres. Rare survivor 
cells escaping from crisis are able to maintain telomere length, in most cases by activation of 
telomerase, and this leads to unlimited proliferative capacity, i.e., cellular immortalization. 
Telomerase, a reverse transcriptase enzyme, is a RNA-dependent DNA polymerase that 
synthesizes telomeric DNA repeats at 3-overhangs. In 1985, the enzyme was first discovered 
in a protozoa, Tetrahymena thermophila79, and interestingly telomerase activity was also found 
in over 90% of malignant cells and in vitro immortalized cells. However, it is inactive in most 
normal human somatic cells.80, 81 In 1988, Moyzis and co-workers reported that telomeres 
consist of a tandem series of guanosine-rich nucleic acid hexamers [(TTAGGG)n] and various 
associated binding proteins, forming a structure that preserves chromosomal stability.82 The 
termini of telomeres consist of 25-200 nucleotides of single-stranded DNA, usually a G-rich 
strand (referred to as the “G-overhang”). It is presumed that most of the remainder of the 
telomere forms duplex DNA by Watson-Crick base pairing, but the G-rich strand is capable of 
Hoogsteen base pairing and forms planar G-quartet structures that stack on each other to form 
G-quadruplexes.83 
 
Figure 1.18: Telomere structure: (A) Telomeric DNA consists of a repetitive DNA sequence 
of a duplex region and single-stranded DNA G-strand overhang. (B) The shelterin complex 
binds to both the duplex and single-stranded DNA regions through specific protein/DNA 
interactions. (C) Formation of t-loop involving strand invasion of the G-overhang to create a 
displacement-loop (D-loop). 
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The ends of telomeres form a lariat-like structure called a t-loop (Figure 1.18)84, which is 
assumed to be formed by strand invasion of the 3′ single strand overhang into the earlier 
double stranded telomeric DNA that is stabilized by an attached shelterin protein (telomeric 
protein complex).85 This protein complex maintains telomere length, promotes t-loop 
formation, recruit telomerase to telomeric ends and thereby protects the ends of chromosomes 
from DNA damage.86-88 
TRF1 and TRF2 are the duplex telomeric binding proteins which are specifically localized to 
the telomeric DNA sequence. TRF1 and TRF2 and their accompanying proteins are primarily 
responsible for stabilizing the complex and forming the t-loop. Such stabilization is essential 
to form the quadruplex structure due to the G-rich nature of the telomere overhang. This 
telomeric repeat binding factor, TRF1, is important for intratelomeric winding.84 Similarly, TRF2 
binds beside the telomere sequence and is important for stabilizing and forming the t-loop as 
TRF2 is mainly abundant at the base of the t-loop.84 Thus TRF1 and TRF2 work together as 
TRF1 forms a loop and TRF2 tightens up the strand and locks it. 
Additionally, duplex telomeric DNA binding proteins have some self-associated proteins.89 For 
example, Human Rap1 (hRap1) protein is combined into the t-loop and interacts with TRF2, 
however there is no reported specific role of hRap1 in humans.90 Shay also reported that 
tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase enzyme, releases from 
the t-complex and can inhibit TRF1. On the other hand, TIN2 stimulates TRF1 function and 
causes it to bind to the telomere.89 The DNA damage response complex, 
RAD50/MRE11/NBS1, also functions along with TRF2, where MRE11 usually functions in 
homologous recombination to repair the disruptions in the DNA double strand.91 It is believed 
that the single stranded tail enters the duplex telomere to stabilize the d-loop at the telomere 
and based on this function in vitro, NBS1 plays the role of unwinding the t-loop via a helicase 
during the S phase of the cell cycle.92 
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1.6.1 Functional Assembly of Human Telomerase 
Telomerase is a reverse transcriptase enzyme consisting of a RNA template complementary 
to the telomeric hexameric repeats (TTAGGG) at the chromosome end, which is responsible 
for lengthening and maintaining the length of the telomeres and subsequent extension of the 
number of cell divisions.93 The telomerase enzyme is composed of a RNA subunit (hTR), a 
protein subunit (hTERT) and other accompanying proteins. In 1992, Blackburn first reported 
that the reverse transcriptase enzyme catalyses the addition of DNA bases (TTAGGG) to the 
telomeric end (3) that corresponds to the RNA template sequence of hTR, and later in 2001 
Wright and co-workers also confirmed the similar functions of hTR.94, 95 Two other proteins, 
p23 and hsp90, are also necessary in vivo to assemble the telomerase components in the 
telomerase complex and this was confirmed in vitro by using recombinant hTR and hTERT 
that were sufficient to reconstruct the enzyme complex.96 
1.6.1.1 RNA Subunit, hTR 
It is already known that repetitive telomere sequences cover the ends of eukaryotic 
chromosomes and protect them from destruction and rearrangements. These telomeric 
repeats are synthesized by the telomerase RNA-protein complex, where the duplicating of the 
RNA component of human telomerase is termed hTR. The RNA part (hTR) of telomerase 
provides the template for the telomeric repeat synthesis. In humans, RNA polymerase-II 
transcribes hTR and hTR is processed at the telomeric 3-end to produce a mature transcript 
of 451 nucleotides.97 The template for reverse transcription lies close to the 5-end of the 
sequence (between nucleotides 46 and 53), and specifies telomeric DNA sequence synthesis. 
The hTR template region is comprised of 11 nucleotides (5'-CUAACCCUAAC) corresponding 
to the hTelo sequence (TTAGGG)n. In general, malignant cell lines and germline tissues 
express higher amounts of hTR compared with normal somatic cells and tissues. 
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1.6.1.2 Protein Subunit, hTERT 
hTERT, or Human Telomerase Reverse Transcriptase, is another vital part of the telomerase 
enzyme. In general, telomerase does not either express or activate during each instance of 
mitotic cell division that results in telomere shortening. However, telomerase can extend 
telomeres in critical condition, which is essential for cells to escape from senescence. hTERT 
is highly expressed in malignant tumours and cancer cell lines but not in normal tissues or 
telomerase-negative cell lines. 
It has been reported that several transcription factors and oncogenes (e.g., c-Myc, Sp1, HIF-
1, AP2) can activate hTERT, whereas many cancer suppressing genes (e.g., p53, WT1 and 
Menin) can initiate several factors with the ability to suppress hTERT activity.98, 99 
1.6.2 Telomeric DNA/RNA Hybrid Duplex 
According to Shaw and co-workers, the DNA/RNA hybrid duplex was first proposed six years 
after the double-helical structure of DNA was reported by Watson and Crick.100 In 1960, the 
first DNA/RNA hybrid duplex structure was synthesized by reacting oligodeoxythymidylic acid 
with polyriboadenylic acid.101 The first DNA/RNA hybrid duplex was formed through the 
annealing of an RNA strand with a complementary DNA strand in 1961.102  
Such hybrid duplexes composed of a DNA and a RNA strand are initiated in various important 
biological processes, for example, hybrids are formed as an intermediate during transcription, 
DNA replication, and reverse transcription process by retroviruses.103 
In 1967, x-ray diffraction studies and CD spectroscopy confirmed the difference of the hybrid 
conformation from than of B-form DNA.104 Though the crystal structure of a DNA/RNA hybrid 
duplex was solved in 1982, hybrid formation during the replication process was discovered in 
1975, making it an appealing drug target.100 
Telomeres, the ends of every chromosome, exist as a protein-attached DNA composite with 
long repeats of a unique six base sequence (5-TTAGGG). Upon activation of telomerase, 
hTERT can add the same six-nucleotide repeating sequence, 5-TTAGGG, to the 3 strand of 
the chromosome by using TERC (where the template region of TERC is 3-CAAUCCCAAUC-
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5).105 The synthesis of a telomeric repeat involves the 3-end of the DNA primer base pairing 
with the RNA template to form a DNA/RNA hybrid duplex positioned within the active site. DNA 
polymerization then proceeds via reverse transcription of the RNA template to synthesize one 
telomeric repeat (TTAGGG) on the 3-end of the DNA primer. The steps of telomerase activity 
and DNA/RNA hybrid duplex formation are as follows (see Figure 1.19)106: 
A. A schematic diagram of the human telomerase enzyme bound to the telomeric DNA 
substrate. Prior to repeat synthesis, the hTR alignment region (green) base pairs with the 
3-end of the telomeric primer DNA (blue) to form a 5-bp DNA/RNA hybrid duplex within 
the active site. The RNA template is controlled by flanking sequences bound to the TERT 
protein, while the 5-region of the hTelo DNA is bound to the TEN domain. The TERT 
protein catalyses polymerization of six deoxyribonucleotides to the 3-end of the DNA 
primer by reverse transcribing the hTR template sequence (orange) (step 1). 
B. After nucleotide addition, a new repeat (red) is produced, while the DNA/RNA hybrid 
duplex length remains constant at the initial 5-bp. Upon getting to the end of the template, 
the DNA/RNA duplex dissociates from the active site (step 2). 
C. Then the DNA/RNA hybrid duplex undergoes strand dissociation (step 3a), and the DNA 
reanneals to either the alignment or the template regions. If the DNA reanneals to the 
template region, the result is non-productive, requiring further strand separation and a new 
attempt at reannealing. If the DNA reanneals to the alignment region (step 3b), the RNA 
template is regenerated. Both strand separation and realignment are presumably 
reversible, as indicated by the double-headed arrows. 
D. The realigned DNA/RNA hybrid duplex is then recaptured by binding to the active site 
(step 4) for further nucleotide addition. Unsuccessful reannealing of the DNA primer to the 
RNA template results in complete dissociation of the product from the enzyme (step 5). 
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Figure 1.19: Schematic of a functioning model for telomerase activity.106 
Hence, binding of small ligands to the DNA/RNA hybrid duplex can theoretically offer a 
therapeutic method to control telomerase activity by preventing telomere extension and/or by 
altering the substrate/enzyme interaction, and/or stopping dissociation of the enzyme from the 
substrate.107 
DNA/RNA hybrid structures are also formed during different genomic functions rather than 
telomerase activation. DNA mediated mRNA synthesis is a set process for protein synthesis 
which initiates at promoter sites within the DNA template, where RNA polymerase generally 
binds to the initiation site, unwinds the helical turn of duplex DNA and starts sequential addition 
of ribonucleotides complementary to the DNA bases. Termination of this process 
accomplishes with the release of the RNA strand from an unstable DNA/RNA hybrid.108 During 
the reverse transcription process, the RNA mediated synthesis of DNA is an integral part of 
the retroviral life cycle, which was observed in 10% of the eukaryotic genome as a direct 
product of reverse transcription109. Reverse transcription is similar to the normal DNA 
transcription process, but the reverse transcriptase enzyme is engaged here to reverse 
transcribe the DNA from a RNA template.109, 110 DNA/RNA hybrid formation can be observed 
during reverse transcriptase mediated DNA synthesis and prior to reverse transcriptase 
mediated RNaseH cleavage of the template RNA strand. DNA/RNA hybrid duplexes play an 
important role in the DNA replication process, which begins with the unwinding of duplex DNA 
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by DNA helicase followed by priming of the DNA strands by proteins and enzymes111 and 
proceeds in leading strand and lagging strand synthesis. Lagging strand synthesis utilizes 
Okazaki fragments (e.g., in eukaryotic cells)112, where DNA/RNA hybrids of 100-200 
nucleotides are formed in the presence of a RNA primer, which is later degraded with the help 
of DNA polymerase and re-sealed using DNA ligase. DNA/RNA hybrid duplex formation is 
essential to initiate the transcription process within mitochondrial DNA and such hybrids serve 
as primers for DNA replication of the leading strand.111, 113 
1.6.2.1 Structure and stability of DNA/RNA hybrid 
An extensive study and literature review of DNA/RNA hybrid stability suggested that by varying 
the percentage of (A)n:(T or U)n content, oligomeric length and the percentage of deoxyribo-
pyrimidine (d(Py)) bases in each of the strands, the stability of such a hybrid could be 
estimated. Lesnik and Freier demonstrated that, typically, an inverse relationship is observed 
between the percentages of (A)n:(T or U)n content in the hybrid duplex and the thermal 
stability; hybrid duplexes of equal d(Py) and d(Pu) content are thermally similar when 
comparing the d(Pu):r(Py) and d(Py):r(Pu) forms; decreasing oligomeric length decreases the 
thermal stability; isolation of (A)n: (T or U)n content to continuous tracts results in a lower 
thermally stability; and continuous tract (A)n:(T or U)n content results in d(Py):r(Pu) thermal 
stability lower than that of the corresponding d(Pu):r(Py) form under physiological 
conditions.114 
DNA/RNA hybrid stability is also related to the ability of the hybrid duplex to associate with a 
third single strand and it has been observed that the d(Py):r(Pu) hybrid cannot accommodate 
a third strand of DNA, while  d(Pu):r(Py) hybrids can be associated with a third strand.115 
Moreover, the stability of hybrid duplexes is linked to the relative stability of the ribose chain 
because the unfavourable van der Waal’s forces experienced  between the sugar and 
pyrimidine bases can result the purine nucleotide being highly stable compared with the 
pyrimidine nucleotide. 
Different researchers resolved the DNA/RNA hybrid structures by using a variety of hybrid 
duplexes consisting of polypyrimidine and polypurine tracts of both DNA and RNA bases.  In 
a brief, studies of the crystal structures of chimeric DNA/RNA hybrids designated them as pure 
  60|Chapter 1 
 
A-form in conformations like RNA duplexes.116, 117 However, NMR analysis of the DNA/RNA 
hybrid structures in solution showed that the DNA strands of hybrid duplexes have helical 
conformations which are transitional between the A- and B-forms DNA.118-120 Researchers also 
tried to define the stability of various forms of DNA/RNA hybrid duplexes and it has been 
reported that the r(purine)-d(pyrimidine) hybrids are more stable than the hybrids formed with 
r(pyrimidine)-d(purine).121-124 The polymeric DNA/RNA hybrid structure was also studied to 
identify the conformational alterations upon changes in relative humidity. Milman and co-
workers showed that in extreme solvated conditions poly(rA):poly(dT) structure is similar to 
that of B-form DNA duplexes.125 However, further analysis by solid state NMR recommends 
that the same hybrid duplex (i.e., poly(rA):poly(dT)) is able to exist as an A-like conformation 
at relatively low humidity.126 Equilibrium Raman spectroscopy later explained the 
conformational differences occur due to alterations in furanose sugar conformation in RNA 
and DNA strands, where the over-all B-like conformation is dictated by the thymidine methyl 
in the d(Pyrimidine) strand.115  
The ribose sugar pucker is the major participant in determination of the helical parameters of 
nucleic acids. In general, the ribose sugar pucker of RNA is found in the C3-endo 
conformation, which facilitates the conformation of homoribonucleic strands to A-form 
conformation. On the other hand, the deoxyribose conformation is much more organised to a 
number of different conformations and usually consists of a C2-endo (or equivalent C3-exo) 
conformation, which is characteristic of the B-form. Another sugar pucker is observed as an 
intermediate between the C3-endo and C2-endo conformations, which is termed as C4-endo 
and arises at various points in the subsequent formation of DNA/RNA hybrids helical 
structures.127 
In 1999, Conn and co-workers resolved the crystal structure of the DNA/RNA hybrid composed 
of d(GCTTCTCTTC)/r(GAAGAGAAGC). They have calculated the average helical parameters 
of the double helix (using the program NEWHEL93, R.E.Dickerson, UCLA), which were 30.4° 
for helix rotation and 2.9 Å for helical rise. Thus 11.8 nucleotides were accommodated per 
complete helical turn and the pitch of the helix was 34.2 Å. These values confirm that the 
hybrid duplex belongs to the A-form DNA structure, which is also consistent with the A-form 
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RNA duplex structure. All deoxyribose moiety, except C20, does not adopt a sugar pucker 
adjacent to C3′-endo, which is believed to be inclined by crystal packing contacts, which is 
typical of the the A-form structures. Moreover, the geometry of the minor groove of the hybrid 
duplex also bore a resemblance to the characteristics of the crystalline A-form double helices, 
such as the average width being 9.8 Å, which is very close to the average width of typical 
crystal structures of hybrid duplexes found in the Nucleic Acid Database.128 
1.6.3 Telomeric G-quadruplex Structure 
In several studies, it was described that telomeric DNA is capable of forming a G-quadruplex 
structure in biological systems. Single-stranded telomeric terminal sequences from a number 
of organisms were found to form G-G paired hairpin type structures,129 which later on were 
defined in Tetrahymena as telomeric DNA.130 Stylonychia lemnae telomeric DNA was used to 
establish the biological existence of the quadruplexes.131 Recently it has been evidenced that 
telomere end-binding proteins, TEBPα and TEBPβ, control in vivo G-quadruplex formation 
because it was confirmed later that phosphorylation of TEBPβ during replication is essential 
to resolve the quadruplex structures.132 In vivo G-quartet formation was further proved by the 
binding and detection of the radiolabelled ligand 360A (2,6-N,N-methylquinolinio- 3-yl-pyridine 
dicarboxamide) and/or the fluorescent ligand BMVC (3,6-bis(1-methyl-4-vinylpyridinium) 
carbazole diiodide. Researchers not only proved the existence of hTelo quadruplex structures, 
but they are also found evidence of the existence of such quadruplexes in the non-coding 
regions of genes, particularly in gene promoter sites. In 2010, it was reported that such 
quadruplexes are present near the transcription start sites of promoter regions which strongly 
supports the link between nuclease-hypersensitive elements (NHE) and quadruplex-forming 
sequences.133 
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Figure 1.20: Probable places of the G-quadruplex structures within cells: in nucleus (a) 
during replication (b) transient single stranded form of DNA (c) telomeric single stranded G-
rich overhangs; outside nucleus (d) G-quadruplexes in mRNA. (G-quadruplex mediated 
blockade during replication, transcription and translation labelled by red cross).134 
 
In an earlier study with Oxytricha nova, it was observed that folding in telomeric DNA and 
formation of quadruplex structures can block the elongation of telomeres by the telomerase 
enzyme and the result of this study demonstrated that interconversion of the telomeric DNA 
into the G-quartet structure causes delayed elongation of the guanine strand by telomerase 
(Figure 1.20 a).135 Moreover, several research laboratories have reported stabilization of 
hTelo G-quadruplex structures through using various groups of drugs that can inhibit telomeric 
elongation by telomerase (Figure 1.20 b). Reported studies demonstrated that drugs that can 
bind and stabilize the G-quadruplex structures of telomeric sequences can also block in vitro 
action of telomerase as well as serving to inhibit telomere elongation in vivo and the 
proliferation of cancer cells (Figure 1.21).136-138 
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Figure 1.21: Telomere length regulation (a) Inhibition of the telomerase enzyme by G-
quadruplex formation at the 3 end, which was further stabilized by ligand interaction 
inhibiting further telomere elongation. (b) Diagram showing the effects of inhibition of 
telomere elongation; critically formed hTelo that ultimately leads to senescence/apoptosis.139 
 
In a recent study in 2014, Komiyama and co-workers showed that telomeric DNA is transcribed 
into telomeric repeat-containing RNA (UUAGGG repeats) in mammalian cells.140 It has also 
been reported that the two-repeats of human telomeric sequence, d(TAGGGT)2, can form a 
dimeric parallel-stranded G-quadruplex structure, whereas a three-repeat, d(TAGGGT)3, and 
a single-repeat, d(TAGGGT), of the human telomeric sequence form a (3+1) dimeric DNA G-
quadruplex structure.141,142 Marin and co-workers showed the formation of a RNA/PNA hybrid 
G-quadruplex structure with RNA and PNA.143 Moreover, it is suspected that telomere RNA 
can bind to telomere DNA by forming an intermolecular DNA/RNA hybrid G-quadruplex 
(Figure 1.22 c), because of difficulties in its identification by typical spectroscopic tools like 
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NMR and crystallography. This is because DNA G-quadruplexes, RNA G-quadruplexes and 
DNA/RNA hybrid quadruplexes can exist together as a mixture in solution. 
 
                 
(a)                                          (b)                                               (c) 
 
Figure 1.22: Illustration of three possible G-quadruplex structures that may exist together as 
a mixture in solution, where (a) tetramer RNA-quadruplex can form by 6-mer hTelo RNA 
sequence, (b) dimeric DNA-quadruplex can form by 16-mer hTelo DNA sequence and (c) 
DNA/RNA hybrid-quadruplex can form by 6-mer RNA and 16-mer hTelo DNA. 
 
NMR studies have already resolved the usual sequence of hTelo G-quadruplex structures 
(Figure 1.23) that are formed by 22-mer hTelo DNA (effective four TTAGGG repeats) in Na+ 
solution and exhibit an anti-parallel topology with one diagonal and two lateral loops.144 
However, the crystal structure of the same sequence in K+ solution showed a complementary 
all-parallel topology with three strand-reversal loops. The sequence d(TTAGGG)2T was also 
solved by NMR spectroscopy and X-ray crystallography in K+ solution, where both experiments 
revealed a bi-molecular parallel topology.141 
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Figure 1.23: Different forms of intramolecular quadruplex formation by the hTelo repeat 
sequence (d[AGGG(TTAGGG)3]), where loops are coloured red, and anti- and syn-guanines 
are coloured cyan and magenta, respectively and W, M and N denote wide, medium and 
narrow grooves, respectively.145 
Other variations in the telomeric sequence have shown different structures as determined by 
NMR. Some of these have resulted from the modification of the sequence in order to solve the 
structure. The wide variety of topologies (Figure 1.24, 1.25) published for sequences related 
to the hTelo DNA sequence indicate the dynamic and heterogeneous nature of the human 
telomeric G-quadruplex. 
More recently, many of the structures published have shown a (3+1) topology (Figure 1.26 c). 
The (3+1) quadruplex topology covers those distinctive patterns of (3+1) syn- and anti- 
glycosidic angles at each G-quartet. 
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Figure 1.24: Folding patterns of the hTelo sequence (22-mer); (A) propeller-type parallel-
stranded intramolecular G-quadruplex formed in K+ solution, (B) basket-type mixed 
parallel/antiparallel-stranded intramolecular G-quadruplex in Na+ solution. 
 
The (3+1)-formed quadruplex topology was first observed in an unequal structure containing 
a three-repeat sequence associated with a separate single-repeat sequence. For instance, 
the sequence d[TTGGG(TTAGGG)3A] exists as a 95% single species in K+ solution, which 
was confirmed by NMR studies of the (3+1) intramolecular arrangement with a single chain-
reversal loop followed by two lateral loops at each end of the quadruplex structure. This is also 
observed in the solution structure of d[A3G3(TTAGGG)3AA], indicating the significant 
stabilizing role of neighbouring sequences. 
         
Figure 1.25: The crystal structure of the bimolecular quadruplex formed by the Oxythricha 
nova telomeric sequence d(G4T4G4) (PDB entry 1JPQ); (a) overall topology is indicated by 
the orange ribbon with purple spheres of K+ ions, and (b) a projection down the central 
passage representing the relative widths of the four grooves.146 
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A similar result was also observed for the NMR structure of d(AG3(TTAGGG)3) in K+ solution. 
Most commonly, the structure is of three G-quartets connected with a double-chain-reversal 
side loop and two lateral loops, each consisting of 3 nucleotides, TTA.147 
 
Figure 1.26: Structures of the hTelo quadruplex for the d[AGGG(TTAGGG)3] sequence, (a) 
in Na+ solution with one diagonal and two lateral loops (PDB entry 143D)144, (b) in K+ solution 
that forms A-DNA with three strand-reversal loops (PDB entry 1KF1)141, (c) in K+ solution, 
that forms B-DNA with one strand-reversal and two lateral loops, as determined by NMR.147, 
148 
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A second form of (3+1) structure results from the two lateral loops followed by one side chain 
reversal loop. This form has mainly been seen in structures where the 3 end of the flanking 
sequence has been altered to include TT. One such structure is that of the NMR structure of 
the sequence d(TAGGG(TTAGGG)3TT) in K+ ion solution.148 In K+ ion solution these two forms 
have been found to exist in equilibrium (Figure 1.27).133 
 
 
(a)                                                                 (b) 
Figure 1.27: (a) Distinct structures of hybrid-1 and hybrid-2, established by NMR studies of 
telomeric G-quadruplexes (here, guanine, adenine and thymine are in yellow, red and blue 
blocks, respectively). (b) DNA secondary structure model formed due to compact-stacking of 
hybrid-type G-quadruplexes in an equilibrium of hybrid-1 and hybrid-2 in K+ solution. 
 
1.6.3.1 G-quadruplex structures in promoter regions 
Quadruplex-forming DNA sequences are not only found in the human telomeric region. They 
are also observed in various genomic loci and are thought to have a potential role in oncogene 
regulation.149, 150 In 2005, two surveys of the human genome by Huppert and co-workers151 
estimated that it contains approximately 375,000 quadruplex-forming sequences, with most 
located in the promoter regions of genes where they have the potential to regulate gene 
expression 152-154. Some major examples of DNA sequences identified as forming quadruplex 
structures in the human genome are listed in the following table:  
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1.7 Telomerase and Cancer 
In 1997, Shay and co-workers reviewed all possible types of human cancers and established 
a very strong correlation between telomerase activity and malignancy. This has led the 
enzyme to become one of the most important tumour markers.81 
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Figure 1.28: Summary of telomerase activity in humans, where tumour samples were 
evaluated in a TRAP assay (telomerase positive samples are compared to matched control 
tissue and denoted in %).81 
 
1.7.1 Mechanisms of Telomerase Up-Regulation in Cancer 
Figure 1.29 describes the detailed mechanisms involved in the up-regulation of telomerase in 
cancer. Many studies have focussed on the role of transcriptional control of hTERT expression 
or on phosphorylation-induced increases in hTERT activity.155-159 Positively acting transcription 
factors and co-regulators include the Myc-oncogene, the E6 protein of oncogenic human 
papillomaviruses, NF-B and - catenin. Upregulated expression may also occur through loss 
of pRb, WT1, Menin and TGF pathway tumour suppressor function. Protein kinase C and 
PKB can phosphorylate hTERT. Mutations within the core promoter region of hTERT are 
common, and these may increase hTERT transcriptional activity by creating new consensus 
binding motifs for ETS transcription factors. hTERT promoter mutations are most common in 
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malignancies like bladder carcinoma, liposarcomas (e.g., fat cells of deep soft tissue), 
hepatocellular carcinoma, squamous cell carcinoma (e.g., tongue), medulloblastomas (i.e., 
malignant primary brain tumour) and glioblastoma (aggressive malignant primary brain 
tumour).160-164 Another mechanism of up-regulation is translocation of the hTERT gene to an 
immunoglobulin gene or other loci in B-cell neoplasms, which presumably contributes to the 
increased hTERT transcription and telomerase activity observed in these tumours.165 The 
human telomerase catalytic subunit (hTERT) and the RNA template molecule (hTR) are both 
present in very low amount in normal cells, and it is likely that the expression of both must be 
increased in order to express sufficient telomerase to prevent telomere shortening in cancer 
cells.166 PAX8, a protein encoded by the PAX8 gene, is able to co-ordinately upregulate both 
hTERT and hTR expression, and the PAX8 expression level correlates with telomerase activity 
in gliomas.167 The copy number of the hTERT and hTR genes is commonly increased in human 
cancers.168 
 
Figure 1.29: Telomerase up-regulation in cancer cells can occur by a variety of 
mechanisms. 
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1.7.2 Telomere Lengthening by ALT 
Some immortalized cell lines maintain telomere length for hundreds of population doublings in 
the absence of telomerase activity, and it was therefore deduced that they must have an 
alternative lengthening of telomeres (ALT) mechanism.169 In contrast to telomerase activity, 
where an RNA template is used for the synthesis of new telomeric DNA170, the ALT mechanism 
involves the elongation of the telomeric DNA sequence from a DNA template via a homologous 
recombination protein (Figure 1.30).171 Somatic cell hybridization analysis has demonstrated 
that normal telomerase-negative human cells, as well as telomerase-positive immortalized 
cells, contain repressors of ALT activity.169, 172, 173 
 
Figure 1.30: Multiple deregulation steps associated progression of the ALT mechanism.174 
 
1.8 Telomerase and the Aging Process 
Telomeres are considered an important part of the cell fate and aging process as the regulation 
of cellular responses to stress and growth stimulation, on the basis of earlier cell divisions and 
DNA damage, are controlled from the telomeric end of a DNA strand. As a minimum, a few 
hundred nucleotides in the telomere repeats protect each chromosome end to evade the 
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activation of DNA restoration pathways. In most somatic cells, repair of critically short or 
‘uncapped’ telomeres by telomerase or recombination is limited, which causes apoptosis or 
cellular senescence due to accumulation of numerous ‘uncapped’ telomeres and the increased 
chance of reduced telomere length. Moreover, telomere length is varied in somatic cells and 
gradually declines with age, which places a block on tumour growth and causes the loss of 
cells with age. 
Aging can be described as the inevitable decay of tissue functionalities that eventually results 
in death. Such functional degeneration can be a consequence of the loss or weakened function 
of post-mitotic cells or from failure in substituting similar types of cells due to the functional 
inability of stem cells to keep up the cellular replication and cell division processes. Variation 
in DNA repair pathways between germ-line cells and stem cells and differences in somatic 
cells’ size and life expectancy among animals present difficulties in understanding an overview 
of the molecular mechanism of aging for different species. 
It has been reported that p53 plays a comprehensive role in typical growth and tumour 
formation, life expectancy and overall fitness.175 In practice, DNA damage signals originate 
from short telomeres and contribute to the activation of p53 and subsequent cellular responses 
to stress. In addition, TRF2 binds to the ataxia telangiectasia mutated (ATM) kinase and can 
inhibit ATM-functionalities, though the DNA damage signals seem to initiate from telomeres 
during each replication cycle. Thus it is suggested that telomeres can shift between closed 
and open states (Figure 1.31) where the possibility of the open state is proportional to the 
overall telomere length of the repeat strand. As telomere length gets shorter with age, the 
number of DNA damage signals originating from short telomeres also increases, subsequently 
increasing the level of activated p53 and causing either the onset of senescence or apoptosis 
activation. It has already been confirmed that telomeres are directly responsible for sustained 
DNA damage signals in senescent cells.176 
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Figure 1.31: Scheme of factors affecting the telomere length in human tissues that also 
contribute to the aging process.177 
1.9 Opportunities for Telomerase Targeted Therapies 
Complex processes, like accumulation of mutations or alterations in gene expression, lead 
normal cells to become tumorigenic, where telomerase activation is observed during one of 
these critical stages.178 In addition, during malignancy, when cancer cells lose the essential 
aspects of proliferative control, cells utilize stabilized genetic material afforded by active 
telomere synthesis to bypass the growth regulatory signals imposed on ordinary tissues. There 
are many aspects of telomere maintenance in cancers that present potential opportunities for 
developing targeted therapies. The most obvious of these are the catalytic events involved in 
synthesis of new telomeric DNA by telomerase or ALT. 
 
The telomerase-catalysed telomere lengthening reaction proceeds via multiple steps, which 
include binding to its substrate, reverse transcription of telomeric DNA, and translocation of 
the enzyme on its extended substrate to continue the lengthening reaction. All of these steps 
could potentially be inhibited (Figure 1.32), and inhibitors of the reverse transcription step 
could target either the template or the catalytic subunit. Telomerase-mediated lengthening 
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could potentially be inhibited by targeting other steps in the overall process, starting with 
expression of the subunits and their assembly into the active enzyme complex. 
 
Figure 1.32: The action of telomerase may be inhibited at multiple points in its "life cycle".83 
 
Telomeres are particular DNA-protein complexes at terminals of chromosomes that represent 
a potential target for anticancer agents.179 Anticancer approaches directed at telomerase 
inhibition can be varied and possible methods include stabilizing telomeric G-quadruplex 
structures, RNA interference (RNA) of the hTERT catalytic subunit and stabilizing DNA/RNA 
hybrid duplex structures towards the large protein surface of the telomerase enzyme. The 
steps in the ALT process involve homologous recombination (HR) proteins and DNA 
synthesis, which are processes vital for the repair and replication of DNA in normal cells. 
Although there may be a therapeutic window where cancer cells, especially those which have 
lost p53 function, are more vulnerable to inhibition of these functions than normal cells, the 
likelihood of toxic side-effects of such inhibition is high. 
Peptides generated by degradation of hTERT are presented on the cell surface, and cytotoxic 
T-lymphocytes (CTL) can recognise these peptides and kill the cell. This makes telomerase a 
potential target for the development of immunotherapies.180, 181 
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1.9.1 Telomeric DNA/RNA Hybrid Duplex as a Target in Cancer 
It is possible to design drugs to bind to specific DNA structures, and the G-rich nature of the 
telomeric sequence has led to extensive efforts to develop drugs that target the telomeric G-
quadruplex DNA. The DNA/RNA hybrid duplex was discovered in 1960. Inhibiting telomerase 
by binding to the hybrid duplex is a new approach for cancer treatment. This duplex structure 
usually forms during the catalytic cycle of telomerase activity. It forms during the original 
annealing of the substrate telomere to the template RNA and during its extension.107, 182 
Recently, it has been established that telomere uncapping results in rapid cell death. 
Uncapping of chromosomal DNA can take place due to ‘damage’ signals at the G-strand 
overhang and/or the corresponding lagging strand that can lead to rapid apoptosis or genomic 
instability. Thus, ligands that ‘uncap’ and/or directly target telomeres are likely to be more 
efficient as a monotherapy and can act more rapidly compared with enzyme inhibitors alone. 
The telomeric DNA/RNA hybrid (DRH) duplex is a novel therapeutic target for potential 
anticancer agents that would work through the inhibition of telomerase. Such hybrid duplex 
structures usually form only during the telomerase catalytic cycle (though such hybrids can be 
formed during the transcription process, which are unstable and dissociate during the 
translation process), thus making them highly selective targets for rational drug discovery.107, 
182 In addition, DRH duplexes are less common structures compared with DNA/DNA duplexes 
in cells183, and contain the specific sequence of TTAGGG. Furthermore, as the DRH duplex is 
bound tightly by the protein unit of telomerase, ligands that bind to this duplex should block 
access to the unique protein surfaces of telomerase. Synthesis of the telomeric repeat involves 
the 3-end of the DNA primer base pairing with the corresponding RNA template to form a 
DRH duplex positioned within the active site. DNA polymerization then continues through RNA 
template reverse transcription to add the telomeric repeat (TTAGGG) onto the 3-end of the 
DNA primer. Thus the template is regenerated through a multi-step process that involves 
separation of the DRH, and realignment of the RNA template relating to the DNA primer, 
followed by re-formation of the DRH. 
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Moreover, diversity in hybrid structures (due to the presence of different nucleobases, purine 
and/or pyrimidine in the DNA strand) offer different backbone conformations and groove 
geometries, usually the A-form, in the DRH duplex that are distinctive features against which 




Figure 1.33: Possible ligand binding mechanisms to inhibit telomerase activity by stabilizing 
the DNA/RNA hybrid duplex, as proposed by West and co-workers.182 
 
As the telomeric DNA/RNA hybrid duplex is a new anticancer drug target, there are only a 
limited number of reported molecules that can selectively stabilize the DRH duplex and stop 
telomere elongation in cancer cells. However, other molecules have previously been reported 
that target other DNA/RNA hybrid duplexes formed within the cells. In 1999, Ren and co-
workers reported 15 different DNA binding agents and explored them by using a 
thermodynamically rigorous competition dialysis procedure, where single-stranded, a variety 
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of double-stranded, multi-stranded triplex and tetraplex forms of DNA, left-handed Z-DNA, 
RNA, and a DNA/RNA hybrid duplex (other than the telomeric DNA/RNA hybrid duplex) were 
used.185 The authors analysed daunorubicin, ethidium bromide, coralyne chloride, 
chromomycin, distamycin, actinomycin D, berberine, berenil, BePI, 1-pyrenemethylamine 
hydrochloride, 5,10,15,20-tetrakis[4-(trimethylammonio)- phenyl]-21H,23H-porphine, DAPI, 
H2TMPyP [meso-tetrakis(N-methyl-4-pyridyl)porphine, NMM (N-methyl mesoporphyrin IX), 
and netropsin in their study. Among fifteen molecules, ethidium bromide (1.17), coralyne 
chloride (1.18) and DAPI (4,6-diamidino-2-phenylindole) (1.19) showed binding affinity for 
poly(rA):poly(dT) hybrid duplexes, which was further confirmed by reviewing equilibrium 
binding assays in previous literature. However, daunorubicin, an anticancer agent, did not 
show any affinity for the hybrid duplex. 
 
Figure 1.34: Some reported molecules that showed binding affinity towards a DNA/RNA 
hybrid duplex (poly(rA):poly(dT)) sequence.185 
 
Structure-selective and sequence-selective ligands for DNA/RNA hybrids have a diverse array 
of possible pharmaceutical applications. For example, the first-formed product of HIV reverse 
transcriptase was a DNA/RNA hybrid duplex.186 Telomerase is a specialized reverse 
transcriptase enzyme, which has protein structure domains closely-related to the HIV reverse 
transcriptase enzyme.187 Besides, since the DNA/RNA hybrid duplex’s thermodynamic stability 
regulates telomerase activity, this can be a small-molecule targeting strategy.107, 188, 189 Barnieri 
and co-workers also observed that the binding of paromomycin (1.20) to the DNA/RNA hybrid 
duplex inhibits both RNase H- and RNase A-mediated cleavage of the RNA strand.190 
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Figure 1.35: Structure of Paromomycin. 
In 2007, Rangarajan and co-workers made some phenanthridine derivatives, which included 
a 5-hexanoic acid derivative, a 5-benzylic acid derivative, N-glutaryl derivatives and the 
carboxamides of all of these.188  
 
According to their report, only one compound (i.e., 3,8-diamino-5-(4-carbamoylbenzyl)-6-
phenyl-1,2-dihydrophenanthridin-5-ium, TeloIC50 = 2.9M) gave similar telomerase inhibition of 
standard ethidium bromide (TeloIC50 = 2.7M); however, the other derivatives showed much 
higher inhibitory concentrations, ranging from 5.6 M to >80 M. 
In 2008, Shaw and co-workers reported a neomycin-ethidium chloride conjugate that binds to 
the DNA/RNA hybrid duplex (poly(dA):poly(rU)) and shows a greater binding constant (Ka = 
4.8±1x106) towards the hybrid sequence than its parent molecules, ethidium bromide and 
neomycin (Figure 1.36).191 
 
Figure 1.36: Structures of neomycin (1.21) and neomycin-methidium conjugate (1.22). 
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In 2010, Wheelhouse and co-workers made a significant advance in DNA/RNA hybrid duplex 
research by investigating a molecule that can preferentially bind to telomeric quadruplex and 
triplex DNA structures, as well as to the hybrid duplex poly(dA)·poly(rU).192 Competition 
dialysis showed a 20-fold preference for duplex DNA associated with the poly(dA)-poly(rU) 
hybrid duplex compared with equivalent RNA, a 3-fold preference over duplex DNA, and 7-
fold preference over the alternative poly(rA)-poly(dT) hybrid sequence. 
 
Figure 1.37: Structure of a novel diaryl substituent and pyrimidine analogue with a selective 
affinity for DNA/RNA hybrid duplexes.192 
Upon reviewing all available literature, there are no reported molecules that target the 
telomeric DNA/RNA hybrid duplex that forms during the catalytic stage of telomerase 
expression. 
1.9.2 Telomeric G-quadruplex as a target  
G-quadruplexes (G-tetrads or G4-DNA) are formed from nucleic acid sequences that are rich 
in guanine and so have the ability to form four-stranded structures. Four guanine bases can 
join together through Hoogsteen hydrogen bonding to form a square planar structure, which 
is known as a guanine tetrad, and two or more guanine tetrads can stack on top of each other 
to form a G-quadruplex structure. The G-quadruplex is stabilized by the presence of a cation, 
especially potassium (K+), which sits in the middle channel between each pair of tetrads.193 
Base stacking interactions, hydrogen bonds, electrostatic interactions and the hydration shell 
are the key factors for stabilizing the quadruplex structure.146 Guanine bases are the key 
requirement for the formation of the base stacking within the G-quadruplex structure. However, 
due to the arrangement of the central guanine O6 carbonyl groups of the G-quartet, which 
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form a square planar structure for each tetrad giving a twist of 30° and rise of 2.73 Å between 
each tetrad step to generate a bi-pyramidal antiprismatic arrangement for the eight O6 atoms 
(Figure 1.38), quadruplex structures become unstable in the presence of stabilizing factors. 
This arrangement of O6 carbonyl atoms forms negatively charged cavities between the G-
tetrads which cations can neutralise. The overall stability of the folded quadruplex largely 
depends on the selection of a suitable cation and its size and charge. 
 
Figure 1.38: (a) Metal ion is shown coordinated between eight carbonyl O6 atoms with an 
average cation-oxygen distance of 2.73 Å; (b) structural illustration of O6-NH bonding for 
each quartet (note, hydrogen bonds are not of an appropriate length). 
In 1991, Zahler and co-workers demonstrated that potassium ions (K+) stabilize G-quadruplex 
structures and are ultimately capable of inhibiting telomerase activity.135 Since then, G-
quadruplex structures were targeted to inhibit telomerase activity. Some research groups 
working in this field are searching for small organic molecules that can bind to stabilize G-
quadruplexes and ultimately block telomerase enzyme activity. 
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Figure 1.39: Roles of telomeric DNA and telomerase; G-quadruplex formation can inhibit 
telomerase activity.194 
In 2011, Alcaro and co-workers reported that the main six diverse conformations of the 
unimolecular hTelo sequence in the presence of Na+ and K+ ions represent unique targets 
against which to design small molecules with improved specificity. The six conformations can 
be found in the Protein Data Bank (PDB)195 under the codes 143D (antiparallel, in Na+)144, 
1KF1 (parallel, in K+)196, 2HY9 (hybrid-1, in K+)197, 2JPZ (hybrid-2, in K+)198, 2JSL (hybrid-1, in 
K+)145, and 2JSM (hybrid-2, in K+)145. 
A number of molecules have been studied to date, which can stabilize the G-quadruplex 
structure either by end stacking or groove binding. Mostly the G-quadruplex stabilization 
happens by stacking and electrostatic interaction. Thus G-quadruplex binding ligands are 
normally planar aromatic molecules that are prone to stack with G-tetrads, while some of them 
are positively charged or have hydrophilic groups to favour electrostatic interaction. It has also 
been proposed that bis- and tris-intercalating drugs show promising activity and selectivity.199, 
200 
In 1997, Sun and co-workers first reported a 2,6-diamidoanthraquinone analogue as a human 
telomerase inhibitor.201 In their study, they demonstrated the G-quadruplex inhibition 
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mechanism for this anthraquinone-type molecule by 1H NMR. The group developed a series 
of 2,6-diamidoanthraquinones as DNA-interactive agents with reduced affinity for duplex DNA. 
A standard primer extension assay (i.e., TRAP assay) was employed to study the relative 
inhibitory activity of 1.24 towards human telomerase, with an IC50 value of 23 µM and complete 
inhibition of telomerase activity at 100 µM.  
 
Figure 1.40: 2,6-Diamidoanthraquinone analogue. 
Following Sun’s work, several series of compounds have been developed and explored by 
different research groups as a G-quadruplex ligand and most of them were developed to 
reduce toxicity, and improve selectivity and efficacy. After observing the G-quadruplex 
targeting potential of anthraquinone type molecules, a number of compounds with similar 
structural features (e.g., di-substituted tricyclic central core) like acridines and fluorenones 
were developed, where acridines showed more potent telomerase inhibitoion with lower 
toxicity. In 1999, Perry and co-workers first described fluorenone-type compounds in 
comparison with the anthraquinone-type compounds.202 This fluorenone series of molecules 
was reported as a wide range of telomerase inhibitors with potential activity (8-12 µM) against 
telomeric G-quadruplex sequences. The authors reported 1.25, with 1-(2-
hydroxymethyl)piperidinyl terminal side arms, as the most potent telomerase inhibitor with an 
IC50 value of 8 M. BRACO19 (1.26), a 3,6-bis(aminoalkyl) substituted acridine, is a rationally 
designed tri-substituted acridine derivative that appears to directly target telomeres. It is a 
member of a series of potent inhibitors that were designed by computer modelling to exploit 
the unique structural features of the DNA quadruplex structure. Specifically, this molecule was 
designed to interact with the three minor grooves of the G-quadruplex in addition to stacking 
on the terminal G-quartet. BRACO19 is a potent G-quadruplex stabilizing agent with a high 
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Tm of 27.5 C at 1 M concentration. Additionally, it has moderate inhibitory activity in the 
TRAP assay (i.e., IC50 = 0.09 M).203-205 In addition, BRACO19 has potent inhibitory activity 
against a number of tumour cell lines 206 and has been shown to inhibit the catalytic function 
of telomerase in human cancer cells and destabilize the telomere capping complex 207. 
However, lack of permeability and a small therapeutic window limited the use of BRACO19 as 
a chemotherapeutic agent.  
 
Figure 1.41: Example of fluorenone and acridine molecules. 
Riou and co-workers identified a series of triazine derivatives in 2002 with potent anti-
telomerase activity at the nanomolar level, where compounds 1.27 and 1.28 gave Tm values 
of 20 °C and 8 °C in a FRET melting assay and IC50 values of 0.041 M and 0.13 M in the 
TRAP assay, respectively.208 Molecular modelling studies were used in 2010 by Sparapani 
and co-workers to design a series of di-substituted triazole-linked acridine compounds.209 
Among the library of novel compounds, 1.29a and 1.29b had good selectively toward the hTelo 
quadruplex sequence compared with duplex DNA; at a 1 M concentration they stabilized the 
hTelo G-quadruplex by 15.8 and 15.5 C, respectively, relative to 0.4-0.6 C stabilization for 
ds-DNA. Non-specific quadruplex binding ability limits the exploration of this type of molecules. 
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Figure 1.42: Example of triazine type molecules. 
Telomestatin (1.30) is a macrocyclic compound first isolated from Streptomyces anulatus210 
and later synthesized in the laboratory as R-telomestatin211. It is one of the most effective 
small-molecule inhibitors of telomerase. With a flat and planar structure and a resemblance to 
the structure of the G-quartet, telomestatin was recognized as a G-quadruplex binding agent, 
whichwas successively confirmed by molecular modelling studies. Telomestatin showed 
preferential interaction with intramolecular compared with intermolecular G-quadruplex 
structures with a 70-fold selectivity for intramolecular quadruplex structures over the duplex 
DNA. Telomestatin demonstrated favourable anticancer activity against different human 
cancer cell lines, where treatment with telomestatin for 3-5 weeks gave repressed telomerase 
activity with reduced telomere length and apoptosis.212 Telomestatin has been studied 
extensively to define the mode of action and it was observed that telomestatin leads to the 
telomere dysfunction and impair chromosomal integrity. In 2003, Tauchi and co-workers 
reported that telomestatin can activate ATM and Chk2 in the BCR-ABL positive leukemia cell 
line and later can raise the expression of p21 and p27, which was thought to be a possible 
way to induce an ATM-dependent DNA damage response.213 In 2006, inhibition of DNA 
binding of POT1 and TRF2 and the loss of G-tails were also reported as possible quadruplex 
stabilization activity by telomestatin.214, 215  
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Figure 1.43: Example of cyclic porphyrines and five-ring acridine.  
TMPyP4 (1.31) is a molecule which was considered by using structure-based drug-design. 
The molecule was selected as a G-quadruplex binding agent based on its physical 
characteristics like the presence of a fused planar ring structure, a positive charge at four 
termini, and suitable size to stack with the G-tetrads. TMPyP4 showed substantial selectivity 
for the G-quadruplex structure over the duplex DNA, and could efficiently inhibit human 
telomerase in HeLa cell extracts. Both in vivo and in vitro results showed that TMPyP4 can 
decrease the rate of proliferation of sea urchin embryos and block the cells at the mitosis 
stage. Moreover, it causes the formation of anaphase bridges and demonstrated an 
antiproliferative effect due to chromosome destabilization.216 In 2002, it was reported that 
TMPyP4 interacts with the c-Myc quadruplex structure of the promoter region and thus can 
downregulate c-Myc expression. It has also been postulated that TMPyP4 contributes to the 
lowering of hTERT expression. 217 However, a major drawback of TMPyP4 to be a G-
quadruplex target agent is its selectivity as TMPyP4 has the ability to bind to duplex DNA, 
DNA/RNA hybrids and triplex DNA.218 The five-ring acridine, RHPS4 (1.32) was originally 
designed to inhibit telomerase due to structural resemblances to previously identified G-
quadruplex structure binding telomerase inhibitors (e.g., BRACO19).219 Long-term exposure 
(i.e., 15 days) of non-acute cytotoxic concentrations of RHPS4 with 21NT breast cancer and 
A431 human vulval cancer cells demonstrated a decrease in cell growth and a noticeable 
decline in cellular telomerase activity. Moreover, RHPS4 was also reported as a quadruplex 
interactive agent as it can stack at the end of G-tetrad.220  
In 2003, Nakatani and co-workers described the binding of a series of naphthyridine dimers 
(e.g., 1.33) to the hTelo sequence221, where in a preliminary FRET assay using a ligand 
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concentration of 30 M in Na-cacodylate buffer, compound 1.33 gave Tm values of 45.6 °C 
and 63.6 °C for the secondary structures of the 9-mer d(TTAGGGTTA) and 15-mer 
d(TTAGGGTTAGGGTTA), respectively. Cyclic naphthalene diimide (1.34) has also been 
reported as a telomeric quadruplex agent, binding with an IC50 value of 0.9 μM in the TRAP 
assay.222  
 
Figure 1.44: Examples of naphthyridine dimer and cyclic naphthalene structures. 
In different studies, cryptolepine-based (i.e., fused indolo-quinoline structure) compounds 
(1.35)223, phenanthroline-based molecules (1.36)224, berberine analogues (1.37) and its dimer 
(1.38)225, 226 , isaindigotone derivatives (1.39)227 were also reported as telomeric quadruplex 
interacting agents.  Several attempts were also made by different research groups to identify 
naturally occuring small molecule (e.g., thymoquinone228,  Cristatin A229) . In 2014, 
Dhamodharan and co-workers reported 1,8-naphthyridine and 1,10-phenanthrolinein based 
bis-benzimidazole carboxamide analogues (1.39 and 1.40) as quadruplex-stabilizing 
agents.230 Moreover, bis-benzimidazole-type compounds are well known for their biological 
properties.231-233 1,3-Phenylene-bis(piperazinyl benzimidazole) skeleton based compounds 
(e.g., 1.41)234, oligo-oxyethylene (polyglycol) spacer connected bis-benzimidazole 
molecules235, benzimidazole-carbazole conjugated compounds236 were also reported to be 
telomeric G-quadruplex stabilizing agent.  
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Figure 1.45: Examples of reported non-cyclic aromatic structures with planar shape and a 
positively charged moiety. 
Urea-based alkylaminoanilino analogues (i.e., non-polycyclic aromatic ligands) were also 
described by Drewe and co-workers in 2008.237 The result of a FRET melting assay showed 
that they gave 1.0-14.1 C and 0.0-5.5 C stabilization toward F21T and duplex DNA 
sequence, respectively, at a 1 M concentration (whereas BRACO19 provided 25.9 C 
stabilization for F21T and 11.2 C for a control duplex DNA sequence). Such findings inspired 
researchers to look for amide linked small molecules which can meet the pharmacokinetic 
requirements to become a drug candidate.   
The G-quadruplex structure is a DNA secondary structure which has been established as a 
potential regulatory element in biologically significant regions, for example in human telomeres 
and in growth related genes’ promoter regions. The presence of quadruplex structures in 
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diverse regions of the genome present a design challenge to develop small molecules based 
on targeted anticancer therapy. For this reason, a number of research groups worldwide are 
working to solve the problem and identify a suitable drug candidate for a quadruplex based 
chemotherapy. 
1.9.3 Antisense oligonucleotides 
Geron Corporation developed an antisense oligonucleotide, Imetelstat (GRN163L), targeting 
hTR. GRN163L is a lipid-conjugated 13-nucleobase-long oligonucleotide sequence which is 
complementary to the RNA template of telomerase, and has high binding affinity to the RNA 
template, thereby directly inhibiting telomerase activity. GRN163L stops telomeric activity due 
to a direct antagonistic effect on the telomerase RNA template. It should be noted that 
GRN163L is not a normal antisense oligonucleotide, but with its 5′-Palmitoyl-
TAGGGTTAGACAA-3′ oligonucleotide chain partially overlaps the hTR template with highly 
specific binding affinity at its active site that ultimately causes the complete inhibition of 
telomerase. GRN163L has demonstrated a favourable pharmacokinetic profile with minimal 
side effects, and is now in phase 1 and 2 clinical trials.238 
1.9.4 Targeting telomere and telomerase-associated proteins 
Tankyrase inhibitors have implications in the inhibition of telomerase activity and function. 
Tankyrase-1, a TRF1-interacting tankyrin-related poly(ADP-ribose) polymerase (PARPs), is 
an enzyme that in humans is encoded by the TNKS gene. Tankyrase-1 releases from the 
telomere and allows the telomere access to the telomerase. Thus, tankyrase inhibitors can 
play a vital role in inhibition of telomere functions by not allowing TRF1 to dissociate from the 
telomere. Olaparib (AZD-2281, 1.42) is a FDA-approved PARP inhibitor and targeted therapy 
of cancers with hereditary BRCA1 or BRCA2 mutations, including ovarian, breast, and 
prostate cancers.239 
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 Figure 1.46: FDA approved poly-ADP ribose polymerase (PARP) inhibitor. 
Tankyrase-1 is usually activated by binding to DNA breaks and subsequently plays roles in 
DNA base excision repair, and is also responsible for modifying the telomere structure by 
exposing telomeric DNA to telomerase. As TRF1 is a negative regulator of telomere 
length, removing of TRF1 from telomeres allows telomerase access to telomeric DNA and thus 
leads to the telomere elongation process in telomerase positive cells. Tankyrase-1 causes 
poly (ADP-ribosyl)ation of TRF1 protein and reduces TRF1 binding to telomeric DNA, leading 
to the ubiquination process and ultimate release of TRF1 from the DNA strand. Moreover, 
tankyrase-1 can directly contribute to telomere elongation by acting as a positive regulator of 
telomere length and causing the dissociation of TRF1 from telomeric DNA. Therefore, 
targeting tankyrases with PARP inhibitors is a novel anticancer therapy approach.240  
Inhibition of Heat Shock Protein 90 (HSP90) is another telomerase targeted anticancer 
strategy. HSP90 is a molecular chaperon protein, which is important for protein folding and 
regulation. In cancer, HSP90 is found to be amplified, which makes HSP90 inhibitor as an 
appealing research area to develop chemotherapeutic agents. Geldanamycin is a good 
example of an HSP90 inhibitor. Originally, the drug was developed as a kinase inhibitor but 
later it was evidenced that geldanamycin can block the ATP-dependent binding of HSP90 to 
p23, which subsequently disrupts the chaperone assembly causing telomerase inhibition.241 
However, due to concurrent high hepatotoxicity and lower solubility of geldanamycin, two more 
analogues 17-AAG and 17-DAMG were developed and are in phase-I and phase-II clinical 
trials at the moment, respectively.  
T-oligo is another novel and specifically targeting anticancer agent, which is comprised of an 
11-nucleobases long, single stranded, oligonucleotide sequence (GTTAGGGTTAG), and 
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homologous to the telomeric overhang sequence. Studies have demonstrated that various T-
oligo treated various tumour cell lines can undergo active DNA damage responses, facilitated 
through the ATM kinase and its effector proteins (i.e., p53, p57, p95/Nbs1 and E2F1), which 
are similar to DNA damage responses originated due to uncapping of telomeres and 
knockdown of TRF2.242  Some other studies have shown inhibition of angiogenesis in cancer 
cell lines due to decrease signal in the VEGF receptor243 and lowered oxidative damage to 
cells after treatment of T-oligo244. However, T-oligo causes transient cell cycle arrest in normal 
cells. 
1.9.5 Small molecule inhibitors of hTERT 
Damm and co-workers reported BIBR1532 (1.43 a) and BIBR1591 (1.43 b), naphthalene-type 
molecules, as highly selective telomerase inhibitors. They demonstrated that both compounds 
inhibited the in vitro processivity of telomerase in a dose dependent manner, with BIBR1532 
and BIBR1591 giving IC50 values of 93 and 470 nm with a nuclear extract from HeLa cells. It 
was reported that BIBR1532 works by directly inhibiting the telomerase enzyme via its active 
site.245 It has also been reported that BIBR1532 can competitively bind to the active site of 
hTERT though it does not block the template copying site for the telomere elongation process. 
Thus it is hypothesised that the molecule either influences the enzyme-DNA-substrate 
complex translocation or causes enzyme dissociation from the telomeric end of DNA. 
 
Figure 1.47: Structure of BIBR1532 and its analogue, small molecules targeting hTERT. 
1.9.6 Telomerase based immunotherapies 
In general, immunotherapy based treatment involves controlling the human immune system to 
destroy cancer cells. Typically, there are two major antigen identifying molecules present in 
humans, cytotoxic T-lymphocytes (CTL) and CD4+ helper T-lymphocytes, which are 
responsible for destroying cells. Within telomerase, hTERT is a potential target antigen and 
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immunotherapy depending on hTERT is considered to be relatively less toxic as the 
expression of hTERT is related only with telomerase, which is much lower (almost null) in 
almost all somatic cells.180 
Two potential telomerase vaccines have been developed, which are now in phase III clinical 
trials.  GRNVAC1 isolates dendritic cells and the RNA that codes for the telomerase protein 
and puts them back into the patient to make cytotoxic T-cells that kill the telomerase-active 
cells. GV1001 (KAEL-GenVax Co Ltd, Korea) is an hTERT-peptide based vaccine and is 
recognized by the immune system that reacts by killing the telomerase-active cells. VX-001, a 
cryptic peptide based vaccine, has completed the phase I/II clinical trial with different stages 
of cancer patients with non-small cell lung cancer, breast cancer, melanoma and 
cholangiocarcinoma. Due to good tolerability and positive correlation between immune 
response and clinical responses in patients with non-small cell lung cancer, VX-001 has been 
scheduled for phase III clinical trial in non-small cell lung cancer patients. 
1.10 Telomerase inhibition measurement 
Sequential loss of the telomere ends of a chromosome due to the semi-conservative DNA 
replication mechanism is the key scheduling mechanism that controls the cells doubling in 
number. On the other hand, the reverse transcriptase enzyme, telomerase, is responsible for 
the elongation of one strand of the telomeric DNA and compensation of its shortening 
throughout the replication process. Thus, telomerase activity functions as a propagation 
indicator; although such activity is not noticed in most somatic cells (exception of embryonic 
tissues, stem cells and reproductive organs). In about 80-90% tumour cells, telomerase activity 
is triggered and plays the role in telomere length elongation, which is used as a marker for the 
diagnosis of neoplastic transformation. Additionally, telomerase activity analysis is a useful 
tool in the search for telomerase inhibitors. All telomerase activity detection assays can be 
classified into three large groups based on direct detection of telomerase activity and 
expression, detection of telomere G-tail length, and detection of alternative lengthening of 
telomere. 
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1.10.1 Detection of telomerase activity and expression 
Several methods have been devised to evaluate and measure the telomerase activity and 
expression of the telomerase components. The telomeric repeat amplification protocol (TRAP) 
is the most common method for detecting telomerase activity that allows one to perform semi-
quantitative and quantitative analyses, using some modifications within the assay (e.g., 
increasing rate of analysis, replacing the radioactive label by non-labelled compounds, and 
reducing the amount of side products, etc.) .80, 246 
1.10.1.1 Telomeric Repeat Amplification Protocol (TRAP) Assay 
The telomeric repeat amplification protocol can be split into three main steps, a) primer 
elongation, b) amplification of telomerase-synthesized DNA, and c) detection. At the 
elongation stage, telomeric repeats are added to the telomere-replicating oligonucleotide 
(TS, 5-AATCCGTCGAGCAGAGTT-3) by telomerase present in the cell extract. Then, PCR-
amplification is carried out towards the telomerase-synthesized DNA with the use of specific 
primers (i.e., telomere-replicating primers and reverse primers). At this stage, different labels 
(e.g., radioactive, fluorescent labels) can be integrated into the telomerase-synthesized DNA. 
Afterwards, electrophoretic separation of PCR products and photographing (in the original 
TRAP assay) are carried out to detect and analyse the expression. Initially, in the TRAP assay, 
PCR products are identified in polyacrylamide gel through the radioactive label, using either a 
radioactively labelled primer or incorporated into the DNA during the PCR process. The 
method allows a qualitative assessment of the activity and enzymatic activity of telomerase in 
cell and tissue extracts. PCR at the second stage of the TRAP assay allows the acquisition of 
a sufficient amount of DNA for gel staining. 
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Figure 1.48: Summary of the original TRAP assay. 
The original TRAP assay had some limitations. For example, use of the initial CX-
oligonucleotide (i.e., 5-(CCCTTA)3CCCTAA-3, used in amplification of PCR products), which 
has a complementarily overlay with TS-oligonucleotide for several base pairs, results in the 
formation of dimeric primers and causes unaccepted products development. An ACX primer 
has been tried to overcome this problem, but a background signal appeared in a concentrated 
tumour extract after using even the optimal ACX primer with the non-complementary TS 
end.247 Moreover, a problem occurred during the use of reverse primers (which is completely 
complementary to the telomeric repeats), where the primers were not annealed during PCR 
and caused a false signal. Generally, such a problem can be resolved by the addition of non-
complementary nucleobases to telomeres with a 5-end non-telomeric “adjunct” made of 6-bp 
to the primer ends. In order to decrease nonspecific signals, a combination of several reverse 
primers are used (e.g., primers RP (5-TAGAGCACAGCCTGTCCGTG-3) and RPC3 (5’-
TAGAGCACAGCCTGTCCGTG(CTAACC)3-3)), which is known as “two-primer” TRAP.248 
Gomez and co-workers reported that oligonucleotide TSG4 (i.e., 5-
GGGATTGGGATTGGGATTGGGTT-3 ) can also be added to the TRAP mixture to evaluate 
the effect of duplex-stabilizing inhibitors.249 Moreover, during the usage of PCR in the signal 
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amplification process, the PCR inhibitors present within the specimen can affect the results in 
detecting telomerase activity. 
Several advancements have been made in the TRAP assay, for example, a scintillation 
proximity assay (SAP) combined-TRAP assay where 5’-biotinylated oligonucleotides act as 
substrates and PCR amplification is carried out in the presence of tritiated (3H) thymidine250, a 
hybridization protection assay-TRAP where acridine bound probes are used to detect 
amplified DNA251, a TRAP-ELISA method, where TRAP is combined with an enzyme-linked 
immunosorbent assay (ELISA)252, a real-time quantitative TRAP assay where RT-PCR is used 
for simultaneous DNA amplification and measurement of the amount of products obtained 
after each amplification cycle253, and an in situ TRAP assay where both substrate and reverse 
primers are labelled by FITC (i.e., fluorescein isothiocyanate), then cell suspension samples 
are immobilized and dried, followed by incubation after addition of TRAP reagents and then in 
situ PCR is performed254. 
1.10.1.2 Direct detection of telomerase-synthesized DNA 
Direct combination of a radioactively labelled substrate can be used to determine telomerase 
activity. In this method, the ability of telomerase can be electrophoretically assessed to 
elongate oligonucleotides in the presence of radio-labelled dNTP (e.g., deoxy-guanosine 
triphosphate (dGTPl) as telomerase-synthesized telomeres are enriched in guanine bases). 
The main disadvantages of this method include the usage of large amounts of radioactive 
isotopes and in many cases observed inadequate sensitivity.255 
Telomerase-synthesized DNA also can be identified in surface plasmon resonance (SPR). 
SPR demonstrates on a metal’s surface under conditions of total internal reflection and is 
characterized by a generic angle of reflection, and consequently, the refraction index. As this 
effect shows itself on the metal surface, it spreads deep into the solution with exponential 
hindering as a distance function, where any interactions between the molecules can change 
the curbed wave and thus affect the characteristics of the surface plasmon, causeing a change 
in resonance angle and refraction index. Changes in refraction index are the characteristic 
measurements for evaluating the interaction between bio-molecules. With the help of a 
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biosensor, SPR is used to determine the activity of telomerase as the corresponding 
elongation of a telomere-replicating oligonucleotide.256, 257 
Moreover, telomerase activity can be determined using oligo-modified magnetic particles and 
NMR, where magnetic particles of an iron oxide are used to modify the oligonucleotides that 
are complementary to telomeric repeats.258 According to the quartz crystal microbalance 
technique, an Au-quartz resonator is also used for a micro-gravitometric analysis of 
telomerase activity.259 Ferrocenyl naphthalene diimide is used to detect the activity of 
telomerase electrochemically, which is based on the ability of telomeric G-quadruplex 
formation. In this method, ferrocenyl naphthalene diimide stoichiometrically binds with DNA 
quadruplexes and stabilizes the structure, and this bound ferrocenyl naphthalene diimide can 
be detected using electrochemical methods. Though this method cannot determine the length 
and position of individual DNA fragments, the sensitivity of this method is adequate to detect 
the telomerase-synthesized DNA without amplification.260 FRET and total internal reflection 
fluorescence microscopy were employed to detect the telomerase activity by individual 
complexes of Tetrahymena thermophila telomerase. 
1.11 Design and Rationale of this Project 
1.11.1 Background 
In 2012, Rahman and co-workers identified thirteen small molecules with varied chemical 
structures through screening 2307 molecules of NCI Diversity Set II, the NCI Natural Products 
Set II and the NCI Mechanistic Diversity Set libraries against human telomeric G-quadruplex 
(F21T, 5d-GGG-TTA-GGGTTA-GGG-TTA-GGG-3) using a FRET-based DNA melting 
assay.261 These compounds (molecular weight range of 327-533 Daltons) showed significant 
selectivity towards the telomeric G-quadruplex compared with duplex DNA and the Tm values 
were 7.3 to 24.2 C at a 1 M ligand concentration. Those molecules were also evaluated 
against a DNA/RNA hybrid duplex sequence (DRH, 5-CCC-UAA-CCC-UAA -TTT-TTT-TTA-
GGG-TTA-GGG-3), where NSC 273829 (1.44) showed 11.5 °C and 3 C stabilization at 5 M 
and 1 M ligand concentrations, respectively, by FRET melting assay (unpublished result). 
Moreover, molecule 1.44 was potent towards the F21T quadruplex sequence (11.8 C at a 1 
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M ligand concentration).261 NSC 273829 is also a drug-like small molecule (logP = 4.60 and 
MW = 442.61 Daltons) and was also reported as active in mouse L1210 leukaemia 
xenografts262 and against leishmania263. 
 
Figure 1.49: Structural features of NCI library compound NSC 273829. 
1.11.2 Rationale of the Project 
It has been reported in different articles that guanine-rich oligonucleotide sequences can fold 
into characteristic four-stranded G-quadruplex structures145, 264 which are observed in 
telomeric DNA repeats and in promoter oncogene sequences and other regulatory regions of 
genes that are particularly involved in cellular proliferation.153 However, the single-stranded 3-
overhang of the hTelo DNA sequence can be stabilized by small molecules to maintain G-
quadruplex structures, thus preventing further annealing and subsequent addition of the 
telomerase enzyme complex (which is overexpressed in most cancer cells) to add further 
hTelo DNA repeats, and causing subsequent inhibition of cell growth and senescence.265, 266 
A number of hTelo sequences that form stable G-quadruplexes have been identified and 
characterised by NMR and crystallographic methods.145, 147, 196, 267, 268 
Additionally, the single-stranded 3-overhang of hTelo DNA forms a heteroduplex structure 
with the RNA-template of the telomerase enzyme complex during the catalytic cycle of 
telomerase expression in cancer cells, which is generally known as a DNA/RNA hybrid. It has 
already been established that the heteroduplex sequence forms during the initial annealing of 
the substrate telomere to the template RNA and during its extension in the 3 direction.107, 182 
Such hybrid duplexes were discovered in 1960 and are appealing objectives for cancer 
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treatment due to their relatively unique structures in cancer cells compared with the DNA/DNA 
duplexes sequence183, specificity in sequence (due to the telomeric repeat of TTAGGG) and 
precise length of the duplex (4-11 base-pairs)269. Most importantly, as the DNA/RNA hybrid 
duplex binds tightly to the protein portion of telomerase, molecules that bind to this hybrid 
duplex will also be able to access the unique protein surfaces of telomerase. Therefore, 
DNA/RNA hybrid duplex-binding molecules may be able to act as a platform for making precise 
analogues to identify the specific telomerase protein surfaces with improved affinity and 
specificity.188 Moreover, the diversity in hybrid structures (due to the presence of different 
nucleobases (purine and/or pyrimidine) on the DNA strand) offers diverse backbone 
conformations and groove geometries in the DNA/RNA hybrid duplex that are distinctive 
features against which synthesised small molecule analogues can be selectively targeted.184 
Small compounds that induce the formation of and/or selectively prevent dissociation of 
DNA/RNA hybrid duplex structures during the telomerase catalytic cycle or bind to G-
quadruplexes are of interest to develop as potential therapeutic candidates, mostly in the 
anticancer drug discovery research area. The G-quadruplex binding agents that have been 
identified so far are mainly based on core functionalized polycyclic heteroaromatic systems 
with acridine, anthraquinone, perylene or porphyrin moieties.201, 202, 270, 271 In general, relatively 
large aromatic ring systems are considered as a priority in G-quadruplex ligand design, since 
they can either interact with the terminal G-quartet plane through  interactions (i.e., end-
stacking) or intercalate between G-quartets. On the other hand, there is no reported molecule 
so far that can target the telomeric DNA/RNA hybrid duplex structure either as a groove binder 
or intercalating agent. Thus this is a novel target in medicinal chemistry and cancer drug 
discovery research. 
Several bulky aromatic functionalities have some shortcomings such as high binding affinity 
by themselves and reduced water solubility due to their hydrophobicity. To eliminate such 
problems, ligands were transformed into various analogues and functionalized by introducing 
one or more cationic side arms (for example, tertiary amine tail) to improve solubility and 
increase the chance of possible binding with phosphate backbones and/or with functional 
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groups available in the loops and grooves of DNA/RNA hybrid duplexes and/or telomeric G-
quadruplex structures. 
1.11.3 Aims and Objectives 
The main aim of the project is to design and synthesize small-molecule ligands capable of 
interacting with telomeric DNA/RNA hybrid duplexes. Small molecules that bind to these 
heteroduplexes may inhibit telomerase activity by stabilizing the structure and thereby 
preventing strand dissociation or by distorting the substrate duplex leading to misalignment of 
the key catalytic groups. As telomerase is frequently overexpressed in cancer cells, the 
DNA/RNA hybrid duplex is considered a very specific and exciting therapeutic target. 
However, due to the unique structure of this heteroduplex, it is very challenging to target this 
sequence; very few studies have been carried out, and only a few compounds have shown 
DNA/RNA hybrid duplex stabilising properties.100, 107, 184, 188, 191 In the present study, NSC 
273829 (1.44) was selected as a lead compound based on our initial screening results and 
the rationale for this selection is discussed in section 1.11.1 and 1.11.2. A series of analogues 
were designed based on initial modelling studies and these ligands have different structural 
diversities and conformational flexibilities. 
 
 
Figure 1.50: Expected outcome from this project targeting DNA/RNA hybrid duplexes to 
inhibit telomerase activity within cancer cells. 
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The specific objectives of the project are as follows: 
1. Synthesise novel DNA/RNA hybrid duplex and/or G-quadruplex ligands using a variety 
of chemical approaches. 
2. Evaluate new molecules using FRET-based DNA thermal denaturation assays to 
evaluate the affinity and selectivity of newly-synthesized ligands towards particular 
DNA sequences (DNA/RNA hybrid duplex and hTelo sequence, F21T). For all the 
experiments, duplex DNA sequences were used as controls for the telomeric DNA 
sequences (F21T), whereas cDRH (where RNA bases of DRH were replaced by 
corresponding DNA bases) was used as a control for DNA/RNA hybrid duplex 
sequences. 
3. Evaluate the novel ligands for cytotoxicity in tumour cell lines. 
4. Use the results to compare the newly-synthesized ligands with those previously 
synthesized to derive structure activity relationships (SARs). SARs should contribute 
to a greater understanding of the interactions of newly-synthesized small molecules 
with G-quadruplex structures and/or DNA/RNA hybrid duplexes. 
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Chapter 2: Methods and Materials  
2.1 Sourcing of Chemicals 
In this research project, all chemical reagents and solvents were purchased commercially from 
Sigma-Aldrich, Maybridge, Acros, Alfa Aesar, TCI Europe, Fluorochem, Biofarma, Fisher 
Scientific and Fluka. 
2.2 Analytical Tools 
The liquid chromatography–mass spectrometry (LC-MS) technique was applied to monitor 
reaction progression and identification of the compounds. LC-MS was performed on a Waters 
Alliance 2695 with water and acetonitrile as the mobile phases. Formic acid (0.1%) was used 
with the acetonitrile to confirm acidic conditions during the course of analysis. The gradient 
conditions were acetonitrile/water (95%) for 2 minutes, which was then increased to 50% 
acetonitrile over 3 minutes. The gradient was then held at 50% acetonitrile for one minute and 
then increased to 95% acetonitrile over 1.5 minutes. The quantity of acetonitrile was then 
returned to 5% over 1.5 minutes and held for 0.5 minutes. The total duration of each run was 
10 minutes. The flow rate was 1.5 mL/min; 200 µL was split via a zero dead volume T-piece 
which passed into the mass spectrometer. The wavelength range of the UV detector was 220-
400 nm. A diode array (535 scans) was functionalised with the system. A monolithic (C-18, 
50X4.60 mm) column was used. 
Proton (1H) and carbon NMR (13C) spectroscopy were carried out on a Bruker Avance 400 
MHz spectrophotometer. Chemical shifts ( H) are cited in ppm (parts per million) and 
referenced to deuterated chloroform (CDCl3, residual signal 1H  = 7.26, 13C  = 77.2), 
deuterated dimethyl sulfoxide (DMSO-d6, residual signal 1H  = 2.54, 13C  = 40.45), 
deuterated methanol (MeOD, residual methanol signal 1H  = 3.31, 13C  = 49.00). Multiplicities 
in 1H NMR spectra are quoted as s = singlet, d = doublet, t = triplet q = quartet, m = multiplet, 
dd = doublet of doublets, ddd = doublet of doublet of doublets, dt = doublet of triplets, td = 
triplet of doublets, spt = septet and br = broad. The code (0) in 13C NMR spectra denotes the 
presence of a quaternary carbon. 
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High resolution mass spectra (HRMS) were obtained on a Thermo Navigator mass 
spectrometer coupled with liquid chromatography (LC) using electrospray ionisation (ES) and 
time-of-flight (TOF) mass spectrometry. Infrared spectra (IR) were recorded on a Perkin Elmer 
spectrum 1000 instrument. 
Every single reaction was checked by analytical thin-layer chromatography (TLC) performed 
on E. Merck silica gel-60 F254 layered plates (0.25 mm). TLC plates were visualized under UV 
light (254 or 360 nm) and/or by staining the plates with either vanillin spray or potassium 
permanganate solution followed by heating. 
2.3 Purification Techniques 
2.3.1 Flash Column Chromatographic Technique 
Compounds were purified by traditional column chromatography using Merck Flash Silica Gel-
60 (230-400 mesh). To get an idea of a proper solvent system, traditional TLC was utilised 
using different solvent systems to obtaine the best separation profile. 
Automated flash column chromatography is an air pressure-driven hybrid of medium pressure 
and short column chromatography, optimized for rapid separations on the basis of UV and 
ELSD detection. A Reveleris® Purification System was used in this project to purify three 
compounds, where the mono-adduct and bi-adduct products’ retention times (rf value) were 
very close to each other. 
2.3.2 Catch and Release Method 
SCX-2 resin cartridges were purchased from Biotage Synthesis (Virginia, USA) with different 
sorbent capacities (500 mg, 1 g, 2 g, 5 g and 10 g). The cartridges contain propylsulfonic acid-
functionalized silica. The strong cation exchange sorbent is a very good choice for basic drug 
extraction. The cartridges were first activated by an initial wash with 2 column volumes of 
dichloromethane and 4 column volumes of methanol. The reaction mixtures were then poured 
onto the cartridge (sorbent mass should be 10 times that of the calculated mass of the product) 
and the solvent was allowed to pass through the cartridges under gravity. The cartridges were 
then washed with dichloromethane (3 times), dimethylformamide (3 times) and methanol (1 
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time) and this cycle was repeated three times to remove the impurities, using a vacuum to 
accelerate the elution. Products were released from the cartridge using 2M ammonia solution 
in methanol and concentrated in vacuo. 
 
Figure 2.1: Procedure for the ‘Catch and Release’ purification method. 
2.3.3 Trituration Technique 
This process was used to purify crude chemical combinations with solid impurities. A solvent 
(either polar or non-polar) was selected in which the desired product was very soluble and the 
unwanted by-products were insoluble (or vice versa). The crude material was washed with the 
solvent and filtered away, leaving the purified product in solid form and any impurities in 
solution. In this project, a few compounds were purified through triturating the crude sample 
with diethyl ether (20-30 mL) to give a white solid which was then filtered and washed with 
diethyl ether to give the pure product. 
2.4 General Amide Coupling Reaction 
In this project, a standard method for amide coupling was employed to prepare all bis-amide 
molecules in libraries 1 to 7. The reaction was carried out using 1-hydroxybenzotriazole (HOBt) 
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and diisopropylcarbodiimide (DIC) and the mechanism for this reaction is illustrated in Figure 
2.2.272 The HOBt/DIC-mediated amide coupling reaction was employed for all reactions due 
to the availability of the reagents and previous use within the research group with good yield. 
Additionally, most of the reactions were made with either dimethylformamide (DMF) or 
dichloromethane (DCM) as the solvent, because the urea by-product is soluble in DMF (easy 
to remove during washing) and the initial activation step is faster in nonpolar solvent like 
DCM.273, 274  
Initially, the activated ester was generated by treating the corresponding acid with HOBt in the 
presence of DIC.275, 276 After its formation, selected diamines were added and in most cases, 
the reaction was completed after 14-18 h. 
 
 
Figure 2.2: Schematic diagram of the HOBt/DIC-mediated amide coupling reaction. 
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2.5 Methods Used for Biophysical and Biological Evaluation 
2.5.1 Fluorescence Resonance Energy Transfer (FRET) Assay 
In 1970, the Fluorescence Resonance Energy Transfer assay, a quantum phenomenon, was 
first applied in biological research, especially in proteins. The FRET assay was first 
demonstrated by Theodor Förster over 70 years ago.277 The principle of this assay is the 
excitation of a fluorophore and transfer of energy from the donor to an acceptor fluorophore 
over dipole-dipole interaction without any discharge of photons. Consequently, the donor 
molecule’s fluorescence is quenched, and the acceptor molecule becomes excited, and finally 
it loses energy via heat or fluorescence emission (also known as sensitized emission) (Figure 
2.3). Such resonance transfer occurs over more than interatomic distances, without 
conversion to thermal energy and any molecular collision. This transfer of energy leads to a 
fall in the donor’s fluorescence intensity and excited state lifetime, and conversely causes an 
increase in the acceptor’s emission intensity. A pair of fluorophores that interact in such a way 
that transfer of fluorescence resonance energy occurs is referred to as a donor/acceptor 
pair.278 
Remedios and co-workers reported that ‘Fluorescence Resonance Energy Transfer’ is a 
spectroscopic process by which energy passes in a non-radiative way between fluorophores 
over distances of 10-100 Å.279 
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Figure 2.3: Principle of the FRET mechanism; the ‘donor’ fluorophore (Do) absorbs a photon 
and transfers this energy by a non-radiative process to the ‘acceptor’ fluorophore (Ac).280 
In theory, the donor fluorophore can directly transfer its excitation energy to the acceptor 
fluorophore through distant dipole-dipole intermolecular coupling in the case of overlaying of 
the fluorescence emission spectrum of the donor fluorophore onto the absorption spectrum of 
the acceptor fluorophore, and if the two fluorophores are within a minimal spatial radius. The 
acceptor molecule quenches the donor molecule’s fluorescence during the energy transfer, 
and if the acceptor itself is a fluorophore then amplified or sensitized fluorescence emission is 
observed. The phenomenon is detected by exciting a specimen containing both donor and 
acceptor fluorophores with light of wavelengths corresponding to the absorption maximum of 
the donor fluorophore, and detecting light emitted at wavelengths centred near the emission 
maximum of the acceptor. 
For effective FRET to occur, the donor and acceptor fluorophores need to be in close proximity 
to each other and the absorption or excitation spectra of the acceptor fluorophore must overlay 
the fluorescence emission spectrum of the donor fluorophore. Förster established that the 
efficiency of the process (E) depends on the inverse sixth-distance between donor and 
acceptor as follows:277 





 Here, Ro = Förster distance, r = Actual distance between donor 
and acceptor fluorophores 
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It is already established that stabilization of the DNA quadruplex and/or duplex helical structure 
due to the addition of a small drug-like molecule results in elevated melting temperature of the 
ligand-bound oligonucleotide compared with the oligonucleotide itself. As a result, the 
difference in melting temperature (TM) of the ligand-bound oligonucleotide and 
oligonucleotide itself gives an indication of the stabilizing efficiency of the molecule to the DNA 
structure. Choice of buffer is an important factor to obtain accurate melting temperatures. 
Usually most real time PCR works within the range of 25-100 °C, and, therefore, the initial 
melting temperature of the quadruplex and/or other sequences used should be within the 
range of 45-55 °C that can be adjusted by using an appropriate buffer.281 Usually, a 
lower melting temperature (TM) will lead to imperfect folding of DNA at low temperatures, 
whereas a higher TM will prevent the analysis of extremely potent ligands. Concerning the 
effect of pH, it is important to note that the properties of fluorescein (FAM)-conjugated 
oligonucleotides are pH-dependent as pHs lower than 7.0 can cause an important 
quenching.282, 283 
Generally, the donor and acceptor fluorophores are different and FRET can be detected either 
by the appearance of acceptor fluorescence or by quenching the fluorescence of the donor 
fluorophore. A fluorescent molecule is always chosen as the donor moiety. With appropriate 
energy of excitation, electrons from the donor fluorophore jump from the ground state (So) to 
an excitation level and these electrons come back to the lowest vibrational state (S1) within a 
very small time space (can be picoseconds) and ultimately fall back to the ground state (So) 
by releasing a photon of light. At the point of fluorescence resonance energy transfer, there is 
competition between the decay of the donor fluorophore and energy transfer to the acceptor 
fluorophore for the falloff of excitation energy. With resonance energy transfer, the energy is 
transferred to the acceptor fluorophore rather than the transfer of a photon and those electrons 
become excited as stated for the donor fluorophore, consecutively. Finally, the successive 
return to the ground state releases photons (Figure 2.4). 
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Figure 2.4: Jablonski diagram illustrating the coupled transitions involved between donor 
emission and acceptor absorbance in FRET. 
A ‘FRET melting assay’ utilizes this basic principle where an increase in temperature leads to 
denaturing or melting of the oligonucleotides, causing an increase in distance (Förster 
distance) between the two fluorophores and ultimately leading to a rise in fluorescence energy. 
This technique has been found to be very useful in investigating various types of nucleic acid 
structures.284 However, availability of suitable labelled substrates limits its use in biological 
systems. However, this is not a problem for studying quadruplex DNA stability as synthetic 
DNA is usually used for all analysis relating to G-quadruplex formation and labelled 
oligonucleotides can be obtained easily.285 
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Figure 2.5: FRET transfer mechanism and application to a ligand on a DNA duplex 
sequence. 
In 2001, Mergny and co-workers first used the FRET technique to investigate the G-quartet 
structures.286 A synthetic oligonucleotide containing a pair of fluorophores on both the 5' and 
3' ends with a suitable Förster diameter that followed the principle of the fluorescence 
resonance energy transfer mechanism was used so that, upon folding, the donor and acceptor 
fluorophores were brought close to each other to allow efficient fluorescence resonance 
energy transfer. 
 
Figure 2.6: Structure of the dual probe-labelled quadruplex, stabilized by a ligand (oval 
shaped) and subsequent schematic representation of FRET-based experiments. 
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FRET gives valuable evidence about nucleic acid structures287, as the mechanism is distance- 
and orientation-dependent277. Considering multi-stranded nucleic acids structures, the 
fluorescence resonance energy transfer method has been effectively applied in the case of 
triple helices288, C-rich quadruplexes (i-motif)283 and c-Myc quadruplex sequences.282 
To conduct the FRET melting assay in our study, 6-carboxyfluorescin (FAM) and 6-
carboxytetramethylrhodamine (TAMRA) were used at the 5' end of oligonucleotide sequences 
as a donor and at the 3' end of oligonucleotide sequences as an acceptor dye, respectively. 
 
 
Figure 2.7: Structure of FAM (2.1) and TAMRA (2.2) 
In principle, at low temperatures the oligonucleotide remains folded to keep the probes within 
the Förster radius (R0) resulting in quenching of the emission radiation of FAM by TAMRA (i.e., 
which were used in this project as a FRET pair). The peak absorbance wavelength for FAM is 
494 nm with a peak emission wavelength at 518 nm. If FAM and TAMRA are tied at the 5’- 
and 3’-ends respectively of an oligonucleotide and this construct is excited at 494 nm, as long 
as the oligonucleotide remains intact, emission will be at 580 nm and not at 518 nm as FAM 
is transferring its energy to TAMRA. As soon as the oligonucleotide is disordered ( i.e., 
disrupted) by either heat or an exonucleolytic reaction excitation at 494 nm will result in 
emission at 518 nm. This is due to the fact that the pair is no longer bound and falls apart from 
Förster distance (Ro). However, an increase in temperature toward the melting point of the 
oligonucleotide leads to unfolding of the oligonucleotide and causes the fluorophores to be 
separated sufficiently that the FRET efficiency is ultimately diminished. The FRET technique 
is a simple, quick, convenient, and cost effective method that can be conducted in a variety of 
ionic conditions and can easily be adjusted for 96-well plate high-throughput screening. For 
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these reasons, it has been adopted by various research groups and a large number of 
molecules with diverse structural features have been screened using this technique. However, 
this method has some disadvantages as well; sometimes it can give false positives due to 
quenching of the donor emission by chromophores present in the ligands and sometimes it 
can produce false negatives because of folding of the DNA sequence with the ligands in such 
a way that the distance between the donor and acceptor fluorophore prevent the effective 
transfer of fluorescence resonance energy. To avoid the problem of false positives, the 
absorbance for the ligands should be checked beforehand to make sure that they do not 
absorb at the same wavelength as the acceptor. The DNA bases, especially the guanines, can 
also cause quenching of the donor emission, hence they should be separated from the donor 
moiety. 
 
2.5.1.1 Procedure involved in FRET Assay 
2.5.1.1.1 Selection of oligonucleotides 
The synthesised molecules were screened against the following oligonucleotides in this study:  
DRH; Telomeric DNA/RNA hybrid duplex – A hairpin DNA/RNA hybrid duplex was used in 
this experiment where the DNA strand corresponds to the human telomeric repeat sequences 
and the RNA strand corresponds to the  RNA template of telomerase (Figure 2.8). 
 
Figure 2.8: (a) Hairpin structure of telomeric DNA/RNA hybrid duplex (red indicates the RNA 
nucleotides) and (b) Hairpin structure of control cDRH duplex. 
cDRH; Control DNA/DNA duplex – A hairpin form of oligonucleotide was used as a control, 
which has an identical sequence and orientation, except that the RNA nucleotides are replaced 
with the corresponding DNA nucleotides (Figure 5B.1 b). 
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F21T; telomeric quadruplex DNA – For quadruplex ligands to function as telomerase 
inhibitors, they must show significant quadruplex-stabilizing ability. A double dye 
oligonucleotide sequence with human telomeric repeats (F21T; 5-FAM-GGG-TTA-GGG-TTA-
GGG-TTA-GGG-TAMRA-3) was used in this experiment. 
cDDS; control duplex DNA sequence – A randomly chosen double dye-containing DNA was 
used as a control for the whole experiment. The sequence that was used was comprised of 
45 DNA bases (5-FAM-TAT AGC TATA TTT TTT TATA GCT ATA-TAMRA-3). 
All oligonucleotide sequences were purchased from Eurogentec, UK with a confirmation of 
RP-HPLC purification and label of product consistency. 
2.5.1.1.2 Methods Adopted for FRET Melting Assay 
Preparation of FRET-Buffer: 500 mL of buffer solution was prepared with potassium 
hydroxide and potassium chloride and adjusted to a pH of 7.4 with cacodylic acid (50 mM and 
500 mM). The buffer was stored in the freezer at -20 °C. 
Annealing of DNA: The fluorescence-tagged oligonucleotide sequences were diluted with 
sterile DEPC water (DNA Grade, Fisher Scientific) to obtain 20 µM solutions. 400 nM solutions 
prepared by serial dilution using FRET-buffer were annealed by heating at 85 °C for 5 minutes 
followed by cooling to room temperature over 3-4 hours (Grant Bio PCH-2 Dry Block 
Heating/Cooling System).  
Preparation of Ligand Solutions: For all ligands, 5 mM stock solutions were made with 
dimethyl sulfoxide (≥ 99.9 %, A.C.S. spectrophotometric grade, Sigma-Aldrich). From these 
stock solutions, 100 µM, 10 µM, 4 µM and 2 µM working solutions were prepared by serial 
dilutions with FRET buffer.  
Preparation of Plates: For the FRET-based DNA melting assay, 50 µL of annealed DNA was 
added to each well of a 96-well plate (Bio-Rad Laboratories), then 50 µL of ligand solution was 
added . Three different concentrations (10 µM, 4 µM and 2 µM) of each compound were tested 
in triplicate. Most commonly, pure FRET buffer instead of ligand solution was added to all wells 
of the first line (A) of the plate to serve as a blank. After 15 minutes of incubation at room 
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temperature, the plate was processed in a DNA Engine Opticon (Continuous Fluorescence 
Detector, MJ Research) and florescence measurements taken over a temperature range from 
30-100 °C at intervals of 0.5 °C. Prior to each measurement, the temperature was kept 
constant for 30 seconds. The incident radiation was emitted at 450-495 nm and detection 
measured at 515-545 nm. 
Data Processing: The achieved data were analysed using the program Origin – Scientific 
Graphing and Analysis Software (Version 7.0, OriginLab Corp.). The increases in melting 
temperatures (Tm) were obtained by subtracting the value of the blank from the measured 
values of each sample. For each concentration of every compound, the average Tm was 
calculated from the three corresponding values and plotted against the concentration of the 
ligand. 
2.5.1.2 Melting curve analysis 
Melting curve analysis examines the dissociation of dsDNA upon heating. As the temperature 
is increased, the double strand dissociates, leading to an increase in absorbance 
(i.e., hyperchromicity). The temperature at which 50% of the DNA is denatured is known as 
the melting point. This melting can be detected using the FRET assay, in which fluorophores 
are attached facing each other at the 3 and 5-end of the complementary strands (for an 
intermolecular duplex) or at the opposite ends of an intramolecular (hairpin) duplex. As the 
temperature is increased there is an increase in the absorbance (or fluorescence), generating 
a melting curve.   
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Figure 2.9: Typical dissociation curve of DNA melting. 
2.5.1.3 Limitation of FRET melting assay 
Sometimes the FRET melting assay can give false positive results due to quenching of the 
donor emission by the planar chromophore present in the ligands, and sometimes can produce 
false negative results because of folding of the oligonucleotide with the ligands in such way 
that the distance between the donor and acceptor prevent efficient FRET from occurring. To 
avoid the problem of false positives, the absorbance of the ligands should be checked prior to 
the assay to make sure that they do not absorb at the same wavelength as the acceptor. The 
DNA bases, especially the guanine, can also cause quenching of the donor emission, and 
hence it should be separated from the donor moiety. 
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2.5.2 Molecular Modelling and Molecular Dynamics (MD) studies1 
Molecular modelling comprises theoretical methods and computational techniques together 
that can be employed to model or imitate the behaviour of molecules towards specific DNA 
sequences or protein structures. The system is used in the areas of computational chemistry, 
new drug design and computational biology to study molecular systems within the body, where 
molecules from small chemical scaffolds to bulky biological molecules can be analysed. The 
general feature of molecular modelling and molecular dynamics techniques is the explanation 
of a chemical scaffold at an atomistic level. 
Molecular modelling techniques allow for the atomic-level evaluation of shape-fit and binding 
affinity of ligands with a receptor, and can be useful tools with which to establish structure-
activity relationships of libraries of ligands and to drive the drug discovery process. Molecular 
docking calculations involve the use of a static crystal structure, and are particularly useful in 
determining shape-fit in a receptor. Molecular dynamics simulations, on the other hand, consist 
of the calculation of the time-dependent behaviour of molecular systems, and have provided 
valuable information on the changes in conformations of biomolecules (for example proteins 
or nucleic acids) as predicted over a certain time course. 
The fields of in silico modelling and molecular dynamics have progressed rapidly through 
technological advancement. The speed of computers has doubled every two years (‘Moore’s 
Law’ 289) for the past number of years, and the use of specialized GPUs and supercomputers 
has allowed the docking of large libraries of molecules and simulation of large 
macromolecules. This has culminated in the 1ms all-atom molecular dynamics simulations of 
BPTI290 using a specially built, massively parallel supercomputer capable of simulations of 
orders of magnitude greater than standard computer systems291. 
Statistical mechanics is central to the concept of molecular dynamics simulations and it is the 
study of microscopic systems to produce macroscopic conclusions. In MD simulations, 
individual atoms within systems are simulated in order to determine features of the system. 
Ensembles are defined as systems which have different microscopic states, but identical 
                                                     
1 Molecular modelling and molecular dynamics studies were conducted by Dr Paul J M 
Jackson and Mr Meir Touitou of IPS, King’s College London. 
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macroscopic ones, and in order to simulate whole systems, averages corresponding to 
experimental observables are defined in terms of ‘ensemble averages’. The central hypothesis 
to this is that over the course of a simulation, all possible macroscopic states should be 
simulated by different microscopic states, and, therefore, at the end of a simulation, the system 
will have passed through all states. From a drug discovery perspective, the simulation of a 
ligand with a receptor should result in the determination of the lowest energy conformation 
(and thus, most biologically likely) combined drug-receptor complex structure. 
In the case of DNA-RNA hybrid drug discovery, a molecular dynamics-driven approach was 
taken, as this allowed for the evaluation of different mechanisms of binding of the ligand library 
(e.g., DRH minor groove binding or intercalation). As the main mechanism of binding of G-
quadruplex-binding agents is through shape-fit and stacking interactions at the G-tetrad 
interface, a molecular docking-based approach was taken to assess ligand binding and 
correlate with FRET melting temperature experiments. 
2.5.2.1 Process involved in molecular modelling experimentation for DNA/RNA hybrid 
duplex 
The DNA/RNA hybrid duplex was constructed by first using make-na 
(http://structure.usc.edu/make-na/server.html) to create the RNA strand, followed by 
construction of the DNA sequence (including the TTT loop) using the AMBER module nab. 
The TTT loop was then covalently linked to the DNA backbone using parameters derived in-
house. All compounds were docked in the minor groove of the DNA/RNA hybrid duplex 
sequence using AMBER xleap, parm99SB and modified parmbsc0 and Gaff AMBER force 
field parameters. Energy minimization was then undertaken in a gradient manner by initially 
placing the DNA or DNA/RNA hybrid duplex under a high force constraint (i.e. 500 kcal mol-
1 Angstrom-2), which was reduced in stages to zero to enable the ligand to find its local energy 
minimum, followed by reduction in force in a periodic manner with a relaxation of restraints. 
Once in equilibrium, production simulations were run for a period of 10 ns, and atomic 
coordinates were saved at 1 ps intervals. Simulations involving the control DNA duplex were 
undertaken in an identical manner with the use of the AMBER module nuc to create the DNA 
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sequence. Analysis of molecular dynamics simulations was undertaken using VMD292, and all 
models were created using Chimera.293 
2.5.2.2 Process involved in molecular modelling experimentation for hTelo Quadruplex 
sequence 
Receptor Preparation: The F21T quadruplex structure was downloaded from the Protein 
Data Bank (PDB ID: 3CDM). The quadruplex was then subjected to a number of preparation 
steps in Chimera, including assignment of partial charges (AMBER ff98SB) and removal of 
hydrogens using the DockPrep module of AMBER, followed by writing to mol2 and pdb files. 
A molecular surface of the receptor was generated using write dms. 
Ligand Preparation: All ligands were constructed and energy minimised using 
ChemBioOffice and exported in pdb format and converted into the Sybyl format mol2 using 
Chimera.293 The DockPrep module in Chimera was then used to assign partial charges to each 
molecule (AM1-BCC charges in this instance), and atom types were subsequently assigned 
via the AMBER GAFF force-field using ANTECHAMBER. 
Docking: Docking experiments were undertaken using the DOCK6 software suite and the 
F21T quadruplex (PDB ID: 3CDM) was used in the study. In each case, the quadruplex 
interface was used as the receptor and the ligand used in the crystallography study was used 
as a guide for the docking site. 
The receptor was prepared (outlined above), and a number of steps were undertaken in 
DOCK6 to isolate the binding pocket of interest. Firstly, spheres were generated around the 
surface of the molecule using sphgen and Sphere_selector was then used to filter results. 
Spheres within 15Å of the ligand were selected for further analysis. This resulted in the 
assessment of the full quadruplex. 
Finally, every ligand was automatically positioned into the spheres with the maximum number 
of conformations set at a high level (500) to explore a large amount of conformational space, 
thus producing a docked ligand/DNA structure. 
  118|Chapter 2 
 
Evaluation of Ligand Binding: The ligand was evaluated based on the DOCK scoring 
function MMGBSA. During the docking process, a grid was created around the receptor. The 
grid was then used to allow rapid score evaluation in DOCK. Prior to scoring, orientations of 
the ligand which exhibited significant steric interactions with the receptor molecule were 
discarded using the bump filter. 
In evaluating ligand/DNA interactions, two factors were considered crucial; shape-fit of the 
molecule to the DNA receptor, and positioning of the molecule on the DNA-binding interface. 
The latter was considered particularly relevant as in order to stabilise the quadruplex structure, 
it is known that ligands must bind to the G-tetrad. 
2.5.2.3 Limitations of MD simulation studies 
A number of limitations are associated with the molecular modelling techniques used in this 
study. In the case of the docking studies, the crystal structure used in the methodology (PDB 
ID 3CDM) represents a structure of the F21T quadruplex. This ligand is not related in any way 
to the ligands synthesised within this study, and until a ligand:DNA complex is crystallised 
containing one of the analogues synthesised within this study, the docking results can only 
provide an estimate of location of binding. Similarly, a limited number of conformations of the 
ligand were explored during docking, and only a single conformation of the quadruplex DNA 
is explored in this type of study. Molecular dynamics simulations, on the other hand, explore 
multiple conformations of both the ligand and DNA and provide a far greater representation of 
the ligand:DNA complex. However, in a similar manner to docking studies, the positioning of 
the ligand on DNA can only be regarded as an estimate. 
In the case of DRH, every effort was made to generate a conformation of the molecule which 
was biologically relevant. Although a crystal structure of the receptor was not available, an A-
form structure containing both DNA and RNA was generated, and then energy minimised. This 
provided a close approximation to the proposed biological structure of the DRH receptor. 
Conformation analysis of the ligand suggested that the lowest energy conformation of the 
structure was a chair-like conformation, and this conformation was then used for MD studies. 
As is the case with docking studies, this, too, is an estimate of the location of binding, and if a 
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crystal structure were available, this would provide confirmation of our estimates generated 
during MD simulations. 
2.5.3 Circular Dichroism (CD) Spectroscopy 
Circular Dichroism (CD) is detected while optically active molecules absorb left and right hand 
circular polarized light in a different way to some extent. Dichroism is a property of absorbing 
light to different magnitudes depending upon the polarization form of the incident stream of 
light; if the absorption of light circularly polarized in a right-handed direction is different from 
the absorption of light circularly polarized in the opposite direction (left handed), then the 
molecule will exhibit circular dichroism.294 CD spectra for different types of secondary structure 
existing in peptides, proteins and/or nucleic acids are not the same due to a varied Cotton 
effect (the typical variation in optical rotatory dispersion and/or circular dichroism in the 
surrounding area of an absorption band for a molecule) of the macromolecules. Therefore, the 
analysis of CD spectra can provide useful evidence about the secondary structures of 
biological macromolecules and their conformations.295 
However, we are not aware of any reports of CD analysis of telomeric DNA/RNA hybrid 
duplexes to date, which is a crucial hybrid sequence that forms during the catalytic pathways 
of telomerase expression. In 1999, Ren and Chaires screened some standard groove binding 
agents and intercalators against thirteen oligonucleotide sequences, where they established 
a CD spectrum of a RNA/DNA hybrid sequence (i.e., poly(rA)-poly(dT)).185 According to the 
spectrum (Figure 2.10), a positive CD signal was observed at around 260 nm and a sharp 
negative CD signal at around 248 nm. 
 
 
Figure 2.10: CD spectrum of RNA/DNA hybrid (i.e., poly(rA)-poly(dT)) in BPES buffer. 
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In 2009, Kypr and co-workers reported that the CD spectrum of A-form DNA of heterogeneous 
structure is generally the same as that of the A-form of the corresponding RNA or DNA-RNA 
hybrid with the same primary structure, which is characterized by a dominant positive signal 
at 260 nm and a negative signal at 210 nm (where the amplitude of the positive signal is 
typically within 7-12 M−1cm−1 depending on the base sequence).296 In 2012, Xu and colleagues 
suggested that the course of DNA/RNA G-quadruplex structure formation is possible within 
living cells and demonstrated this by using a model of the human telomeric DNA sequence 
and corresponding RNA template (Figure 2.11).297 It was observed in their study that the CD 
spectrum of telomeric DNA shows a positive CD signal at around 290 nm and a negative CD 
signal at around 265 nm (in presence of monovalent Na+); however, upon addition of the 
complementary RNA strand to the telomeric DNA, the CD signal at around 290 nm 
disappeared and a strong positive signal was observed at around 260 nm and a negative 
signal at around 240 nm that is identical to the transformation of anti-parallel DNA to a parallel 
G-quadruplex. Interestingly the CD spectrum for the hybrid sequence also bears resemblance 
to the finding of Ren and Chaires. Thus the CD spectrum for the telomeric DNA/RNA hybrid is 
yet to be established, for which reason, in our study, a control CD spectrum was used that was 




Figure 2.11: Conversion of CD spectra due to formation of hTelo DNA/complementary RNA 
sequence-assisted hybrid quadruplexes, in presence of both monovalent cation Na+ and K+, 
as reported by Xu and colleagues.297 
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The CD spectroscopy method has become one of the essential techniques for studying G-
quadruplex structures, more specifically telomeric G-quadruplexes and ligand interactions. It 
measures the conformational changes in the DNA structure which are induced by modification 
of the environment; for example, the nature and/or concentration of counter ions, temperature, 
pH or the addition of crowding agents as well as chemical modifications. 
Human telomeric G-quadruplex DNA (hTelo) can form distinct assemblies due to its special 
hexamer repeat sequence of TTAGGG. In addition, the conformations formed by hTelo 
sequences of different lengths are also diverse. Despite having varied spectra due to the 
length of the repeat sequence, there is some relationship between their CD signals as well. 
Figure 2.8 describes the CD spectra of samples Ao, Bo and Co with mono, di and tetra-repeats 
of the TTAGGG sequence, respectively; they have a reasonable similarity with a negative CD 
signal at 240 nm and a positive CD signal at around 260 nm.298 In this G-quadruplex structure, 
each strand runs in the same direction, where all guanine residues (from different strands) in 
each G-quartet plane are in anti-conformations. 
                              
(a)                                                                           (b) 
Figure 2.12: (a) Molecular arrangement and outlined map of parallel quadruplex structure (b) 
CD spectra reported by Xiaoyan and co-workers for Ao = TTAGGG, Bo = (TTAGGG)2 and Co 
= (TTAGGG)4 in Tris-HCI buffer without monovalent metal ions at 20°C, pH 7.5.299 
 
  122|Chapter 2 
 
CD analysis also showed that there are weak positive signals at around 290 nm in curves of 
Bo and Co, where the CD signal for Co is more intense due to its G-rich sequences that can 
fold again to form hairpin dimer structures with anti-parallel conformation (Figure 2.8 b).300 
Contrary to the parallel quadruplex assemblies, the guanine glycosidic twisting angles in the 
G-quartet can appear in alternative syn- and/or anti-conformation and thus their CD signal can 
be characterized by a negative peak at 260 nm and a positive peak at 295 nm.301  
Additionally, Williamson and co-workers established that addition of monovalent cations (Na+) 
changes the G-quadruplex structures remarkably and has different effects on sequences due 
to varied lengths of DNA repeats.302 For these reasons, monovalent cations (e.g., K+ and/or 
Na+) are essential for quadruplex formation since they can form a coordination complex to 
stabilize the G-quartet structure. For example, Xiaoyan and co-workers also reported the effect 
of Na+ (80 mrnol/L Na+ in solution) and K+ (80 mrnol/L K+ in solution) on the telomeric G-
quadruplex sequence of TTAGGG. The authors observed that due to the variation in telomeric 
repeat lengths for (TTAGGG)n, the sequence can form an intermolecular quadruplex structure 
(n = 1), intramolecular hairpin structure and subsequent dimeric anti-parallel conformation (n 
= 2) and monomolecular quadruplex structure (n = 4). However, the aforesaid results have 
revealed that CD spectra of sequences of different lengths were varied by minor changes. In 
the presence of 80 mmol/L Na+ in the buffer solution, ANa (TTAGGG sequence) did not show 
any obvious change, although, for the CD signals for BNa ((TTAGGG)2 sequence) and CNa 
((TTAGGG)4 sequence), at around 240 nm the negative bands disappear, 260 nm positive 
bands shifted to 250 nm, a new negative signal was detected at around 260 nm and a positive 
signal was detected at around 290 nm.299 
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(a)                                                    (b) 
Figure 2.13: CD spectra of TTAGGG (A), (TTAGGG)2 (B) and (TTAGGG)4 (C) in Tris-HCI 
buffer at 20°C, pH 7.5 in presence of (a) 80 mrnol/L Na+ in solution, (b) 80 mmol/L K+ in 
solution, as reported by Xiaoyan and co-workers.299 
 
In 2000, Xiaoyan and co-workers suggested that i) the hTelo sequence can form quadruplex 
structures in vitro and in the absence of metal ions can exist mostly in a parallel conformation; 
however, with the escalation of repetitive frequency of TTAGGG and a subsequent increase 
in sequence length, hTelo is increasingly likely to form an anti-parallel conformation, ii) 
monovalent cations, K+ and Na+ can stabilise the quadruplex structures and help in the 
formation of an anti-parallel conformation (note, Na+ can only stabilise anti-parallel 
conformations whereas K+ can stabilise both).299 
 
2.5.3.1 Procedure involved in CD Analysis 
2.5.3.1.1 Oligonucleotides Used in CD Analysis 
The 14 selected molecules with good and moderate selectivity towards DNA/RNA hybrid 
duplexes and hTelo sequences (based on preliminary FRET results and molecular modelling 
studies) were screened against DRH (DNA/RNA hybrid duplexes), cDRH (control DNA/DNA 
duplexes), F21T (telomeric quadruplex DNA sequence) (section 2.5.1.1.1). 
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2.5.3.1.2 Methods Used for CD Analysis 
Simultaneous UV absorption and CD spectra were acquired on either Chirascan or Chirascan 
Plus spectrometers (Applied Photophysics, Leatherhead, UK). The instruments were flushed 
with pure nitrogen gas throughout the measurements. Far-UV spectra were recorded from 450 
to 200 nm with a 1 nm spectral bandwidth, 0.5 nm stepsize and a 1 s spectrometer time-per-
point. A rectangular 0.5 mm path length was employed. Unless otherwise stated, all spectra 
were measured at 25 C (temperature controller made by Quantum NorthWest, Model-
TC125). During data processing, a spectrum of the DNA media or solution was buffer-
subtracted and Savitsky-Golay smoothing with a convolution width of 5 points applied. CD 
spectra were normalized for concentration and path length and expressed in terms of molar 
ellipticity per residue. Secondary structure analyses were performed using CDPro. 
Preparation of CD-Buffer: Two types of buffer were prepared with Tris 
(Tris(hydroxymethyl)aminomethane), hydrochloric acid (HCl) and sodium chloride. For DRH 
and cDRH sequences, 50 mM Tris was prepared, adjusted to pH 7.4 with hydrochloric acid (1 
N) and labelled as 50 mM ‘Tris-HCl’. For the F21T sequence, 200 mL of buffer solution was 
prepared with 50 mM Tris and 100 mM sodium chloride in distilled water, adjusted to pH 7.4 
with hydrochloric acid (1 N) and labelled as ‘Tris-NaCl-HCl’. The buffer was stored in the 
freezer at -20 °C. 
Preparation of DNA: The oligonucleotide sequences were diluted with sterile DEPC water 
(DNA Grade, Fisher Scientific) to obtain 100 µM solutions. Five µM solutions of DNA were 
prepared using CD-buffer (Tris-HCl for DRH and cDRH, Tris-KCl-HCl for F21T). The DNA 
solutions were stored in the freezer at -20 °C. 
Preparation of Ligand Solutions: For all 14 ligands, 5 mM stock solutions were made with 
dimethyl sulfoxide (≥ 99.9 %, A.C.S. spectrophotometric grade, Sigma-Aldrich). From these 
stock solutions, 5 µM, 10 μM, 15 µM, 20 µM and 25 µM working solutions were prepared 
during experimentation with DNA solutions. 
Preparation of Sample for Binding Titration Curve: For the CD-based DNA binding titration 
assay, 1,000 µL of respective buffer was first scanned and subsequently 1 μL of ligand was 
added to the same cuvette (filled with buffer) to scan one more time. Following the first step, 
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the cuvette was cleaned properly and dried with a N2 flow. Afterwards, 1,000 μL of DNA 
solution was scanned to measure the appropriate wavelength for each type of DNA sequence. 
After determining the proper wavelength, 1 μL of ligand solution was added to the same 
cuvette to make a ligand concentration of 5 μM, which was then scanned again. Subsequently, 
an additional 1 μL of ligand solution was added into the cuvette to make the 10 to 25 µM ligand 
concentrations for each scanning. CD measurements were taken at 25 °C at a wavelength of 
200-450 nm. 
2.5.3.2 Limitations of CD spectroscopic analysis 
Measurement of circular dichroism is difficult in the presence of typical aqueous buffer systems 
that can show differential absorption of circularly polarized light. That is why 
phosphate, sulphate, carbonate, and acetate buffers are generally used, if necessary, as 
extremely dilute solutions (e.g., 10-50 mM). In the case of far-UV CD analysis, a TRIS buffer 
system is completely avoided. In some cases, fluoride needs to be substituted for chloride ion 
as fluoride absorbs less in the far-UV. To minimize solvent absorption, shorter path length 
cells (e.g., 0.1 mm) are used for the far-UV CD analysis. In addition, for  to * orbital 
absorption bands of the amide bonds lie partly in the vacuum ultraviolet region (i.e., 
wavelengths less than about 200 nm), which is essentially inaccessible in air because of the 
strong absorption of light by oxygen at these wavelengths. To eliminate this problem, a 
continuous nitrogen flow is supplied to the instrument to confirm an oxygen-free instrument. 
2.5.4 Cytotoxicity Test with MTT Assay 
Cytotoxicity is the feature of any molecule or drug showing toxicity and/or growth-inhibitory 
effect towards a targeted cell line. In research, cytotoxicity studies are broadly carried out to 
screen molecules for their cytotoxicity. It is a balancing tool to ensure a novel molecule is toxic 
to the desired cell line (for example, breast cancer cell line, MDA-MB-231) and safe for normal 
healthy cell lines, so as to avoid an adverse toxic effect. Researchers usually look for cytotoxic 
compounds to develop therapeutic agents aiming for the quickly-dividing melanoma cells or 
screen ‘hit molecules’ from preliminary high-throughput drug screenings for undesirable 
cytotoxic effects. 
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Cytotoxicity can be evaluated by using the MTT dye (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide), for which the assay is popularly known as the MTT assay. A 
colorimetric reaction is used in this assay to measure the reducing potential of the cell. In this 
assay, usually viable cells reduce the MTT reagent (2.3) to a coloured formazan product (2.4), 
which is visible under a photometer (usually between 500 and 600 nm). There are several 
tetrazolium dyes, like XTT, MTS and WSTs, which are also used in conjunction with the 
intermediate electron acceptor 1-methoxy phenazine methosulphate (PMS) for the cytotoxicity 
assay. The sulforhodamine B (SRB) assay is another cytotoxicity assay that is widely used by 
different research groups. 
The MTT assay relies on cell metabolic activity, where the MTT is reduced as a result of NADH 
formation by the metabolically active cells and thus NADP(H)-dependent cellular 
oxidoreductase enzymes reflect the number of viable cells present under defined conditions 
(Figure 2.14). These enzymes are capable of reducing the tetrazolium dye MTT (2.3) to the 
insoluble, purple-coloured formazan (2.4).303, 304 Usually, the MTT assay is carried out in dark 
conditions due to its light sensitiveness. As the NAD(H) is mostly formed within the 
mitochondria of the cell, 1-methoxy-phenazine methosulphate (2.5) is needed as the electron-
carrier to transfer the reduction equivalents from the mitochondial matrix into the medium. Due 
to its mechanism of action, the MTT assay can only detect the viable cells. Tetrazolium dye 
assays are used to evaluate the cytotoxicity (loss of living cells) or the cytostatic efficacy 
(modification from proliferation to latency of active cells) of prospective drug-like molecules 
and toxic materials. 
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Figure 2.14: Schematic diagram illustrating the conversion of MTT to formazan (purple) in 
the presence of an electron acceptor, 1-methoxy-phenazine. 
2.5.4.1 Procedure involved in MTT Assay 
2.5.4.1.1 Cell lines used for MTT Assay 
The HeLa (Cervical cancer), MDA-MB-231 (Triple negative breast cancer) and NCI H1975 
(Non-small cell lung cancer) cell lines used in this assay were obtained from the American 
Type Culture Collection (Manassas, VA). 
2.5.4.1.2 Method and Materials for MTT Assay 
The MTT assay is comprised of a number of crucial steps, from cell splitting to 96-well plate 
reading in a photometer. The steps below were followed to process the MTT assay for each 
type of cell line: 
Cell Culture: HeLa and MDA-MB231 cell lines were cultivated in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with 10% foetal bovine serum (FBS), 1% penicillin and 
streptomycin and 1% MEMNEAA (200x) non-essential amino acids. NCI H1975 cell lines were 
grown in RPMI-1640 supplemented with 10% foetal bovine serum (FBS) and 1% penicillin and 
streptomycin. These cells were maintained in an incubator at 37 °C with 5% CO2. 
Cell Passaging: Cell passaging or splitting is a procedure that allows cells to be kept alive 
and growing under culture conditions for prolonged periods. Cells should be passed when they 
are 90-100% confluent. In this process, a small number of confluent cells are transferred into 
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a new vessel since a high density of rapidly dividing cells is related to cells going into 
senescence. Suspension cultures can be simply split with a small amount of culture comprising 
a few cells diluted into a larger volume of fresh media. However, in the case of adherent 
cultures, cells first need to be detached with trypsin, and then a small number of detached 
cells can be used to seed a new culture. 
Ethanol (70%) was used to clean the fume hood, equipment, flask and pipette before starting 
any process. By that time, DPBS (Dulbecco’s Phosphate Buffered Saline) and DMEM 
(Dulbecco's Modified Eagle Medium) were taken out of the fridge to become warm and ready 
to use. Cells contained in a T-flask were taken from the incubator and checked under a 
microscope (dead cells floated and appeared round-shaped, whereas growing cells were 
attached to the bottom surface in a rod-shaped and clustered fashion). Previous media was 
aspirated by using a vacuum pump (a sharp pointed pipette, 2 mL, was used for this purpose). 
Five mL of DPBS was added to wash previous media fully and clean the T-flask, which was 
aspirated again to remove the floating dead cells as well. One mL of trypsin-EDTA was added 
to detach the growing cells and the flask was then incubated at 37 C in a 5% CO2 incubator 
for 2 minutes. Ten mL of DMEM was added to inactivate the trypsin; afterwards the total 
suspension was transferred into a falcon tube for centrifugation (2.5 minutes, 21 C, 1.5 rpm). 
All the supernatant medium was aspirated out, leaving the cells at the bottom of the tube. 
Finally, 5 mL of DMEM was added and mixed properly and an appropriate amount of cell 
suspension transferred to a newly-labelled T-flask according to the next passage time. 
Furthermore, an appropriate amount of DMEM was added to the same T-flask to make a total 
volume of 15 mL (in general, 15 mL is the optimum volume for the survival of cells in a T-flask). 
Lastly, the new T-flask was returned to the incubator (37 C, 5% CO2) for the next splitting 
schedule. Cells were passaged every 2 to 3 days. 
Cell Count and Plate Preparation (Seeding of Cells): Seeding is the process of spreading 
a defined amount (in volume or cell number) of a cell suspension onto a plate. For our 
experiments, 96-well polypropylene plates were used which are free of binding affinity for 
proteins or DNA, allowing complete sample recovery. These plates can withstand 
temperatures of -80 to +121°C. For the seeding process, initially general cell culture procedure 
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and precautions were taken (e.g., 70% ethanol was used to clean the fume hood, equipment, 
flask and pipette, DPBS and DMEM were taken from the fridge to become warm and ready to 
use, cells contained in the T-flask were taken out from the incubator and checked under a 
microscope). Afterwards previous media was aspirated by using a vacuum pump, and 5 mL 
DPBS was added to wash previous media fully and clean the T-flask, which was aspirated 
again to remove the floating dead cells as well. One mL trypsin-EDTA was added to detach 
the growing cells and the flask was incubated at 37 C in 5% CO2 incubator for 2 minutes. Ten 
mL DMEM was added to inactivate trypsin; afterwards the total suspension was transferred 
into a falcon tube for centrifugation (2.5 minute, 21 C, 1.5 rpm) and all the supernatant 
medium was aspirated out leaving the cells at the bottom of the tube. Then, 1 mL of DMEM 
was added to suspend the cells. A haemocytometer was used to count cells, where a mixture 
of cells was made with typan blue stain (10 μL cells/90 μL stain) to visualize the cells under 
an electron microscope. An appropriate amount of cell suspension was taken to make a 
dilution of cells with DMEM to confirm about 106 cells per well. Afterwards, a multichannel 
pipette was used to seed cells onto the plate, which was then returned for incubation at 37 C 
in a 5% CO2 incubator (incubation time was varied from 24-72 hours). 
 
Figure 2.15: MTT assay plate layout in general. 
Addition of Tested Sample: In this stage, the previous medium was aspirated out from every 
well by using sharp pipette tips and replaced with an equal amount (100 μL) of fresh medium 
and ligand of appropriate concentration, made from a 5 mM stock solution by using DMSO, 
which were then added onto the cell seeded plate. Lastly, the plate was returned for further 
incubation at 37 C in a 5% CO2 incubator (incubation time was varied from 24-72 hours). 
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Plate Reading and Spectrometric Analysis: The final stage was reading the data from the 
processed plate. Firstly, old medium was aspirated off from each well after the predetermined 
incubation period and subsequently each well was washed with 100 μL of medium (high 
glucose content but without phenol red). Then all medium was aspirated off from each well 
and 100 μL of previously made MTT/medium phenol red-free solution was added into each 
well. A further 4 hours of incubation was undertaken at 37 C in a 5% CO2 incubator and 
afterwards the medium was aspirated off from each well and 100 μL of DMSO added to 
dissolve the crystals formed. The plate was again incubated for 5 minutes at 37 C in a 5% 
CO2 incubator and subsequently placed in a shaker for 5 minutes (500 rpm) to remove all air 
bubbles. 
Absorbance was then taken by an Infinite 200Pro plate reader at a 570 nm wavelength and 
the data were processed with the help of Tecan i-control application software. 
Of note, MTT solution was prepared in a 1:10 dilution with phenol red-free medium; e.g., 1 mL 
of MTT was added into 9 mL of phenol red-free medium. The final solution was filtered through 
a 0.2 μM filter and kept in the dark at 4 C. Such solutions can be stored for up to a month. 
2.5.4.2 Limitations of MTT assay 
MTT assay has many limitations such as lack of sensitivity, chemical interference, toxicity, and 
batch-to-batch variation of reagents. The absorbance method of detection used by the MTT 
assay is generally less sensitive than fluorescent and luminescent methods for spotting viable 
cell number. The detection sensitivity differs widely among cell types and depends on the 
metabolic activity of the tested cell type. Usually tetrazolium reduction assays can detect 200-
1000 cells per well under ideal settings which can be improved by optimizing the concentration 
of MTT and the incubation time; although the incubation time is restricted by the toxicity of the 
MTT reagent. Assay conditions affect the chemical or enzymatic reduction of MTT. A variety 
of chemical compounds (e.g., reducing agents like ascorbic acid, glutathione, coenzyme A, 
polyphenolic compounds) are known to interfere with the MTT assay. Moreover, chemicals 
that uncouple electron transport from oxidative phosphorylation of ATP can interfere with the 
MTT assay. Continuing exposure of MTT reagent to light and high pH of the culture medium 
can also result in production of formazan and higher background absorbance. Appropriate 
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controls are necessary to avoid such chemical interferences. Riss and co-workers also 
reported that MTT reagent exhibits cytotoxic effects to eukaryotic cells. 
Although the MTT assay results associate with the number of viable cells in standard culture 
conditions, the rate of tetrazolium reduction may imitate the general metabolic activity or the 
rate of glycolytic NADH production. The rate of MTT reduction can change with pH, glucose 
content of medium and the physiological state of the cells. Mitochondria are not the only source 
of MTT reduction; more recent studies revealed that NADH is responsible for most MTT 
reduction which is associated with the cytoplasm, membranes in the endosome/lysosome 
compartment and the plasma membrane, along with the mitochondria. It is now taken into 
consideration that MTT reduction at the plasma membrane is responsible for the observation 
of formazan crystals taking place outside of cells.305, 306 
2.5.5 Preliminary Biological Evaluation 
2.5.5.1 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Assay 
Most of the methods used for studying DNA/ligand interactions are based on the polymerase 
chain reaction, or PCR, and one of the most commonly used methods in PCR is RT-PCR. This 
is a useful tool to study the interference of drug molecules with polymerase activity to obtain 
evidence about ligand-mediated stabilization of a targeted DNA sequence (for example, a G-
quadruplex DNA sequence).307 
RT-PCR is a qualitative measure of gene expression that works through the formation of 
complementary DNA (cDNA) transcripts from RNA using reverse transcriptase enzyme. Then, 
the resulting cDNA is amplified with the help of the polymerase chain reaction.308 The PCR 
procedure involves denaturation, annealing and extension reactions of the oligonucleotide to 
achieve the amplified PCR product.309 As RT-PCR is a qualitative measure for gene 
expression, it is a useful tool for detecting the mRNA expression.310 
In order to determine the gene expression for a tumour or melanoma cell growth, the RNA is 
extracted from the targeted cancer cells and subsequent synthesis of cDNA is done with the 
help of a reverse transcriptase enzyme. The desired gene and internal standards are then 
intensified using the PCR method in a separate reaction tube. Afterwards, the gel 
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electrophoresis, autoradiography and detection processes are carried out sequentially in later 
steps. Lastly, the relative measurement of gene expression is made according to the up-
regulation or down-regulation of expressed genes and by comparing the size of the bands 
(spots) of sample and control in gel electrophoresis.240 
 
Figure 2.16: Schematic representation of the steps involved in the RT-PCR process. 
To quantify the gene expression, real-time RT-PCR is also extensively used due to its quick 
screening capabilities for large numbers of samples and can be implemented with the Light 
Cycler hTERT.309, 311 Emrich and co-workers describe RT-PCR as a rapid method that 
combines amplification and detection in a single step and as a sensitive technique which is 
advantageous for a limited amount of sample.309 
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Telomerase activity has a significant relationship with the expression of human telomerase 
reverse transcriptase (hTERT).308, 312 Thus this is a useful tool to evaluate any novel drug/small 
molecule for its telomerase inhibitory efficacy. It is to be noted that hTERT mRNA is 
overexpressed or upregulated in some tumours, for example ovarian malignant tumours312 
and hepatocellular carcinoma313. As the activity of the hTERT promoter is suppressed in most 
human somatic cells, hTERT is an appropriate indicator to use to characterise the expression 
of cytotoxic genes in malignant cells.311 In 2007, Sun and co-workers reported the application 
of RT-PCR to investigate telomerase activity. The authors also suggested that hTERT 
expression is the rate-limiting factor of telomerase activity and that it could be a possible 
marker for ovarian cancer investigation.312 In 2011, Shay and co-workers established that 
treatment with cisplatin could downregulate telomerase activity and hTERT mRNA expression 
in a time- and dose-dependent manner.314 Thus both studies involving RT-PCR showed a 
significant connection between hTERT mRNA expression and telomerase activity in 
telomerase-positive cells. 
2.5.5.1.1 Procedure involved in RT-PCR Assay 
The MDA-MB-231 cell line was used in the RT-PCR assays. The cells were seeded at a cell 
density of 1 x 106 cells per well in a 6-well plate. The plate was incubated for 24 hours for cell 
attachment. After that, cells were stimulated with 1 mg/mL Escherichia coli 026:B6-LPS 
(Sigma) in LPS and compound wells. The compounds at concentrations of either 1 µM or 10 
µM were used in the cell stimulation and were incubated for 8 hours. Cell pellets of MDA-MB-
231 cells from each well (control, LPS, and LPS plus compound wells) were extracted. After 
cultivation, an RNeasy kit (Qiagen) was used to extract RNA from the cell pellets. RNA was 
reversed transcribed to a cDNA template using a High Capacity RNA-to-cDNA Kit (Applied 
Biosystems). The amplification of hTERT and cyclin B genes was performed with Platinum 
Taq DNA polymerase (Invitrogen). The primer sequence used in this study for hTERT was 5-
GGAGCAAGTTGCAAAGCATTG-3 (F) and 5-TCCCACGACGTAGTCCATGTT-3 (R).315 The 
primer sequence of cyclin B was 5-AAGAGCTTTAACTTTGGTCTGGG-3 (F) and 5-
CTTTGTAAGTCCTTGATTTACCATG-3.316 PCR amplification was performed as follows; 30 
cycles of denaturation at 95 °C for 30 sec, annealing at 55 °C for 30 sec and extension stage 
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at 72 °C for 1 minute 30 sec. The amplified products were analysed by gel electrophoresis 
using 1.5% agarose gel (Sigma) and stained with GelredTM nucleic acid gel stain 10,000 X 
(Biotium). The product band was captured under ultraviolet light. The band intensity of sample 
was compared with a control. 
2.5.5.2 Electrophoretic Mobility Shift Assay (EMSA) 
In general, the electrophoretic mobility shift assay (EMSA) is an affinity electrophoresis 
procedure by which protein/DNA or protein/RNA interactions can be studied. The assay is 
usually carried out on either a polyacrylamide (PAM) gel or agarose gel for a short period of 
1.5-2 h for a 15- to 20-cm gel.317 Upon application of a low electric field, the macromolecules 
(for example, DNA, RNA, protein) themselves and/or the drug-macromolecule conjugates 
move through the gel at a variety of speeds due to their different sizes and charges. In practice, 
the control lane (the macromolecule without any ligand or drug) contains a single band 
corresponding to the unbound oligonucleotide fragment. However, if the ligand or drug is 
capable of binding to the oligonucleotide or other macromolecules, the lane with drug (or 
compound) will show a larger band shifted up in the second ladder, ultimately indicating a 
positive sign of drug-DNA binding. 
 
Figure 2.17: The general principle of the electrophoretic mobility shift assay. 
 
Though the electrophoretic mobility shift assay was developed to study the DNA-binding 
properties of proteins, in this project the assay was primarily used to investigate the shifting of 
ligand-bound DNA compared with DNA itself.  
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2.5.5.2.1 Procedure involved in EMSA  
Electrophoretic mobility shift assays were performed as binding analyses. Band shifts were 
detected under ultraviolet light. One hundred µM of the oligonucleotide DNA/RNA hybrid 
duplex (DRH, TTAGGGTTAGGGTTTTTTGGG) was used as a control. The experiment was 
performed in 4% agarose gel. The compounds were tested at a 2.5 M concentration diluted 
with 10-times Tris Acetate EDTA (TAE) buffer. Loading conditions were as follows: the control 
well was a mixture of 10 µL of Oligo-DRH and 10 µL of TAE buffer solutions, and test wells 
were mixtures of 10 µL of Oligo-DRH and 10 µL of compound (2.5 M) solutions. Bands were 
photographed under ultraviolet light. 
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Chapter 3A: Chemistry: Results and Discussion  
3A.1 Introduction 
The DNA/RNA hybrid duplex is a unique structure within the human body which typically forms 
during the catalytic activity of the upregulated telomerase of malignant cells. In order for 
telomerase to function correctly, this heteroduplex assembly needs to go through subsequent 
association and dissociation of the RNA template from the telomeric overhang. Thus it is 
hypothesised that stabilization of the heteroduplex after association steps can stop the 
dissociation of the RNA template and successively allow the DNA to signal entry into 
senescence. Though this DNA/RNA hybrid duplex may be a unique and specific target, there 
were no previously reported works found concerning it and relating to the field of drug 
discovery. In 2010, Wheelhouse and co-workers reported 4,6-bis-[4’-[[2’’-
(dimethylamino)ethyl]-mercapto]phenyl]pyrimidine dihydrobromide as a preferential ligand for 
telomeric quadruplexes, triplex DNA structures and hybrid poly(dA)·poly(rU) heteroduplexes 
(1.23, Figure 1.37).192 Though the heteroduplex structure used in their study was not a 
telomeric DNA/RNA hybrid duplex, the authors demonstrated a bis-molecule accompanied by 
a tertiary amine tail that can interact and/or wrap around the minor groove of the DNA/RNA 
hybrid duplex. It has been confirmed that the molecule has an approximately 20-fold selection 
preference for both backbone and base orientation in the poly(dA)·poly(rU) heteroduplex over 
the comparable RNA, 7-fold over the alternative poly(rA) and 3-fold over duplex DNA. 
However, the study of Wheelhouse and co-workers in 2010 concluded that a G-quadruplex 
binder can also stabilize the DNA/RNA hybrid structure as well. Assuming this assertion to be 
true, a number of molecules were reviewed in this project to identify a suitable lead for further 
developments of new analogues which could be drug candidates. 
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Figure 3A.1: Experimental approach to develop small molecule targeting telomeric 
DNA/RNA hybrid duplex. 
In 2012, an article based on screening 2307 NCI library molecules by Rahman and co-workers 
provided new chemical scaffolds with which to develop G-quadruplex targeting agents.261 
Based on preliminary FRET melting results and previously reported key biological activity, they 
identified 13 different scaffolds (for example, bis-benzothiazole, tetrahydropyrimidine, 
hydroxystilbamidine, bis-dihydro-1H-imidazolphenylisophthalamide, bis-quinoline-amine, 
hydroxyquinoline-quinolinium, quinoline-amine-acrylamide and fused imidazo-quinoline 
scaffolds) from the NCI Diversity Set II, the NCI Natural Products Set II and the NCI 
Mechanistic Diversity Set libraries. Among these 13 scaffolds, compound NSC 273826 
showed a 20-fold binding preference towards telomeric G-quadruplex over a duplex DNA 
sequence. Additionally, the molecule was reported as active against L1210 leukaemia 
xenografts (in mice).262 This bis-quinoline-amine ligand with a heptamethylene spacer (NSC 
273829) also showed about 3.2 C stabilization towards DNA/RNA hybrid duplex structures 
(in-house unpublished data). As the compound falls into the Lipinski Rule of Five for drug-
likeness318, this project was developed to modify the compound and synthesize and/or 
rationalize the importance of the spacer length in stabilising the DNA/RNA hybrid duplex. 
To optimise the identified hit compound NSC 273829, a series of analogues were synthesized 
with the help of a molecular modelling study and solution phase chemistry. Initial molecular 
modelling suggested incorporation of a methylene spacer between the bis-intercalating group 
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and the terminal phenyl group that were connected by methylene spacers containing 4-10 
carbons. The following general structure was identified as the early synthetic candidate for this 
project. 
 
Figure 3A.2: General structure of the library-1 molecules. 
To explore further the role of methylene linkers and the terminal bis-intercalating group, a 
number of focused libraries were synthesized. The general structures of these libraries are 
summarised below. 
 
Figure 3A.3: General structures of other library molecules synthesized in this project. 
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3A.2 Molecules in Library-1 
3A.2.1 Design Rationale of Library-1 Molecules 
In the NCI library molecule NSC 273829, two 7-amino-2-methyl quinoline side arms were 
connected by a 7-methylene spacer in secondary amine form (Figure 3A.4). This project was 
designed to synthesize more analogues of NSC 273829 with increased binding affinity and 
selectivity towards DNA/RNA hybrid duplexes. In an initial attempt, molecular modelling was 
used where it was identified that the 1-benzyl-1H-benzo[d]imidazole moiety can fit into the 
telomeric DNA/RNA hybrid duplex. It was also confirmed by the molecular modelling studies 
that the single methylene spacer between benzimidazole and phenyl moieties is responsible 
for a kink the structure and the pointing of the nucleobases into the DRH duplex structure 
(Figure 3A.4). 
 
Figure 3A.4: The benzimidazole building block used in the synthesis of library-1 molecules. 
In addition, benzimidazole was used as side bulky arms with the aim of being the intercalating 
part of the molecule. It is already known that heterocyclic compounds are very commonly 
utilized in the development of new drugs with new modes of action. Among heterocyclic 
scaffolds, benzimidazole products have a very significant role due to their wide spectra of 
biological functionalities. A benzimidazole core and its analogue compounds were described 
as being physiologically and pharmacologically potent and it was observed that an application 
of this group of pharmacophores can be used for treating some diseases like epilepsy, 
diabetes and infertility. Additionally, benzimidazole core-containing molecules have 
antibacterial, antifungal, antitubercular319, antimalarial320, anti-inflammatory, analgesic, 
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antiamoebic321, antihypertensive322, antiallergic323, antikinase and anti-HIV-1324, antiulcerative, 
antioxidant and anticancer233, 325, antiproliferative 232 and antitumor326-328 activities. With the 
help of molecular modelling, benzimidazole connected with a phenylene moiety by a single 
methylene spacer was chosen for synthesis of the first set of molecules in library-1. 
To investigate the importance of the length of the methylene spacer between the two terminal 
building blocks, varied numbers of methylene linkers were utilized while keeping them relevant 
to the lead compound, NSC 273829. Moreover, phenylene and biphenylene spacers were also 
used in synthesizing library-1 molecules to evaluate the impact of rigidity on compounds 
targeting DRH sequences. 
 
 
Figure 3A.5: Comparison between library-1 molecules and NSC 273829. 
3A.2.2 Synthesis of bis-benzimidazole molecules in library-1 
The general HOBt/DIC-mediated amide coupling method, as discussed in section 2.4, was 
employed to prepare the library-1 molecules, which are shown in Table 3A.1. All the 
compounds were synthesized at room temperature using dimethylformamide as a solvent 
(general reaction scheme is shown in Figure 3A.6) and the compounds were labelled as bis-
benzimidazole molecules. Most of the reactions were straightforward and were finished after 
being left to react overnight. 
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Figure 3A.6: General synthetic scheme for library-1 molecules. 
In general, to synthesize the library-1 molecules a solution of 4-((1H-benzo[d]imidazol-1-
yl)methyl)benzoic acid (0.20 mmol) in dimethylformamide (7 mL) was treated with 1-
hydroxybenzotriazole (HOBt) (0.40 mmol) and N,N'-diisopropylcarbodiimide (DIC) (0.35 mmol) 
at room temperature. After an initial activation step (formation of activated acid ester, usually 
20-30 minutes), the respective diamine (0.24 mmol) was added to the reaction mixture and 
allowed to stir overnight. To achieve compound 3.5, after initial observation (approximately 9 
h) via LC-MS, an additional 0.10 mmol of acid was added to consume excess amine. Upon 
confirmation of bi-adduct formation via LC-MS after another 7 h, the reaction was quenched 
with water and extracted with ethyl acetate (discussed in experimental section, Appendix 1). 
Compounds 3.6 and 3.7 were also achieved via a similar process; however, compound 3.8 
could not be synthesised in this way. During quenching of the reaction with water, the reaction 
mixture formed a cloudy solution. While ethyl acetate was being used to extract the organic 
phase, a thick white precipitate was formed. This was collected by filtration and freeze dried 
to achieve the compound. Compounds 3.2 and 3.9 were also achieved by following a similar 
protocol to that used for compound 3.8. In the case of the synthesis and purification of 
compound 3.4, a similar protocol was used; however, neither the desired product’s NMR 
spectrum nor its mass-to-charge ratio (m/z) were observed in the ethyl acetate fractions. 
Hence it was decided to extract the compound by using methanol instead of ethyl acetate and 
finally the product was collected in the methanol extract but in lower amount than expected 
(yield 52%). As methanol is miscible with water (used for quenching the reaction), it was 
assumed that a portion of the compound was left in the water phase. Compound 3.3 could not 
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be purified straight away using the extraction method. Due to the presence of impurities in the 
combined ethyl acetate fractions, flash column chromatography was employed to achieve the 
pure compound 3.3. However, due to a second round of purification, a good amount of 
compound 3.3 was either lost in the mobile phase or stacked in the stationary phase and 
ultimately gave a yield of 23%. Synthesis of compound 3.10 was difficult, and in the initial ~24 
h of reaction LC-MS indicated that there was no formation of product. Hence an additional 
0.20 mmol of acid was added to the reaction mixture and left for another ~24 h to form the 
complete product. Almost two days were needed to consume all the reactant diamine and form 
the desired product, 3.10. Upon the addition of water (to quench the reaction), a white thick 
precipitate was formed (similar to compound 3.8). Ethyl acetate was added, but the whole 
reaction mixture became thicker with the addition. Afterwards, n-hexane was used in the 
reaction mixture, which allowed the total mixture to be cooled in an ice bath. Finally, the 
product precipitated  from the reaction mixture, and was removed by filtration freeze dried to 
achieve the pure compound. 
Table 3A.1: Bis-benzimidazole molecules in library-1. 
Compound 
Structure 



































3A.3 Molecules in Library-2 
3A.3.1 Design rationale of library-2 molecules  
To investigate further the role of the single methylene spacer between the phenylene ring and 
the terminal benzimidazole ring (Figure 3A.5), library-2 molecules were designed without the 
phenylene ring and the single methylene spacer. For this purpose, three types of terminal 
building blocks were used to achieve the library-2 molecules, and these were further classified 
into three sub-groups, 2A, 2B and 2C with 2-methylquinoline, 6-fluoro-2-methylquinoline and 
3H-14-indole terminal blocks, respectively. 
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Figure 3A.7: Structural variation from library-1 molecules to library-2A, -2B and -2C 
molecules and features in common with NSC 273829. 
To synthesize library-2A molecules, 2-methylquinoline was used as a terminal building block 
due to its structural similarity to the quinoline ring present in the NCI library compound NSC 
273829. Similarly, 6-fluoro-2-methylquinoline was used as a terminal building block in library-
2B molecules due to its structural similarity to the quinoline ring present in NSC 273829 and 
library-2A molecules. It has already been established that an intercalating unit should have a 
planar surface so that the molecule and/or the partial structure can sit in between the grooves 
like the filler of a sandwich. In this library of molecules, electronegative fluorine was used in 
the terminal block which would prevent the molecule from intercalating and thus provide a 
signal of importance of the single methylene spacer attached to the benzimidazole in library-
1 molecules in kinking the structure in order to fit for intercalation. To pursue a similar 
investigation, 3H-14-indole, which is similar to the terminal building block in the library-1 
molecules and commercially available, was used in the synthesis of the library-2C molecules. 
3A.3.2 Synthesis of bis-quinoline type molecules in library-2A 
Library-2A molecules were achieved by following a general HOBt/DIC-mediated amide 
coupling reaction in dimethylformamide (section 3A.1). The reactions were very 
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straightforward and quick (6-7 h) compared with those of the library-1 molecules. Most of the 
compounds were purified by column chromatography using a polar solvent system (e.g., 
dichloromethane/isopropanol, ethyl acetate/methanol) and achieved in a moderate yield (24-
65%). A general synthetic scheme and list of compounds belonging to this library are given in 
Figure 3A.8 and Table 3A.2, respectively. 
 
 
Figure 3A.8: General synthetic scheme for library-2A molecules. 
To achieve this library of molecules, 2-methylquinoline-4-carboxylic acid (0.44 mmol), HOBt 
(0.83 mmol) and DIC (0.73 mmol) were successively solubilized in dimethylformamide and 
allowed to stir at room temperature. After an initial activation step of approximately 30 minutes, 
the respective diamine (0.21 mmol) was added and allowed to react to completion to give the 
desired molecule. All the starting materials were soluble in dimethylformamide and reacted 
quickly, and thus most of the reaction had completed after 6-7 h. Distilled water was used to 
quench each reaction and the desired products were extracted with ethyl acetate (discussed 
in experimental section A.1.2). Most of the compounds were purified through flash column 
chromatography; for example, compounds 3.12 and 3.15 were obtained with 
dichloromethane/isopropyl alcohol (0-30%) and ethyl acetate/methanol (0-10%), respectively.  
However, the purification of compound 3.14 was not so direct and was not purified after an 
initial attempt using n-hexane/ethyl acetate (0-80%). Afterwards, all the crude was collected 
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via flushing with ethyl acetate (100%). Finally, ethyl acetate/methanol (0-0.5%) was 
successfully used to elute the pure desired compound.  
On the other hand, extraction and purification of compound 3.13 was long and difficult. During 
the extraction process, upon the addition of 15% lithium chloride in aqueous solution, the 
reaction mixture formed a fluffy, insoluble layer which was filtered and dissolved in methanol. 
As LC-MS showed some impurities in the methanol were contained in the product, and so 
petroleum ether was used to precipitate the product in methanol. Upon addition of a small 
amount of petroleum ether, the product precipitated in the round bottomed flask within an hour. 
Finally, the product was filtered, washed with water and freeze dried to achieve the pure 
compound.  
Compound 3.16 also formed a yellow precipitate during the extraction process with ethyl 
acetate; the precipitate was filtered and dissolved in methanol. Finally, the product was purified 
by flash column chromatography using ethyl acetate/methanol/2M ammonia solution in 
methanol (80/15/5).  
Extractions of compounds 3.17 and 3.18 were also tried with ethyl acetate, but the reaction 
mixture generated a fluffy layer during the extraction process. This was removed by filtration 
and freeze dried to give 3.17 and 3.18 in 38% and 55% yields, respectively.  
However, compound 3.13 was obtained by recrystallization from ethyl acetate and 15% lithium 
chloride in aqueous solution, and compounds 3.17 and 3.18 were collected following the 
freeze drying of the ethyl acetate fraction of the crude reaction mixture. 
Table 3A.2: Bis-quinoline molecules in library-2A. 
Compound 
Structure 
(Chemical name, formula, MW, logP) 
Yield (%) 



























3A.3.3 Synthesis of bis-(6-fluoro-2-methylquinoline) molecules in library-2B  
Library-2 molecules were synthesized by using 6-fluoro-2-methylquinoline-4-carboxylic acid 
(0.24 mmol), HOBt (0.49 mmol) and DIC (0.43 mmol). As all of the starting materials were 
soluble in dimethylformamide (DMF), all reactions used to synthesize this library of molecules 
were carried out in DMF. Respective diamines (0.12 mmol) were added into the stirred reaction 
mixtures after the initial activation step. The general reaction scheme is shown below (Figure 
3A.9). A total of six molecules were synthesized in this library, listed in Table 3A.3. 
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Figure 3A.9: General synthetic scheme for library-2B molecules. 
Water was used to quench each reaction and extractions were made with ethyl acetate. The 
combined organic phases were washed with a saturated aqueous solution of sodium 
bicarbonate, dried over magnesium sulphate, filtered and concentrated. Compound 3.23 was 
purified by flash column chromatography using n-hexane/ethyl acetate (0-70%). 
The reactions for compounds 3.24 and 3.25 were longer, approximately 24 h. In both cases, 
additional acid (0.24 mmol) was added to force the reaction to completion, but there was no 
change in the rate of diamine consumption (by the acid). Finally, the reactions were finished 
after a day and products were purified by flash column chromatography. The reaction to 
synthesize compound 3.22 was finished after around 15 h; however, the initial attempt at 
purification with dichloromethane/ethyl acetate/methanol (97/2/1) was not successful. The 
desired product was eluted with impurities within first three column volumes of mobile phase. 
Then the combined organic phases were dried and purification was attempted by 
recrystallization with dichloromethane and diethyl ether. The process was successful though 
the yield was very low (25%).  
Similarly, a recrystallization process was applied to purify compounds 3.20 and 3.21 by using 
dichloromethane and diethyl ether, with low yields achieved in both cases. The reaction times 
for compounds 3.20 and 3.21 were shorter (approximately 7.5 h) compared with the other 
members of this library, which was assumed to be a benign cause of poor yield and also 
indicated that not all of the starting materials were consumed in the reaction. As the required 
amounts of compounds were obtained, reactions for longer periods were not tried. 
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Table 3A.3: Bis-(6-fluoro-2-methylquinoline) molecules in library-2B. 
Compound 
Structure 





























3A.3.4 Synthesis of bis-indole molecules in library-2C 
Library-2C molecules were synthesized to compare them with the library-1 molecules to find 
the importance of the phenylene in between the benzimidazole and amide functionalities of 
the library-1 molecules. In this library of molecules, the benzimidazole was replaced by an 
indole structure and the phenylene group was removed to establish the importance of the 
single methylene spacer in between the benzimidazole and phenylene. In this synthesis, 1H-
indole-5-carboxylic acid was used as the side arms, which were connected by a methylene 
spacer through amide bonding. The general reaction scheme and list of compounds are 
presented in Figure 3A.10 and Table 3A.4, respectively. 
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Figure 3A.10: General synthetic scheme for library-2C molecules. 
 
To synthesize the library-2C molecules, 1H-indole-5-carboxylic acid (0.16 mmol), HOBt (0.31 
mmol) and DIC (0.27 mmol) were used and the reactions were carried out in 
dimethylformamide for better solubility. The respective diamines were added to the reaction 
mixture after the initial activation step. Similar to the previous library of molecules, reactions 
were quenched with water and extracted with ethyl acetate. The organic phases were 
combined, washed with a saturated aqueous solution of sodium bicarbonate, dried over 
magnesium sulphate, filtered and concentrated.  
Reaction time was varied from reaction-to-reaction, but in most cases was 20-36 h. For 
example, compound 3.27 was formed after ~24 h reaction time, then extracted (discussed 
earlier) and purified by flash column chromatography with n-hexane/ethyl acetate (0-70%). 
The longest time was for synthesizing compound 3.31, which was 36 h. All compounds were 
purified by flash column chromatography by using either n-hexane/ethyl acetate or 
methanol/ethyl acetate. Though the reaction times were longer than for the other molecules, 
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Table 3A.4: Bis-indole molecules in library-2C. 
Compound 
Structure 
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3A.4 Molecules in Library-3 
3A.4.1 Design Rationale of Library-3 Molecules 
For further investigation of structural features in the library-1 molecules, 7-fluoro-1,2,3,4-
tetrahydroacridine (3.32) and 2-fluoro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinoline moieties 
(3.37) were incorporated as the terminal blocks in library-3 molecules, where it was tried to 
keep structural correlation between the other library molecules and the lead NCI compound. 
The library-3 molecules were classified into two sub-groups, 3A and 3B, according to the 
terminal building blocks. 
In the library-3A, terminal 7-fluoro-1,2,3,4-tetrahydroacridine moieties were used to generate 
some extent of bulkiness within the compound as well as to distort structural planarity due to 
the attached cyclohexane ring. This was hypothesized and confirmed through a 3D view of 
the molecule (Figure 3A.11) that the cyclohexane moiety would not be in the same plane as 
the methyl-quinoline moiety and thuswould make a kink in the ring structure and prevent the 
intercalation process. Similar approaches were used in the synthesis of library-3B molecules 
using 2-fluoro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinoline moieties. 
 
Figure 3A.11: Effect of the insertion of cyclohexyl and cycloheptyl rings in library-3A and -
3B; 3D view shows the distortion in the molecule’s planarity. 
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3A.4.2 Synthesis of bis-acridine type molecules in library-3A  
In this library, a total of four compounds were synthesized using 7-fluoro-1,2,3,4-
tetrahydroacridine-9-carboxylic acid (0.31 mmol), HOBt (0.61 mmol) and DIC (0.57 
mmol).These starting materials were dissolved in dimethylformamide and allowed to stir to 
reach the activation stage. Afterwards, the respective diamines (0.15 mmol) were added and 
allowed to stir overnight (approximately 15 h). Reactions were straightforward and upon 
confirmation of the consumption of all the starting material, the reactions were quenched with 
water and subsequently extracted with ethyl acetate. Organic phases were combined and 
washed with an aqueous solution of sodium bicarbonate and dried over magnesium sulphate, 
filtered and concentrated. The general reaction scheme and compound details are reported in 
Figure 3A.12 and Table 3A.5, respectively. 
 
Figure 3A.12: General synthetic scheme for library-3A molecules. 
All the compounds were purified by flash column chromatography with ethyl acetate/methanol 
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Table 3A.5: Bis-acridine type molecules in library-3A. 
Compound 
Structure 
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In the case of compound 3.34, automated flash chromatography was used for purification with 
4% methanol in ethyl acetate; this was assumed to be the cause of the low yield as higher 
percentages of methanol can elute the product faster, but with impurities. 
 
3A.4.3 Synthesis of bis- (2-fluoro-7,8,9,10-tetrahydro-6H-cyclohepta[b] quinoline-11-
carboxamide in library-3B  
In this synthesis, 2-fluoro-7,8,9,10-tetrahydro-6H-cyclohepta[b] quinoline-11-carboxylic acid 
was used as terminal building blocks, connected by a methylene spacer through amide 
bonding. A suspension of 2-fluoro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinoline-11-
carboxylic acid (0.48 mmol) was stirred in dichloromethane with HOBt (0.96 mmol) and DIC 
(0.84 mmol) at room temperature. Dichloromethane was used as solvent for this class of 
molecule due to the acid’s solubility in dichloromethane. After the initial activation step, the 
respective diamines (0.20 mmol) were added and the reactions left until completion. Upon 
confirmation of this by LC-MS and TLC, reactions were quenched with water and extracted 
with ethyl acetate. Organics were combined, washed with a saturated aqueous solution of 
sodium bicarbonate, dried over anhydrous magnesium sulphate, filtered and concentrated. A 
total of six compounds were synthesized in this library. The general reaction scheme and list 
of compounds are recorded in Figure 3A.13 and Table 3A.6, respectively. 
 
Figure 3A.13: General synthetic scheme for library-3B molecules. 
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The first molecule of this library, 3.40, could not be achieved as a bis-adduct, although the 
starting materials were consumed after 24 h reaction time. To synthesize the bis-amide-
coupled material, an initial mono-amide product was purified by flash column chromatography 
using n-hexane/ethyl acetate (0-40%). Organics were combined and dried under vacuum. 
Thereafter, the mono-adduct compound was allowed to react again with additional acid (0.19 
mmol), DIC (0.33 mmol) and HOBt (0.38 mmol). Overnight, the reaction reached completion 
and formation of the desired product was identified by LC-MS. Finally, purification was carried 
out by flash column chromatography with ethyl acetate/methanol (0-1%) to give 3.40 as a pale 
yellow solid. Similar difficulties were encountered during the synthesis of compound 3.39.  
However, in this case the protocol followed for compound 3.40 did not work here; instead, a 
new reaction was carried out in dimethylformamide and, surprisingly, the reaction was finished 
after 17 h and the desired compound 3.39 was formed. The reaction was quenched with water 
and extracted with ethyl acetate. More importantly, the pure compound was obtained from the 
combined organic phases (ethyl acetate) without need of further purification. 
The reaction to produce compound 3.38 took an exceptionally long time. In this synthesis, 
additional acid (0.48 mmol), HOBt (0.96 mmol) and DIC (0.84 mmol) were added to the 
reaction mixture after 36 h to force the reaction to completion. Finally, the reaction was 
completed after three days and the compound was purified by the ‘Catch and release method’ 
using a 10 g SCX-2 cartridge. However, none of the reactions required second time setup 
and/or addition of extra acid and coupling reagents, and most of them were completed after 
being left overnight (approximately 12-14 h).  
Compounds 3.41, 3.42 and 3.43 were obtained by following a similar purification technique as 
that followed for 3.40. 
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Table 3A.6: Bis- (2-fluoro-7,8,9,10-tetrahydro-6H-cyclohepta[b] quinoline-11-carboxamide 
molecules in library-3B. 
Compound 
Structure 



























3A.5 Molecules in Library-4 
3A.5.1 Design Rationale of Library-4 Molecules 
To investigate whether the flexibility of the methylene spacers is essential to bis-intercalate 
with and stabilise the DNA/RNA hybrid duplex, and whether groove binding can be a possible 
mode of action to stabilise the DNA/RNA hybrid structure, library-4 molecules were 
synthesized using rigid and planar linkers. Additionally, six types of tertiary amine-containing 
side arms were utilized, assuming their conversion in situ into positively-charged species 
which would be attracted towards the minor groove of the DNA/RNA hybrid duplex sequence 
through electrostatic interactions. 
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Figure 3A.14: Structural features of library-4 molecules. 
 
3A.5.2 Synthesis of bis-benzofuran molecules in library-4 
Library-4 molecules were synthesized to rationalize the importance of flexibility as a minor 
groove binding agent for the telomeric DNA/RNA hybrid structure. All the molecules in this 
library were synthesized using biphenylene and/or bipyridine spacers, where the carbon 
number within the spacer unit was the same as the ‘hit’ compound 3.6, which was eight. A 
total of thirteen molecules were synthesized in this library (listed in Table 3A.7), by using [2,2-
bipyridine]-5,5-dicarboxylic acid (3.44), [1,1-biphenyl]-4,4- dicarboxylic acid (3.45) and [2,2-
bipyridine]-4,4-dicarboxylic acid (3.46) as spacer units to connect the benzofuran (3.47) 
structure at the 5-C position. 
Additionally, six tertiary amine tails (3.48-3.53, Figure 3A.15) were also connected at the 2-C 
position of the benzofuran moiety (3.47, Figure 3A.15) by amide coupling reactions to achieve 
a monoamide-coupled product. To achieve the tertiary amine tail-linked product, three major 
types of tertiary amines were chosen (for example, dimethyl azane, pyrrolidine and pyridine) 
and the connecting methylene spacer was varied in length from 3-4 carbons. 
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Figure 3A.15: Main building blocks used in the synthesis library-4 molecules. 
The final compound was achieved after 3 steps of reaction. Initially, a solution of 5-
nitrobenzofuran-2-carboxylic acid in dichloromethane was reacted with tertiary amine tails in 
the presence of HOBt and DIC. Every reaction finished after 1-2 h and the amide-coupled 
product was purified using SCX-2 cartridges by the ‘Catch and release method’ (see section 
2.3.2). 
 
Figure 3A.16: Monoamide coupled product (1st step) 
In the second step, a hydrogenation process was employed to obtain 5-NH2 products of 3.54-
3.59. To achieve this, the reactant compound (3.54-3.59, Figure 3A.16) was dissolved in 
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either ethyl acetate or ethanol (maximum 150 mL) and a slurry of 10% Pd/C (10% w/w 
compared with the reactant) in the same solvent was added. The mixture was hydrogenated 
in a Parr Hydrogenator at 35-40 mbar until the H2 uptake was finished. The progress of the 
reaction was monitored by either TLC or LC-MS. The reaction mixture was filtered through a 
layer of celite (diatomaceous earth) and the residue washed with either ethyl acetate or 
ethanol. The solvent was removed under vacuum using a rotary evaporator to obtain the 
reduced product (3.60-3.65, Figure 3A.17). 
 
Figure 3A.17: Hydrogenated monoamide-coupled product (2nd step) 
 
In the final step, the hydrogenated monoamide-coupled product was reacted with either [2,2-
bipyridine]-5,5-dicarboxylic acid (3.44) or [1,1-biphenyl]-4,4-dicarboxylic acid (3.45) to 
achieve the bis-amide molecules. Only one compound, 3.68, was synthesized by using [2,2-
bipyridine]-4,4-dicarboxylic acid (3.46) as a spacer to evaluate the correlation between the 
curvature of the compound and binding affinity towards the telomeric DNA/RNA hybrid duplex 
sequence. The general reaction scheme is described in Figure 3A.18. 
 




Figure 3A.18: General scheme of reaction involved in the synthesis of library-4 molecules. 
 
Library-4 molecules were difficult to purify though all of them have a tertiary amine, which is 
believed to be stacked in the strong cation exchange sorbent within SCX-2 cartridges. In an 
initial attempt, the reaction mixture was poured through the activated cartridge and impurities 
allowed to elute out. However, it was observed that the cartridge became blocked by the 
stacked molecules within it, and thus did not allow any solvent to pass through. In the 
preliminary trial, the cartridge needed to be broken to obtain the slurry of silica mixed with the 
desired compound, which was then re-dissolved in methanol and filtered to collect the product. 
However, the product was not pure enough as the methanol dissolved a small amount of silica, 
which was mixed with the compound. To avoid this problem, compounds were purified in a 
different way. Firstly, the reaction mixture was placed in a round bottomed flask and a small 
amount of toluene (5-6 mL) was added to it. Subsequently, n-hexane was added in excess 
amount to form a cloudy solution that finally created a white precipitate of compound. 
Afterwards, the precipitate was collected on a sintered funnel and roughly dried under vacuum. 
LC-MS confirmed the respective product mass-to-charge (m/z) ratio, which ultimately 
confirmed the success of the purification. To achieve the highest compound purity, the product 
was washed with acetonitrile/water (50/50) and freeze dried. LC-MS, 1H NMR, 13C NMR, IR 
and HRMS analyses were carried out to check the compound’s quality and purity. 
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Table 3A.7: Bis-benzofuran type molecules in library-4. 
Compound 
Structure 
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Chapter 3B: Biophysical and Biological Evaluation: Results 
and Discussion 
3B.1 Fluorescence Resonance Energy Transfer (FRET) Assay 
Firstly, the library-1 molecules were assessed against the telomeric DNA/RNA hybrid duplex 
(DRH) sequence (TTA-GGG-TTA-GGG-TTT-TTT-CCC-UAA-CCC-UAA) along with a control 
cDRH DNA sequence (a hairpin DNA sequence in which the uridine (U) of the DRH duplex 
sequence had been replaced with thymidine (T)). According to the preliminary biophysical 
observations (see Table-3B.1), compound 3.6 was the most selective towards the DRH duplex 
compared with the cDRH (where RNA bases of DRH were replaced by corresponding DNA 
bases) structure (i.e., a 9-folds selectivity), stabilizing the heteroduplex by ΔTm values of 9.5 
and 7.2 C at 2 M and 1 M ligand concentrations, respectively. In the case of library-1 
molecules, chains of 3 and 5-10 methylene units were used for the central spacer, which 
connected to the 1-benzyl-1H-benzo[d]imidazole units via amide linkages (Figure 3B.1). 
Compared with NSC 273829, compound 3.6 was modified by changing the length of the 
spacer, in addition to including phenyl (compound 3.9) and biphenyl (compound 3.10) units to 
determine the impact of flexibility and rigidity on binding to the minor groove of telomeric 
DNA/RNA hybrid duplex sequences. Interestingly, it had been known for some time that there 
was a correlation between the linker length connecting the 1-benzyl-1H-benzo[d]imidazole 
units and DRH stabilizing activity, and this was further confirmed by molecular modelling and 
dynamics studies (section 3B.2). 
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Figure 3B.1: Structural features and highlighted modifications in library-1 molecules. 
According to Table 3B.1 (i.e., data from the FRET melting assay), DRH stabilizing activity 
could be ranked in the order 3.6 > 3.8 > 3.5 > 3.7 > 3.10 > 3.3 > 3.4 > 3.2 > 3.9 at a 1 M 
ligand concentration, whereas stabilizing activity for cDRH was very poor. In a DNA targeting 
drug design study, selectivity of novel molecules towards the targeted DNA compared with 
control duplex DNA is desirable to eliminate unwanted toxicity. 
In this study, a duplex hairpin DNA structure (labelled as cDRH) was used as a control, and to 
evaluate selectivity toward the targeted DNA/RNA hybrid duplex. It was observed that 3.4, 3.6 
(Figure 3B.2) and 3.8 were the most selective toward the DNA/RNA hybrid duplex compared 
with the control sequence. In molecules 3.9 and 3.10, the flexible methylene spacer had been 
replaced with the planar phenyl (4-carbon distance) and biphenyl units (8-carbon distance) to 
establish the impact of flexibility or rigidity of structure on DNA-drug binding. However, 3.9 and 
3.10 did not show either improved selectivity or stabilization towards the DNA/RNA hybrid 
duplex. Molecular modelling and molecular dynamics studies suggested the possible reasons 
for the lower activities of 3.9 and 3.10 (see Section 3B.2.1). 
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(a)                                                                         (b) 
Figure 3B.2: FRET melting curve for compound 3.6 at three concentrations (5 M, 2 M and 
1 M), where (a) change of intensity of fluorescence over the change of temperature (-dI/dT) 
and (b) increment of fluorescence due to increase of temperature. 
Table 3B.1: FRET melting assay results for library-1 molecules with telomeric DNA/RNA 
hybrid duplex (DRH) and control cDRH sequences. 
Compound 




2 M 1 M 2 M 1 M 2 M 1 M 
3.2 2.4±0.2 0.6±0.0 1.8±0.1 0.5±0.0 1.3 1.2 
3.3 5.4±0.2 2.4±0.0 1.5±0.0 0.6±0.0 3.6 4.0 
3.4 5.6±0.3 2.3±0.0 3.3±0.1 0.2±0.0 1.7 11.5 
3.5 8.6±0.2 4.5±0.0 3.2±0.2 1.3±0.0 2.7 3.5 
3.6 9.5±0.1 7.2±0.0 1.3±0.1 0.8±0.0 7.3 9.0 
3.7 6.8±0.3 4.5±0.5 2.3±0.2 1.2±0.0 2.9 3.7 
3.8 8.2±0.1 6.8±0.0 1.4±0.3 0.9±0.0 5.9 7.6 
3.9 1.2±0.0 0.5±0.0 0.8±0.2 0.3±0.0 1.5 1.7 
3.10 3.6±0.1 3.2±0.0 1.2±0.4 0.6±0.0 3.0 5.3 
 
Library-1 molecules were also assessed against the telomeric G-quadruplex sequence (hTelo) 
F21T. A dual-labelled oligonucleotide sequence that forms an intramolecular G-quadruplex 
structure in the presence of a monovalent cation (Na+/K+) was used for the quadruplex 
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stabilization assay. In this study, the FAM-TAMRA dual-labelled oligomer (5´d-GGG-TTA-
GGG-TTA-GGG-TTA-GGG-3´) was used to represent the F21T DNA sequence. Library-1 
molecules provided a good stabilizing efficacy for the F21T sequence, with ΔTm values ranging 
from 5.8-9.0 C and 4.5-6.5 C at 2 M and 1 M ligand concentrations, respectively (Table 
3B.2). Compound 3.6 showed moderate stabilization of the hTelo sequence (ΔTm = 8.8 and 
6.5 C at 2 M and 1 M ligand concentrations, respectively), which suggested that it might 
be a good candidate for further development as a dual mechanism telomerase inhibitor that 
could stabilize both the telomeric DNA/RNA hybrid duplex and the hTelo sequence (either by 
intercalating and/or minor groove binding). 
 
Table 3B.2: FRET melting assay results for library-1 molecules with telomeric G-quadruplex 
(F21T) and control duplex DNA (cDDS) sequences. 
Compound 




2 M 1 M 2 M 1 M 2 M 1 M 
3.2 3.5±0.0 1.4±0.0 1.0±0.1 0.8±0.0 3.5 1.7 
3.3 8.8±0.1 5.8±0.0 1.3±0.2 1.0±0.0 6.8 5.8 
3.4 5.8±0.3 4.5±0.0 1.2±0.0 0.8±0.0 4.8 5.6 
3.5 8.5±0.0 5.5±0.0 1.2±0.2 1.0±0.0 7.1 5.5 
3.6 8.8±0.4 6.5±0.0 1.0±0.0 0.7±0.0 8.8 9.3 
3.7 9.0±0.2 6.5±0.0 1.5±0.2 0.9±0.0 6.0 7.2 
3.8 7.8±0.2 6.2±0.0 1.5±0.2 0.8±0.0 6.0 7.5 
3.9 1.6±0.2 0.2±0.0 1.1±0.1 0.3±0.0 1.5 0.7 
3.10 1.5±0.2 0.5±0.0 1.0±0.3 0.5±0.0 1.5 1.0 
 
However, upon changing the methylene spacer to a planar structure with non-flexible 
phenylene and biphenylene spacers (i.e., 3.9 and 3.10), the stabilization properties dropped 
to 0.2 and 0.5 C, respectively, at the same concentration. Interestingly, reducing the 
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methylene spacer to a three-carbon length (3.2) also caused a noticeable decrease in 
stabilizing effect (i.e., ΔTm = 1.4 C at 1 M concentration). 
The other library molecules were also evaluated by FRET melting assay against telomeric 
DNA/RNA hybrid duplexes (DRH), telomeric G-quadruplex sequences (F21T) and two control 
DNA duplex sequences (i.e., cDRH and cDDS) at 5, 2 and 1 M ligand concentrations. 
However, none provided stabilization of 0.5 C at the highest ligand concentration (i.e., 5 M) 
toward the telomeric DNA/RNA hybrid duplex. 
Interestingly, the molecules in library-3B showed moderate DRH stabilization properties (i.e., 
ΔTm = 3.2-6.5 C for 2 M conc. and ΔTm = 2.3-3.5 C for 1 M conc.), while a 2 M 
concentration of library-3B molecules also stabilized the cDRH sequence by a significant 
amount (i.e., ΔTm = 1.3-3.3 C). Thus, the FRET melting result for library-3B molecules 
indicated that they were non-selective binders of the DRH sequence. Individual FRET melting 
temperatures are listed in Table 3B.3. 
Table 3B.3: FRET melting assay results for library-3B molecules with telomeric DNA/RNA 
hybrid duplex (DRH) and control cDRH sequences. 
Compound 




2 M 1 M 2 M 1 M 2 M 1 M 
3.38 6.5±0.1 3.5±0.0 2.3±0.0 0.5±0.0 2.8 7.0 
3.39 5.5±0.2 3.3±0.0 3.3±0.0 0.8±0.0 1.7 4.1 
3.40 3.2±0.0 2.3±0.0 2.3±0.1 1.2±0.0 1.4 1.9 
3.41 5.5±0.3 3.4±0.0 3.2±0.0 1.3±0.0 1.7 2.6 
3.42 6.5±0.1 3.2±0.0 1.3±0.1 0.8±0.0 5.0 4.0 
3.43 4.7±0.2 2.3±0.0 2.2±0.1 1.2±0.0 2.1 1.9 
In addition, the library-3B molecules caused moderate stabilization of the hTelo DNA 
sequence (F21T) with ΔTm values of 3.5-7.5 C (at a 2 M ligand concentration) and 2.0-4.5 
C (at a 1 M ligand concentration), which are presented in Table 3B.4. According to the FRET 
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melting data for library-3B molecules, it was observed that 3.38 (i.e., contains a five methylene 
spacer) was selective towards both DRH and hTelo sequences compared with the respective 
control DNA sequences at a 1 M ligand concentration, which suggested further investigation. 
Table 3B.4: FRET melting assay results for library-3B molecules with telomeric G-quadruplex 
(F21T) and control duplex DNA (cDDS) sequences. 
Compound 




2 M 1 M 2 M 1 M 2 M 1 M 
3.38 4.8±0.2 4.5±0.0 1.2±0.2 0.7±0.0 4.0 6.4 
3.39 6.5±0.1 4.5±0.0 1.4±0.2 0.9±0.0 4.6 5.0 
3.40 3.5±0.0 2.5±0.0 1.1±0.2 0.6±0.0 3.2 4.2 
3.41 7.5±0.6 2.7±0.5 1.0±0.0 0.5±0.0 7.5 5.4 
3.42 6.5±0.2 3.5±0.0 1.5±0.2 0.7±0.0 4.3 5.0 
3.43 5.3±0.3 2.0±0.0 1.3±0.0 0.8±0.0 4.1 2.5 
 
A double-labelled 45-base pair DNA sequence was used in this study as a control (cDDS, 
Section 5B.1.1). As the designed molecules of library-1 were synthesized based on the NCI 
diversity set, it was expected that the synthesized analogues would not stabilize duplex DNA. 
However, a few of them did, at the lower ΔTm values of 0.5-1.5 C for a 1 M ligand 
concentration. It was assumed that the dimethyl sulfoxide (DMSO) used to dissolve the 
molecules prior to assay may cause some degree of stabilization, so control experiments were 
carried out. It was also confirmed by FRET melting experiments that the lead compounds 3.3, 
3.6 and 3.8 gave ΔTm values of 0.2-0.9 C at a 1 M concentration with control duplex DNA 
indicating a profound selectivity for DRH sequences versus duplex DNA sequences. 
To study the impact of the spacer unit on affinity for the telomeric DNA/RNA hybrid duplex 
sequence, several new molecules were synthesized. According to FRET results, ΔTm values 
were reduced by approximately 50% when the methylene spacer was increased or decreased 
in length from the optimum. Compound 3.6 was also transformed into a rigid structure by 
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replacing the flexible methylene chain with -electron-containing phenylene and biphenylene 
moieties (e.g., 3.9 and 3.10 respectively). For these molecules, only a 0.2-0.5 C increase in 
ΔTm was observed for the telomeric DNA/RNA hybrid duplex with a much higher affinity for 
duplex DNA. The conformation and geometry of standard duplex DNA is much wider than that 
of A-form hybrid duplex DNA, in which the minor grooves are much narrower and tighter, which 
could explain the observed results. Additionally, in order to intercalate between nucleobases, 
a molecule needs to be either crescent-shaped or more planar with the presence of a -
system. Thus the results suggest that the 8-methylene spacer is the ideal length for binding to 
the targeted hybrid duplex DNA sequence and allows the molecule to bis-intercalate into the 
nucleobases of the hybrid duplex. Moreover, this linker length is sufficiently flexible towards 
the minor groove of the hybrid duplex and allows the molecule to wrap around the hybrid 
structure as well as intercalate in-between nucleobases within the terminal planar -system 
scaffold. 
3B.2 Molecular Modelling and Molecular Dynamics (MD) Studies2 
Molecular modelling comprises both theoretical methods and computational techniques that 
can be employed together to model or imitate the behaviour of molecules toward specific DNA 
sequences or protein structures. They are used in the areas of drug design and computational 
biology for studying molecular systems, where molecules ranging from small chemical 
scaffolds to large biological macromolecules can be analysed. A common feature of molecular 
modelling techniques is the atomistic level of description of a chemical scaffold. 
Molecular dynamics were undertaken using AMBER v11329 to rationalize the stabilisation of 
the telomeric DNA/RNA hybrid duplex sequence 5-TTA-GGG-TTA-GGG-TTT-TTT- CCC-
UAA-CCC-UAA-3 by compounds 3.4 and 3.6 (Figure 3B.3) compared to other members of 
library-1 (for example, compound 3.3). The minor groove of the hybrid sequence was chosen 
as the likely point of interaction for the molecules due to the similarity in structure of the 
molecules to the minor groove binders propamidine330 and pentamidine331. A previous study 
                                                     
2 The molecular modelling and molecular dynamics studies described here were carried out by Dr Paul J M Jackson 
and Mr Meir Touitou within the Institute of Pharmaceutical Sciences (IPS) at King’s College London. 
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has suggested that DNA/RNA hybrid duplex-interactive molecules may act at least partly 
through an intercalation mechanism192, so intercalation was also investigated as a potential 
mode of binding. In order to investigate their mechanisms of action, selected molecules in the 
series (for example, compounds 3.3, 3.6 and 3.7 and 3.8) were docked in the minor groove 
and simulations were carried out over a time period of 10 ns in implicit solvent. 
 
Figure 3B.3: Molecular model of the DNA/RNA hybrid duplex (5-TTA-GGG-TTA-GGG-TTT-
TTT- CCC-UAA-CCC-UAA-3). The RNA strand is represented in red and the DNA strand in 
grey. DNA and RNA bases are indicated in stick form. 
The results from simulations suggested that both compounds 3.4 and 3.6 (molecules with 9- 
and 11.5- fold selectivity for the telomeric DNA/RNA hybrid duplex over the cDRH sequence 
at concentrations of 1 μM, respectively) have a potential dual mechanism of action, whereby 
most of the molecule binds in the minor groove but both the benzimidazole moieties may 
concurrently intercalate into the DNA. This intercalation process is facilitated by the CH2 group 
between the phenyl and benzimidazole moieties, which allows flexibility of the benzofused 
moiety and a favourable change in curvature of the ligand. 
In the case of compound 3.6, the flexible octamethylene linker appears to form favourable van 
der Waal’s interactions with the central TA portion (i.e., T8:A23, T9:A22), with one 
benzimidazole moiety intercalating between G10:C21 and G11:C20 and the second 
benzimidazole intercalating between T7:A24 and T8:A23. As such, the molecule spans four 
base-pairs (5’-TTA-G-3’) (Figure 3B.4). Therefore, it is proposed that the synchronous minor 
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groove binding and intercalating ability of both 3.4 and 3.6 contribute significantly to their 
enhanced affinity for telomeric DNA/RNA hybrid duplex sequences. 
To investigate further the interaction of this molecule set with cDRH, simulations in implicit 
solvent were also undertaken of compounds 3.3, 3.6 and 3.7 interacting with a duplex DNA 
sequence (i.e., 5-TTA-GGG-TTA-GGG-TTT-TTT-CCC-TAA-CCC-TAA-3) equivalent to the 
DNA/RNA hybrid duplex structure. In these simulations, 3.3, 3.6 and 3.7 remained in the minor 
groove of the DNA for the duration of the simulation, occupying a similar orientation to 
pentamidine and propamidine and forming van der Waal’s interactions with the DNA bases 
below. However, in these experiments, the benzimidazole moieties of the molecules did not 
intercalate into the DNA but instead oriented at angles perpendicular to the central methylene 
linker of the ligand (Figure 3B.4). This difference in interaction (i.e., intercalation with the DRH 
sequence but not with the cDRH sequence) was further supported by free energy of binding 
calculations (kcal/mol) for each ligand in implicit solvent, which indicated a greater affinity of 
each of the library-1 molecules for the telomeric DNA/RNA hybrid duplex compared with the 
control cDRH sequence. 
 
Figure 3B.4: Snapshot of a 10ns implicit solvent molecular dynamics simulation of 
compound 3.6 (blue spheres) interacting with DRH. Both benzimidazole moieties of the 
molecule intercalate between base pairs; one between G11:C20 and G10:C21 (green) and 
the second between A23:T8 and A24:T7 (both yellow). 
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Figure 3B.5: Snapshot of a 10ns explicit solvent molecular dynamics simulation of 
compound 3.6 (blue and yellow spheres) interacting with the control duplex sequence, 
cDRH. Both benzimidazole portions (yellow) point away from the DNA groove and do not 
interact with the cDRH. 
Simulations of 3.8 illustrate the molecule binding to DRH in a similar manner to that of 
compound 3.6. The central methylene linker forms non-covalent interactions with the central 
tract of DNA (in this instance the sequence 5-GTTA-3), and forms a dual intercalation in the 
DRH structure (between G4:C27 and G5:C26 A9, and between nucleobases A9 and G10) 
(Figure 3B.6). It is likely that this intercalation contributes to the molecule’s moderate 
observed stability of DRH (6.8 °C in FRET melting experiments). This feature, coupled with its 
ability to bind to a long (seven base-pair) sequence, may also explain the potent cytotoxicity 
observed for the molecule. Free energy of binding calculations also suggest that 3.4 
possesses a preference for DRH compared with the control cDRH DNA sequence. 
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Figure 3B.6: Snapshot of a 10ns implicit solvent molecular dynamics simulation of 3.8 (blue 
spheres) with DRH. Both benzimidazole moieties of the molecule intercalate the sequence; 
one between G4:C27 and G5:C26 (green) and the second between the A9 and A10 
nucleobases (yellow). 
Further support for the superior interaction of library-1 molecules with the DRH sequence was 
evident from the fact that the molecules do not have the same curvature (“isohelicity”) as DNA 
minor groove binders (for example netropsin332 or pentamidine331), and the shallower topology 
of the telomeric DNA/RNA hybrid duplex may accommodate the less curved library-1 
molecules to a greater extent. It follows that NSC-273829 is also less isohelical than the duplex 
DNA minor-groove binding agents (for example distamycin), and as such shows enhanced 
interaction with the telomeric DNA/RNA hybrid duplex compared with duplex DNA (Figure 
3B.7). 
 




Figure 3B.7: Snapshot of a 10ns explicit solvent molecular dynamics simulation of NSC 
273829 (green spheres) interacting with the DRH sequence (top, grey and red) and the 
cDRH (bottom, grey). The molecule is accommodated in each, but the shape-fit of the 
molecule to the DRH is more favourable due to the different topological features of the DRH 
structure. 
The free energy of binding calculations correlated with the experimental results, and 
suggested that the library-1 molecules interact with the DRH sequence with a higher affinity 
compared with control hairpin duplex DNA (cDRH). It was also evident that compounds 3.4 
and 3.6 (i.e., those possessing the greatest stabilisation potential for DRH) contain an even 
number of methylenes (6- and 8-methylene spacers, respectively), whereas other molecules 
  181|Chapter 3B 
 
in the series (i.e., compounds 3.3, 3.5 and 3.7) contain an odd number of methylenes (5-, 7- 
and 9-methylene spacers, respectively). Therefore, it was hypothesised that there is a greater 
potential for dual intercalation in the case of ligands containing an even number of methylenes 
(i.e., compound 3.4 and 3.6), potentially explaining their higher affinity for telomeric DNA/RNA 
hybrid duplex sequences. This was supported by the molecular dynamics simulations, in which 
compound 3.6 was observed to be bis-intercalating with DNA (Figure 3B.5). This could be 
due to slight changes in the curvature of the molecules, or it is possible that an even-numbered 
linker may orient the benzimidazoles in a downward-facing direction, while an odd-numbered 
linker may facilitate the opposite. 
Table 3B.5: Free energy of binding calculations (kcal/mol) of the intercalation of library-1 
molecules and NSC 273829 with DRH and cDRH in explicit solvent. 
Molecules 




Compound 3.3 - 46.17 - 44.54 
Compound 3.6 - 51.49 - 48.27 
Compound 3.8 -53.62 -49.44 
Compound 3.7 - 59.93 - 55.71 
NSC-273829 - 29.76 - 35.59 
 
Additionally, measurements of compound spacer length relating to the distance between the 
G10 and A23 nucleobases of the telomeric DNA/RNA hybrid duplex sequence were calculated 
through molecular modelling studies using VMD software. Using this approach, it was 
estimated that the methylene spacer between the phenyl-benzimidazole moieties of 
compound 3.6 was 15.64 Å while that between G1 and G5 of the DRH sequence was 13.13 
Å. The distance of the methylene spacer between the quinoline moieties was also measured 
for NSC 273829 and found to be 9.97 Å, relatively shorter than the bis-intercalation distance 
(between G1 and G5) for the telomeric DNA/RNA hybrid duplex sequence. The flexibility of 
the methylene spacer between the two phenylene moieties added to the flexibility, allowing 
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compound 3.6 to bind in the minor groove of DRH, with most of the molecule bound in the 
minor groove and with the two benzimidazole moieties intercalated between nucleobases in 
the DRH sequence. However, changing the length of the methylene spacer and thus changing 
either the distance between the benzimidazole units or the type of spacer (for example, 
inducing rigidity in the case of 3.9) caused either partial intercalation (for example, in the case 
of molecule 3.72), weak interaction with the minor groove or no ligand-DNA interaction at all. 
For example, in the case of compound 3.39 (library-3B), the methylene linker of the molecule 
interacts with the DRH sequence to some degree, but the fluorotetrahydroacridine substituents 
fail to intercalate into the DNA/RNA hybrid duplex structure, and instead form intra-molecular 
stacking interactions. The lack of intercalation of the terminal substituents is most likely due to 
the large nature of these substituents relative to the purine/pyrimidine bases (i.e., see Figure 
3B.8). 
 
Figure 3B.8: Snapshot of a 10ns molecular dynamics simulation of compound 3.39 (green) 
in the minor groove of the DRH structure. The molecule does not intercalate into the DRH 
structure and fails to form any significant bonding. 
 
Compound 3.22, on the other hand, forms non-covalent interactions (for example, van der 
Waal’s interactions) within the minor groove of DRH, but does not intercalate into the structure 
in any way (Figure 3B.9). Instead, the fluoromethylquiniline moieties of the ligand point along 
the floor of the minor groove of DRH and do not form H-bonds with the DNA/RNA bases. 
Presumably, this contributes to the lack of stabilisation observed in the FRET experiments, 
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and highlights the importance of intercalation as the primary mechanism for stabilisation of 
DRH. 
 
Figure 3B.9: Snapshot of a 10ns molecular dynamics simulation of compound 3.22 (yellow) 
seated in the minor groove of the DRH structure. The molecule does not intercalate within 
the DNA and fails to form any significant bonding interactions with the DRH structure. 
 
Compound 3.10 was designed as an analogue of 3.6, with a benzofused moiety linked via a 
biphenyl to the central linker. In this instance, the central linker was composed of a number of 
ring structures, and this ligand was designed to establish the importance of the flexible 
methylene linker in 3.6. Simulations suggested that it is likely that compound 3.10 only part-
intercalates into the DRH structure, and this is reflected in the poor FRET stabilisation 
temperatures observed for this molecule (i.e., Tm values were 3.6 and 3.2 C at 2 M and 1 
M ligand concentrations, respectively). The central biphenyl linker rigidifies the ligand 
structure, thereby preventing it from intercalating into DNA (Figure 3B.10). Furthermore, the 
molecule does not form any electrostatic interactions (e.g., H-bonds) with the DNA/RNA floor, 
suggesting that its shape and orientation in the minor groove are not conducive to DRH 
interaction. 
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Figure 3B.10: Snapshot of a 10ns molecular dynamics simulation of compound 3.10 (blue) 
seated in the minor groove of the DRH structure. The molecule part-intercalates into the 
DRH structure but fails to form significant bonding interactions with the DRH structure. 
Compound 3.9 has a similar type of structure to 3.10, although the number of ring structures 
was decreased to investigate whether a reduction in the number of benzenes may induce 
more favourable interactivity with the DRH structure. Molecular dynamics simulations 
conducted over a 10ns time-period suggested that, in a similar manner to 3.10, compound 3.9 
produces few interactions with the minor groove floor, and does not intercalate with DRH in 
any way. The benzimidazoles at both terminals of the molecule point out of the DNA (i.e., 
Figure 3B.11), and so are not capable of intercalation. Also, the reduction in size of the phenyl 
linker has little effect on the interaction of the molecule with DRH, and the molecular models 
show that the methylene linker between benzofused moieties is critical for DRH binding to 
occur. 
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Figure 3B.11: Snapshot of a 10ns molecular dynamics simulation of compound 3.9 (blue) 
seated within the minor groove of the DRH structure. The molecule does not intercalate 
within the DRH structure, and fails to form any significant interactions with the DRH 
structure. 
In an identical manner to 3.22, both compounds 3.14 and 3.29 bind in the minor groove of 
DRH. However, they do not intercalate into the DRH structure, and do not form any significant 
interactions with the groove floor, and this was reflected in the poor DRH stabilisation 
temperatures observed in the FRET melting studies. 
In summary, from the molecular modelling and molecular dynamics studies of the ligands 
synthesized to interact with the telomeric DNA/RNA hybrid duplex, it can be concluded that 
the molecular dynamics simulations of all libraries (library 1-4) provide insight into the binding 
mechanism of these ligands. It is evident from these simulations that a number of traits are 
critical for DRH binding. First, a methylene linker must be present in order for intercalation into 
the DRH structure to occur. Furthermore, linkers of even-numbered length stabilise DRH to a 
greater extent than odd-numbered linkers, and this occurs due to the orientation of the 
benzimidazole groups. An even-numbered linker will orient both benzimidazoles in a 
downward-facing direction, whereas an odd-numbered linker will result in only one 
benzimidazole moiety pointing downwards, and as a result will induce less stabilisation. 
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Secondly, a flexible linker between the benzimidazole units is critical for activity, and this is 
evident from simulations of compounds 3.9 and 3.10, in which rigidifying the linker through the 
introduction of phenyls removes the molecule’s ability to intercalate into DNA. Finally, the 
overall shape of the molecule is critical for effective stabilisation of DRH, and this is evident 
from the simulations of compounds 3.29 and 3.14 in which the molecules bind into the minor 
groove, but do not have the appropriate shape to intercalate. 
In addition to modelling studies on the DRH sequence, further molecular modelling and 
molecular dynamics investigations were undertaken in an effort to rationalise the results of the 
FRET binding experiments undertaken on all the library molecules (except library-4, bis-
benzofuran type compounds) with the F21T telomeric G-quadruplex. The F21T G-quadruplex 
(PDB ID: 3CDM333) was used as the DNA receptor, and the molecules of library-1 to library-3 
were docked with the quadruplex using an established protocol optimised within our 
laboratories. 
The FRET binding results suggested that molecules containing phenyl-benzimidazole 
moieties separated by a methylene (i.e., compounds 3.3, 3.4, 3.5, 3.6 and 3.7) stabilise DNA 
to some degree, with stabilisation temperatures between 0.2 °C and 6.5 °C (for a 1 M ligand 
concentration) observed for library-1. Docking studies showed that, although the molecules 
are large and do not have the required curvature to stabilise the quadruplex interface, some 
members of the series have the potential to bis-intercalate with the DNA quadruplex structure. 
For example, compound 3.5, which has an F21T stabilisation temperature of 5.5 °C, was 
observed through the modelling to bis-intercalate with DNA with one benzimidazole interacting 
with the top face of the quadruplex and the second benzimidazole interacting with the bottom 
face (Figure 3B.12). Interestingly, a strong correlation (R2 value of 0.77) was observed 
between the FRET melting temperatures and the GBSA (in general, GBSA refers to a 
Generalized Born model augmented with the hydrophobic solvent accessible surface area 
(SA), which is the most frequently used implicit solvent model combination) docking scores, 
suggesting that the docking results are an accurate representation of the ligand-DNA complex. 
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Figure 3B.12: Image of the highest scoring (GBSA) docked pose of compound 3.5 (black) 
interacting with the F21T quadruplex (PDB ID: 3CDM) (blue and white). The benzimidazole 
moieties interact with the top and bottom faces of the quadruplex through van der Waal’s 
interactions, thus providing stabilisation. 
Docking studies were also undertaken on one member of each of library, for example library-
2A, -2B, -2C, 3A and -3B (see Table 3B.6), in an effort to rationalise their lack of affinity for 
the quadruplex structure. Study design was based on the library-1 molecule set, where 
compound 3.6 (with a carbon linker number of eight) was shown to interact with the highest 
affinity for telomeric quadruplex DNA. Molecules corresponding to compound 3.6 (i.e., with a 
linker number or span equivalent to compound 3.6) were chosen from each of the libraries 
(except library-4), and were docked on the F21T quadruplex. 
Although the binding scores were reasonably favourable for some examples (e.g., compound 
3.9) (see Table 3B.6), visual analysis of the models suggested that little stabilisation of the G-
quadruplex structure was occurring. For example, in the case of compound 3.9, Figure 3B.13, 
the molecule did not either stack on the quadruplex interface or form van der Waal’s 
interactions with guanine bases. The shape, size, curvature and length of the molecule were 
not conducive to quadruplex interaction as it had little similarity to known quadruplex stabilisers 
(e.g., the biaryl polyamides). Furthermore, the docked orientation of the ligand was not at the 
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centre of the quadruplex, and as such would not be expected to stabilise the telomeric 
quadruplex to a great extent. 
 
Figure 3B.13: Highest scoring (GBSA) docked pose of compound 3.9 (black) interacting 
with the F21T quadruplex (PDB ID: 3CDM) (blue and white). The molecule does not form 
stacking interactions with the quadruplex due to a poor shape-fit. 
 
The FRET binding results suggest that library-3B molecules possess some degree of binding 
affinity for the quadruplex structure (for example, Tm of compound 3.39 = 4.5 °C at 1 M 
concentration), and this is most likely due to one of the fluorotetrahydroquinoline substituents 
(i.e., library-3B) interacting with guanine bases at the quadruplex interface, thereby resulting 
in moderate stabilisation. Docking results support this hypothesis, and illustrate one half of the 
dimer forming van der Waal’s interactions with the interface, but with the second half of the 
dimer failing to interact (Figure 3B.14). 
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Figure 3B.14: Highest scoring (GBSA) docked pose of compound 3.39 (cyan) interacting 
with the F21T quadruplex (PDB ID: 3CDM) (blue and white). One fluoro-tetrahydroacridine 
moiety of the dimer forms stacking interactions with the DNA bases (blue nucleotides), whilst 
the second moiety fails to interact. 
All other libraries were observed to stabilise the G-quadruplex by 2-3 °C in the FRET studies. 
Such stabilisation is likely to occur via non-specific interactions, and this was reflected in 
docking results. The results for compounds 3.14, 3.22 and 3.29 docked on the F21T 
quadruplex illustrate this, and show the molecules binding non-specifically to the side of the 






  190|Chapter 3B 
 
Table 3B.6: Docking scores (GBSA) of selected members from libraries 1-3 interacting with 
the F21T quadruplex (PDB ID: 3CDM). 
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3B.3 Circular Dichroism (CD) Analysis 
There is very little information available on CD data relating to DNA/RNA hybrid duplexes, 
especially those originating in the telomeric region of DNA. It is established that DNA/RNA 
hybrid duplexes can form an A-form DNA-type conformation and winding334, and in 2012 Xu 
and colleagues reported that the hTelo DNA sequence can form a hybrid G-quadruplex within 
living cells in the presence of a complementary RNA sequence297. These researchers reported 
that the CD spectrum of telomeric DNA shows a positive CD signal at 290 nm and a negative 
signal at 265 nm (in the presence of Na+). However, upon the addition of complementary RNA 
to the telomeric DNA, the peak at 290 nm disappears and is replaced by a strong positive peak 
at 260 nm and also shows a negative signal at around 240 nm. This change is similar to that 
observed for the transformation of antiparallel DNA to a parallel G-quadruplex. Moreover, a 
CD spectrum for RNA/DNA hybrid sequence (i.e., poly(rA)-poly(dT)) also depicted (Figure 
2.10) a positive CD signal at around 260 nm and a sharp negative CD signal at around 248 
nm.185 Thus it can be postulated that the hybrid sequence can show a negative signal at 
around 240 nm, which was identical to our CD spectroscopic analysis (Figure 3B.16). 
Furthermore, Vorlíčková and co-workers in 2012 reported different CD spectra for various 
conformations of DNA structures, and for a DNA/RNA hybrid structure.335 In their study, they 
used a DNA/RNA hybrid duplex in which the RNA sequence was 
r(GCGGCGACUGGUGAGUACGC), and the CD spectrum showed a strong positive CD signal 
at 275 nm and a negative one at 210 nm.  
In this project, a hairpin-structured telomeric DNA/RNA hybrid duplex (DRH) (Figure 3B.15 a) 
was used to carry out the CD analysis, identical in structure to the DRH sequence used in the 
FRET assay, but without the labels and also the molecular modelling and molecular dynamics 
studies. A control DNA/DNA duplex (cDRH) was also used in the CD analysis, where the RNA 
nucleotides of DRH were replaced by DNA bases (Figure 3B.15 b). 
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Figure 3B.15: Hairpin structures of (a) the telomeric DNA/RNA hybrid duplex used in the CD 
studies (red indicates the RNA nucleotides) and (b) the control cDRH sequence. 
The CD spectrum of the hybrid duplex sequence (DRH) in Tris-HCl (50 mM) was initially 
measured and gave an intense positive CD signal at around 271 nm and a small negative CD 
signal at around 237 nm (Figure 3B.15 a). A CD spectrum of cDRH was also measured and 
showed a strong positive CD signal at around 269 nm and a negative one at around 241 nm 
(Figure 3B.15 b). 
 
 
Figure 3B.16: CD spectrum of (a) the telomeric DNA/RNA hybrid duplex sequence (DRH), 
and (b) the control DNA duplex (cDRH). 
Fourteen selected compounds were evaluated for their ability to interact with the telomeric 
DNA/RNA hybrid duplex and control cDRH sequences based on changes to the CD spectra. 
These fourteen molecules were carefully chosen on the basis of the FRET melting assay 
results and the molecular modelling and molecular dynamics studies. On this basis, seven bis-
benzimidazole-type molecules were chosen from library-1 (i.e., 3.4, 3.5, 3.6, 3.7, 3.8, 3.9 and 
3.10), two bis-benzofuran-type molecules from library-4 (i.e., 3.69 and 3.71) and one molecule 
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from each of the other libraries (i.e., 3.14, 3.23, 3.28, 3.35 and 3.40). These molecules were 
chosen, based on previous FRET and modelling results, since they contained either seven-
methylene or eight-methylene spacers between their two side arms. 
The bis-benzimidazole compounds, 3.5, 3.6, 3.7 and 3.8, showed concentration-dependent 
red shifts in the positive CD signal of between 1-4 nm. In the first instance, compound 3.5 in a 
1:1 equivalent concentration with DRH (5 M) gave a red shift of 1.2 nm for the positive signal 
at around 273 nm (Figure 3B.17 a). Additionally, the initial concentration of 3.5 (5 M) gave a 
hypochromic shift in the positive signal (i.e., CDmdeg = 1.22). However, there was no 
noticeable change in the negative CD signal. On increasing the ligand concentrations (2-5 
equivalents with DRH), the positive CD signal shifted further to the right and gave a red shift 
(at around 274 nm) at the highest ligand/DNA ratio (1:5). Moreover, the highest ligand 
concentration (i.e., 25 M) caused the maximum change in intensity of the CD signal (i.e., 
CDmdeg = 7.29) in the positive region. There was only a very small change in the intensity 
of the CD signal in the negative region without any blue and/or red shift. Compound 3.5 was 
also evaluated with the cDRH sequence, but no ligand-DNA interaction was observed up to 1-
5 equivalents of drug (Figure 3B.17 b), confirming the selectivity of the bis-benzimidazole 
molecule for the DNA/RNA hybrid duplex. 
Figure 3B.17: CD spectrum of compound 3.5 with (a) DRH (5 M) and (b) cDRH in Tris 
buffer (pH 7.4) at 0-5 equivalents ligand concentration (path length 10 mm). 
In the case of compound 3.6, the shifting of the CD signal in the positive region was more 
pronounced (Figure 3B.18 a). CD signals were observed at around 272.2, 273.0, 274.5, 275.0 
and 275.5 nm (red shifts) for compound 3.6 with 1, 2, 3, 4 and 5 equivalents of ligand-DNA, 
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respectively. In addition to the red shift, there were hypochromic shifts similar to those 
observed for 3.5. The highest concentration of 3.6 (i.e., 25 M) lowered the positive peak 
intensity by up to 24.11 CD mdeg (where, the CDmdeg = 9.23). Compound 3.6 also shifted 
the negative CD signal, where the maximum red shift (238.02 nm) was observed at the 5 
equivalent ligand concentration (i.e., at 25 M). All of these shifts and changes in intensity 
suggested that compound 3.6 was interacting with the DNA/RNA hybrid duplex sequence. 
This also supported data from the FRET melting assay which showed that compound 3.6 
stabilized the DRH sequence by 7.2 C at a 1 M concentration. Similarly, the unchanged CD 
spectrum on addition of 3.6 to the cDRH sequence (Figure 3B.18 b) reflected the FRET 
melting results (i.e., DRH/cDRH selectivity = 9.0 at a 1 M ligand concentration).  
 
Figure 3B.18: CD spectrum of compound 3.6 with (a) DRH (5 M) and (b) cDRH in Tris 
buffer (pH 7.4) at 0-5 equivalents ligand concentration (path length 10 mm). 
 
Compound 3.8 also imposes both the red shift and hypochromic shifts on the positive CD 
signal. 1, 2, 3, 4 and 5 equivalents of 3.8 caused shifts in the positive signal by 1.46, 2.72, 
2.99, 3.91 and 4.37 nm, respectively, towards the right of the spectrum, with the furthest signal 
observed at around 276 nm for the highest ligand-DNA ratio (Figure 3B.19 a). CDmdeg 
changes of 3.56 and 11.56 were observed for the lowest (i.e., 1 eq) and highest (i.e., 5 eq) 
ligand concentrations, respectively. However, for the negative CD signal, there was little 
change with only 0.54 nm shifts observed for the highest ligand concentration. In this case, 
the CD data also correlated with the FRET melting results for 3.8 (i.e., Tm = 6.8 C, 
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DRH/cDRH selectivity = 7.6 at a 1 M ligand concentration). According to Figure 3B.19 b, no 
interaction was observed between the ligand and cDRH, confirming the molecule’s selectivity 
towards the DRH sequence. 
 
Figure 3B.19: CD spectrum of compound 3.8 with (a) DRH (5 M) and (b) cDRH in Tris 
buffer (pH 7.4) at 0-5 equivalents ligand concentration (path length 10 mm). 
Compound 3.7 showed selective interaction with the DRH sequence compared to the cDRH 
sequence according to the CD analysis (Figure 3B.20). The compound shifted the CD signal 
to around 277 nm and 272 nm for 5 and 1 equivalents of ligand concentration, respectively. 
Furthermore, 3.7 also caused a hypochromic shift of up to 12.83 mdeg for a 25 M ligand 
concentration. However, no changes were seen with the cDRH sequence, confirming the lack 
of interactions observed in the FRET experiments. 
 
Figure 3B.20: CD spectrum of compound 3.7 with (a) DRH (5 M) and (b) cDRH in Tris 
buffer (pH 7.4) at 0-5 equivalents ligand concentration (path length 10 mm). 
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On the other hand, due to changes in methylene spacer length (3.4) and type (e.g., phenylene 
and biphenylene) (3.9 and 3.10), those compounds did not show any affinity for the DRH 
sequence. 
 
Figure 3B.21: CD spectrum of compounds (a) 3.4, (b) 3.9 and (c) 3.10 interacting with the 
DNA/RNA hybrid duplex sequence (5 M) in Tris buffer (pH 7.4) at 0-5 equivalents ligand 
concentration (path length 10 mm). 
Molecular modelling and molecular dynamics studies suggested that such bis-benzimidazole-
type molecules may interact with the telomeric DNA/RNA hybrid duplex via a dual mechanism 
involving both intercalation of the benzimidazole moieties between nucleobases and minor 
groove binding by the methylene spacer unit. However, MD studies on compound 3.6 
confirmed that both benzimidazole units of the molecule can potentially intercalate, with one 
benzimidazole moiety inserting between G11:C20 and G10:C21 and the second between 
A23:T8 and A24:T7 (Figure 3B.4). Further molecular modelling and molecular dynamics 
studies established that certain lengths of the spacer unit can allow the molecule to intercalate 
via its benzimidazole moieties. For 3.6, it was estimated that the methylene spacer between 
the phenyl-benzimidazole moieties was 15.64 Å, while the distance between G1 and G5 in 
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DRH was calculated to be 13.13 Å. Moreover, compounds 3.9 and 3.10 were designed to have 
the flexible methylene spacer replaced with planar phenylene and biphenylene spacers, 
respectively. Thus, it can be hypothesized that the rigidity of the planar spacer system prevents 
the molecules from having the appropriate curvature to fit into the DRH sequence. 
 
Figure 3B.22: Highlighted features of the bis-benzimidazole molecules showing compound 
3.6 as an example. The phenylene and biphenylene spacers are present in 3.9 and 3.10, 
respectively. 
One bis-(2-fluoro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinoline-11-carboxamide type 
molecule (3.40) with a seven-methylene spacer was selected from library-3B for CD analysis. 
Though the molecule did not show very good selectivity for the DRH sequence compared with 
the cDRH in the FRET melting assay, the compound gave noticeable CD signal changes in 
both the positive and negative regions of the spectrum (Figure 3B.23). The compound gave 
a Tm value of 2.3 C at a 1 M ligand concentration with a DRH/cDRH selectivity of 1.9, which 
did not correspond well with the CD results. The CD signal showed a 3.05 nm red shift for the 
positive signal with 5 equivalents of ligand (i.e., 25 M) for the DRH sequence, but in the 
negative region of the spectrum there was little change. The CD signal shifted toward the 
positive region according to the ligand concentration. Although the CD signal gave a positive 
indication of ligand/DNA interaction, molecular modelling and molecular dynamics studies on 
compound 3.33 (a similar library molecule) established that the methylene linker of the 
molecule may bind to the DRH sequence to some degree, but the fluorotetrahydroacridine 
substituents fail to intercalate into the DNA/RNA hybrid duplex structure, instead forming 
intramolecular stacking interactions. Thus, it can be concluded that the changes in CD signals 
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for compound 3.40 might be due only to the methylene spacer, which explains why the 
compound is not very selective for the DNA/RNA hybrid duplex over the cDRH sequence. 
 
  
Figure 3B.23: CD spectrum of compound 3.40 with (a) DRH (5 M) and (b) cDRH in Tris 
buffer (pH 7.4) at 0-5 equivalents ligand concentration (path length 10 mm). 
 
In this study, the bis-indole ligand 3.28, the bis-acridine ligand 3.35, the bis-(6-fluoro-2-
methylquinoline) ligand 3.23, the bis-quinoline ligand 3.14 and the bis-benzofuran ligands 3.69 
and 3.71 were also studied for interaction with the telomeric DNA/RNA hybrid duplex sequence 
(Figure 3B.24) and cDRH sequence by CD. However, none of these ligands induced any 
changes (red/blue shift) in the CD signals for the DRH sequence with 0-5 equivalents ligand-
DNA concentration. However, a very small hypochromic shift in the positive CD signal 
occurred with the increase in ligand concentration, which was between 0-2 CD mdeg. Not 
surprisingly, all the ligands were inactive in the FRET melting assay, and no ligand-DNA 
interactions were obvious from the molecular modelling and molecular dynamics studies. 
According to the MD simulations, the terminal planar structures of each of the different 
molecule types (i.e., bis-indole, bis-acridine, bis-(6-fluoro-2-methylquinoline) and bis-
quinoline) were connected through seven- and/or eight-methylene spacers through amide 
bonding, thus allowing the molecules to interact with the minor groove of the DRH sequence 
to some extent but not facilitating intercalation (i.e., the planar terminal side arms were either 
pointing out or only partially intercalating between nucleobases). 




Figure 3B.24: CD spectrum of compounds (a) 3.14, (b) 3.23, (c) 3.28 and (d) 3.35 
intercalating with DRH (5 M) in Tris buffer (pH 7.4) at 0-5 equivalents ligand concentration 
(path length 10 mm). 
 
As hypothesized from the molecular modelling and molecular dynamics studies, a ligand 
needs to be curved and crescent-shaped to interact with the DNA/RNA hybrid duplex, an 
observation established from the MD simulations of library-1 molecules, especially compound 
3.6. To confirm this hypothesis, two more molecules were synthesized within library-1 by 
incorporating phenylene and biphenylene spacers instead of the methylene spacer as in 
compounds 3.9 and 3.10, respectively. In the CD analysis, no changes in the CD signal were 
observed, thus confirming the lack of affinity of the molecules for the DNA/RNA hybrid duplex 
(Figure 3B.25). This CD result correlated with the FRET melting results in which compounds 
3.9 and 3.10 gave Tm values of 0.5 and 3.2 C at 1 M ligand concentrations, respectively, 
with DRH/cDRH selectivity of 1.7-fold and 5.3-fold, respectively. Molecular modelling and 
molecular dynamics studies confirmed that molecules 3.9 and 3.10 are rigid and planar 
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structures compared with molecules containing methylene spacers. Thus they do not have the 
curved shape necessary to fit into the minor groove of the DRH sequence. 
 
Figure 3B.25: CD spectrum of the interaction of compounds (a) 3.9 and (b) 3.10 with DRH 
(5 M) in Tris buffer (pH 7.4) at 0-5 equivalents ligand concentration (path length 10 mm). 
 
This study confirmed that the molecules need to have a curved shape, and have a degree of 
flexibility, as well as an appropriate length of the central linker in order to bind in the minor 
groove and intercalate between nucleobases (i.e., compounds 3.2-3.7). For this reason, the 
methylene spacer between the benzimidazole and phenylene moieties (i.e., Figure 3B.22) is 
crucial. As some of the other molecules have methylene spacers of similar length to those in 
the library-1 molecules and also contain intercalating side arms, none of the molecules 
interacted with the telomeric DNA/RNA hybrid duplex. 
Fourteen compounds were also evaluated for their interactions with the human telomeric G-
quadruplex sequence (F21T; 5-GGG-TTA-GGG-TTA-GGG-TTA-GGG-3).  
Human telomeric DNA includes several kilo-nucleobases of tandem duplications of the 
sequence 5'-TTAGGG that include a terminal single-stranded overhang of approximately 200 
nucleotides. Intramolecular quadruplexes can adopt different topologies and can form lateral, 
edgewise and/or diagonal loops. CD experiments can identify the folding patterns and parallel 
or antiparallel configurations of G-quadruplexes.  
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It has been reported that parallel quadruplexes provide CD spectra with a 260 nm strong 
positive band and a 240 nm negative band, while an antiparallel topology provides a positive 
band at 290 nm.7, 300, 336 The CD spectrum of the hTelo quadruplex sequence can show bands 
representing the presence of both parallel and antiparallel structures.7 According to 
Paramasivan and co-workers, parallel quadruplexes display a positive CD signal at around 
265 nm and a negative one at around 240 nm. On the other hand, the antiparallel quadruplexes 
provide a positive CD signal at around 295 nm and a negative signal at around 260 nm.337 In 
2012, Nicoludis and co-workers reported the CD spectra for the human telomeric sequence 
(d[AG3(TTAGGG)3]) in 5 mM K+, 50 mM Na+ and 100 mM Li+ buffer at 25 °C.338 The study 
showed two positive signals at around 290 and 240 nm and a sharp negative CD signal at 
around 260 nm in the presence of Na-buffer (Figure 3B.26 a), which is identical to our study 
CD spectrum (Figure 3B.26 b).  
In our study, the hTelo G-quadruplex showed the presence of mixed parallel and antiparallel 
topologies, with a 295 nm positive CD signal, a negative signal at around 265 nm and a further 
positive signal at around 245 nm. 
 
Figure 3B.26: CD spectrum of (a) human telomeric sequence ((d[AG3(TTAGGG)3])) in 50 
mM Na-buffer and (b) telomeric G-quadruplex sequence (F21T) in Tris buffer (pH 7.4) in the 
presence of 100 mM NaCl. 
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A CD titration assay (Figure 3B.27) was carried out with 0-5 equivalents of fourteen selected 
ligands. However, none of the bis-benzimidazole-type molecules in library-1 caused any 
changes to the CD spectrum, even at 5 equivalents. These results contrasted with the FRET 
melting assay results (Table 3B.2) and molecular modelling and molecular dynamics studies 
(Section 3B.2.1 and Figure 3B.12) which suggested that the molecules do not interact with 
the telomeric G-quadruplex sequence. In addition to library-1 molecules, compounds 3.14 (bis-
quinoline), 3.28 (bis-indole), 3.35 (bis-acridine type), 3.40 (bis- fluorotetrahydroquinoline) and 
3.71 (bis-benzofuran) did not show any ligand-DNA interaction at 1-5 equivalents of ligand 
concentration. 
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Figure 3B.27: CD spectrum of compounds (a) 3.4, (b) 3.5, (c) 3.6, (d) 3.7, (e) 3.8, (f) 3.9 and 
(g) 3.10 interacting with the F21T sequence in Tris buffer (pH 7.39) in the presence of 100 
mM NaCl at 0-5 equivalents ligand concentration (path length 10 mm). 
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Interestingly, compound 3.23 (bis-(6-fluoro-2-methylquinoline) and 3.69 (bis-benzofuran type, 
with a butyl-pyrrolidine tertiary amine tail) gave hypochromic shifts in the positive region of the 
CD spectrum. However, none of the molecules caused shifts of the CD signal toward the left 
or right of the x-axis (Figure 3B.28). 
 
Figure 3B.28: CD spectrum of the interaction of compounds (a) 3.23 and (b) 3.69 with the 
telomeric G-quadruplex sequence (F21T) in Tris buffer (pH 7.39) in the presence of 100 mM 
NaCl at 0-5 equivalents ligand concentration (path length 10 mm). 
 
In conclusion, the CD results presented here appear to confirm that the molecules in library-1 
(except 3.2, 3.9 and 3.10) interact with the telomeric DNA/RNA hybrid duplex. Although CD 
data cannot confirm a molecule’s mode of action as either stabilizing or destabilizing, based 
on the FRET melting results and molecular modelling studies, it can be hypothesized that the 
molecules stabilize the telomeric DNA/RNA hybrid duplex sequence. 
3B.4 Cytotoxicity Test Using the MTT Assay 
Novel potential anticancer agents are often initially evaluated for their cytotoxicity towards a 
panel of tumour cell lines. Although such in vitro cytotoxicity assays cannot predict either in 
vivo efficacy or toxicity, they can be valuable in the selection of novel compounds to progress 
to further pre-clinical studies. There are a number of different assays available, using both 
direct and indirect markers. In this project, the MTT assay was employed which uses the MTT 
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dye to make the cells visible, if still alive. 
The characteristic parameter determined in this assay is the IC50 value which is the 
concentration at which 50% of cells die in the presence of the test molecule. One potential 
limit of the MTT assay is that it cannot distinguish between the cytocidal and cytostatic effects 
of a test molecule. However, the MTT assay is widely used due to its rapid, versatile and 
quantitative characteristics, and its reproducibility. The assay is based on the conversion of 
MTT to a purple formazan metabolite by mitochondrial enzymes within living cells304, a process 
that is inhibited in the presence of a cytotoxic test molecule. This purple colour can be 
measured and quantitated. 
The novel compounds synthesized in this project were evaluated in three human cancer cell 
lines: MDA-MB-231 (triple negative breast cancer cell line), HeLa (cervical cancer cell line) 
and NCI H1975 (non-small cell lung cancer cell line). 
In total, forty-nine compounds were evaluated at a concentration of 25 μM by the MTT assay 
for their cytotoxic efficiency in the MDA-MB-231 cell line. Following this, 16 molecules with the 
lowest IC50 values were selected for further studies in the other two cancer cell lines (HeLa 
and NCI H1975). Compounds with IC50 values of 100 μM or above were considered as 
inactive. In this study, percentages are based on the assumption that the optical density of the 
cells without the compound present is 100%. 
 
3B.4.1 MTT Assay Results with MDA-MB-231 Cell Line (Breast Cancer Cell Line) 
In this study, the MDA-MB-231 cell line was seeded at 10,000 cells/well for the MTT assay. 
According to the IC50 concentrations described in Table 3B.7, the selected compounds from 
libraries -1 and -3B had greater cytotoxicity in the MDA-MB-231 cell line compared with the 
selected compounds from library-4. 
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Table 3B.7: Cytotoxic activities of compounds from library-1, library-3B and library-4 in the 
MDA-MB-231 cell line. 
Library Compound 
IC50 Values (M) 








3.4 3.4 μM 0.4007 
3.5 4.2 μM 0.8256 
3.6 1.1 μM 0.6440 
3.7 9.2 μM 0.6933 







 3.39 10.8 μM 0.8266 
3.42 3.6 μM 0.7530 







3.66 > 100 μM 0.9029 
3.68 > 100 μM 0.7067 
3.69 > 100 μM 0.4862 
3.71 15.1 μM 0.9163 
3.73 > 100 μM 0.2428 
3.75 5.8 μM 0.6942 
3.77 5.6 μM 0.8815 
3.78 6.3 μM 0.8615 
 
The IC50 values of most of the selected compounds from library-1 and library-3B were below 
10 μM. Compound 3.6 had the lowest IC50 value of 1.1 M from the library-1 molecules. It is 
noteworthy that this compound also showed the best selectivity for the telomeric DNA/RNA 
hybrid duplex sequence and telomeric G-quadruplex sequence compared with the respective 
control DNA sequences in the FRET melting assay at a 1 M ligand concentration (Table 
3B.1). However, compound 3.43 from library-3B had the lowest IC50 value (i.e., 0.5 M) among 
all tested compounds in the MDA-MB-231 cell line. In addition, the compound was the best fit 
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within the same oligonucleotide sequence in the molecular modeling and molecular dynamics 
studies (Figure 3B.4). It should also be noted that telomerase expression is higher in the MDA-
MB-231 cell line due to upregulation of hTERT. Thus, the results for this breast cancer cell line 
with compound 3.6 suggest that the compound may be downregulating hTERT expression, 
thus leading to telomerase inhibition. Compounds 3.4, 3.5, 3.8 and 3.42 which have six-, 
seven-, ten-, and nine-methylene spacers, respectively, were also potent in this assay. 
However, compounds 3.4 and 3.8 had comparatively better activity than 3.5, the rank order of 
which correlates with the hypothesis generated in the molecular modelling and molecular 
dynamics studies that molecules with even-numbered methylene spacers are more active than 
those with odd-numbers. Moreover, due to introducing rigidity in compounds 3.9 and 3.10 
(though the C-number in the spacer unit is similar), these molecules lost activity in the MTT 
assay, also supporting the FRET results and the MD simulation studies that suggest the need 
for flexibility within the crescent-shaped molecules. Compounds 3.75, 3.77 and 3.78 from 
library-4 molecules gave IC50 values below 10 M, although these compounds did not stabilize 
the DRH sequence in the FRET melting assay and there was no other evidence for ligand-
DNA interaction in both the MD simulations and CD studies. Further investigations would be 
required to obtain information on the mode of action of these compounds. 
3B.4.2 MTT Assay Results with HeLa Cell Line (Cervical Cancer Cell Line) 
As the confluency rate of HeLa cells is higher than those of the other cell lines studied, HeLa 
was seeded at a lower density (i.e., 5,000 cells per well) for this experiment. All sixteen 
compounds were evaluated against this cell line, where six compounds showed IC50 values 
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Table 3B.8: Cytotoxic activities of novel compounds from library-1, library-3B and library-4 in 
the HeLa cell line. 
Library Compound 
IC50 Value (M) 








3.4 > 100 μM 0.5789 
3.5 75.0 μM 0.8320 
3.6 4.2 M 0.8469 
3.7 > 100 μM 0.6079 







 3.39 28.6 μM  0.9311 
3.42 8.5 μM  0.9413 







3.66 > 100 μM 0.7295 
3.68 > 100 μM 0.9524 
3.69 > 100 μM 0.5601 
3.71 3.9 μM  0.8554 
3.73 8.8 μM  0.4796 
3.75 21.5 μM  0.7190 
3.77 > 100 μM 0.6579 
3.78 > 100 μM 0.5343 
 
For the HeLa cells, the bis-benzimidazole molecule 3.8 (library-1) had the best antiproliferative 
activity (i.e., IC50 = 2.7 M). Compound 3.6 also had potent antiproliferative activity with an 
IC50 value of 4.2 M. In addition, 3.43 gave an IC50 value of 1.2 M, although this did not 
correlate with the molecular modelling and dynamics results. On the other hand, among the 
other selected compound from the same library, the bis-benzofuran-type molecule 3.71 
(library-4) gave the greatest inhibition of HeLa cell proliferation with an IC50 value of 3.9 μM. 
  209|Chapter 3B 
 
3B.4.3 MTT Assay Results with NCI H1975 Cell Line (Non-Small Lung Cancer Cell Line) 
The cell density of NCI H1975 seeding for the MTT assay was 10,000 cells/well. Less than 
50% of the compounds evaluated showed antiproliferative activity toward this cell line with 
library-1 and library-3B compounds showing greater activity than those of library-4. Among the 
tested compounds, 3.8 showed most promising activity with an IC50 value of 1.5 μM. 
Table 3B.9: Cytotoxic activity of novel compounds in library-1, library-3B and library-4 against 
the NCI H1975 cell line. 
Library Compound 
IC50 Value (M) 








3.4 > 100 μM 0.8420 
3.5 16.8 μM  0.9623 
3.6 11.8 μM  0.9623 
3.7 15.3 μM 0.9398 







 3.39 49.3 μM 0.8490 
3.42 > 100 μM 0.9420 







3.66 > 100 μM 0.5931 
3.68 > 100 μM 0.5778 
3.69 > 100 μM 0.6982 
3.71 > 100 μM 0.7663 
3.73 > 100 μM 0.6796 
3.75 75.0 μM 0.6732 
3.77 > 100 μM 0.6795 
3.78 > 100 μM 0.8393 
 
The results from across the three cell lines indicate that compounds 3.6, 3.8 and 3.43 are 
highly cytotoxic molecules, and the viability of cultured MDA-MB-231, HeLa and NCI H1975 
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cells was significantly decreased during 72 h incubation in the presence of these compounds 
(IC50 values ranged from 0.5 to 11.8 M). The data suggested that 3.8 was the most cytotoxic 
candidate across the three cell lines with the lowest range of IC50 values (i.e., 1.5 M to 4.2 
μM). The variation in structure of these molecules could be related to their activity. For 
example, the methylene spacers of compounds 3.4, 3.6 and 3.8 are 6-, 8- and 10-methylenes, 
respectively (Table 3A.1). According to the IC50 values for these three compounds, those with 
longer methylene spacers had the greater cytotoxic activities and this also correlated with the 
FRET melting assay, and the MD and CD data. A study by Wright and co-workers 
demonstrated higher relative telomerase activity and hTERT mRNA in the MDA-MB-231 cell 
line compared with HeLa cell line.35 Therefore, the greater activity in the MDA-MB-231 breast 
cancer cells could be due to the ability of these novel compounds to inhibit telomerase.  
In addition, data analyzed using GraphPad Prism software showed a good fit of the data 
quantified in terms of R2 and the precision of fit value in terms of 95% confidence interval.339 
The low R2 and wide 95% confidence interval indicated low variation in the data. Even though 
there was no general rule for R2, its expected value in this study was more than 0.7. The 
possible reason for this was the variation of cell density in each well. 
3B.5 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Assay 
The reverse transcriptase-PCR assay was used to determine the effect of the ‘hit’ compounds 
on the expression of genes relating to the upregulation and/or downregulation of telomerase. 
The genes of interest in this analysis were hTERT and cyclin B. 
It has already been demonstrated that there is a relationship between apoptosis and 
telomerase activity, and several anticancer agents induce apoptosis by downregulating 
telomerase activity. Sebastian and co-workers also reported that telomerase activation is an 
important step in human carcinogenesis.293 In contrast, suppression of this enzyme’s activity 
has a key role in tumour suppression in normal human somatic cells.157 Therefore, abnormally 
active telomerase has become an attractive target for cancer treatment. Additionally, 
downregulation of either hTERT340 or hTR341 expression has been reported as associated with 
the induction of apoptosis. hTERT, the telomeric reverse transcriptase, is the catalytic subunit 
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of telomerase.35, 342 hTERT acts as an especially important factor in upregulating telomerase 
activity in human cancer cells. Wu and co-workers have reported that the hTERT promoter is 
rich in c-Myc binding sites which can mediate hTERT transcriptional activation directly.155 This 
finding is also consistent with another report suggesting a link between c-Myc overexpression 
and induction of telomerase activity.343 
Moreover, Kang and co-workers have reported that the expression of the hTERT subunit 
comprising two putative Akt-phosphorylation sites is also upregulated in several cancer cells, 
where Akt-kinase has been identified as an enhancer of telomerase activity through the 
phosphorylation of hTERT.344 In a study by Sun and co-workers, the authors established the 
dose-dependent downregulation of the hTERT gene and telomerase activity in cisplatin-
treated human ovarian cancer cells.312 There are a number of studies showing that expression 
of hTERT is associated with the level of telomerase activity.245, 312, 313, 345-347 For these reasons, 
it was decided to study the effect of a number of selected compounds on hTERT expression 
and telomerase activity. 
Cyclin B is a mitotic cyclin, a class of protein that controls cell progression during the cell cycle 
by initiating cyclin-dependent kinase (Cdk) enzymes.348 During the cell cycle, the amount of 
cyclin B and the activity of the cyclin B-Cdk complex (also known as maturation promoting 
factor or mitosis promoting factor, MPF) increases until the point of mitosis, when levels drop 
sharply due to degradation of the cyclin B-Cdk complex.349 Therefore, cyclin B plays an 
essential role in a variety of cancer types,350, 351 as it is essential for cells to enter mitosis and, 
consequently, for cell division. Thus, the level of cyclin B can deregulate cell growth leading to 
the formation of tumours. In contrast, if cyclin B levels drop, then the MPF complex cannot 
form, and cells cannot enter the M-phase which leads to a slowing of cell division.319,320 
In addition, Begnami and co-workers have reported that the high levels of cyclin B in gastric 
cancers are indicative of poor diagnosis and lymph node metastasis.352 
In 2011, McKerlie and co-workers reported that Cdk1 specifically phosphorylates the threonine 
371 (T371) residue of TRF1 (telomeric repeat binding factor 1) during the mitotic cell cycle, 
and that TRF1 is involved in the regulation of the telomere structure. Such phosphorylation is 
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related to the loss of telomere-bound TRF1 and TIN2 proteins, consequently causing a 
reduction in telomere heterochromatin.353 Thus cyclin B can be used as a surrogate biomarker 
for telomerase expression within cancer cells. Therefore, cyclin B expression was studied in 
order to understand the mechanism of action of the tested compounds on tumour cell division. 
The most active four compounds (3.6, 3.8, 3.43 and 3.71) from the cytotoxicity assay were 
studied for their effects on gene expression in tumour cells using a RT-PCR protocol. 
3B.5.1 hTERT Expression 
The qualitative analysis of gene expression was carried out by observing a decrease in band 
intensity in the sample lane (D+) compared with the LPS control (L+). Suppression of the 
hTERT gene was detected for compounds 3.6 (at 1 µM), 3.8 (at 1 µM and 5 µM) and 3.71 (at 
10 µM) (Figure 3B.29 a, b, c and e). The band intensity for 3.8 (at 1 M) was a little more 
intense, however at 5 µM, hTERT expression was completely inhibited. On the other hand, 
compound 3.43 was inactive, and no suppression of hTERT expression was obtained (Figure 
3B.29 c). 
In 2001, Damm and colleagues reported lists of genes which were downregulated and 
upregulated by long-term treatment (i.e., 7, 28 and 56 days) with a telomerase inhibitor.245 
Their study revealed that an effective telomerase inhibitor can downregulate hTERT 
expression up to 5-fold. In our study, cells were exposed to the tested compounds for 8 h, and 
during that short time of exposure compounds 3.6 and 3.8 were observed to have some 
inhibitory effect on hTERT expression. Moreover, the exposure period was less than the 
incubation time in this study, a similar protocol to that followed in the cytotoxicity evaluation 
experiment. 
In summary, based on these preliminary results, it can be concluded that molecules 3.6 and 
3.8 are promising candidates for further evaluation for telomerase inhibitory activity. 
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Figure 3B.29: Reversed Transcriptase-PCR results for modulation of hTERT gene 
expression by (a) Compound 3.6 (1 μM), (b) Compound 3.8 (1 μM), (c) Compound 3.8 (5 
μM), (d) Compound 3.43 (1 μM) and (e) Compound 3.71 (10 μM). La: 100 bp DNA ladder, C 
: cell control, L: Cell stimulated with LPS, D: Cell stimulated with LPS and compound, + : RT 
enzyme, -: No RT enzyme. 
3B.5.2 Cyclin B Expression 
Similarly, four compounds, 3.6, 3.8, 3.43 and 3.71, were evaluated using the same RT-PCR 
assay for effects on cyclin B expression in MDA-MB-231 cells. The gels showed a slight 
downregulation of cyclin B upon addition of compound 3.6 at a 1 M concentration (Figure 
3B.30 a). However, the other ligands, 3.8, 3.43 and 3.71, did not cause any significant changes 
in terms of band intensity at a 1 M concentration. For this reason, compounds 3.8 and 3.71 
were assessed at the higher concentrations of 5 M and 10 M, respectively. At a 5 M 
concentration, there was a very small change in the intensity of the band for compound 3.8 
(Figure 3B.30 c). 
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It is noteworthy that Damm and co-workers reported downregulation of cyclin B in NCI-H460 
cells after prolonged treatment (i.e., 7, 28 and 56 days) with the telomerase inhibitor 
BIBR1591.245 In the future, longer incubation times for compounds 3.8, 3.43 and 3.71 could 
be investigated. 
 
Figure 3B.30: RT-PCR results for evaluation of the effect on Cyclin B gene expression in 
MDA-MB-231 cells by (a) Compound 3.6 (1 μM), (b) Compound 3.8 (1 μM), (c) Compound 
3.8 (5 μM), (d) Compound 3.43 (1 μM) and (e) Compound 3.71 (10 μM). La: 100 bp DNA 
ladder, C: cell control, L: Cell stimulated with LPS, D: Cell stimulated with LPS and 
compound, +: RT enzyme, -: No RT enzyme. 
In 2008, Androic and co-workers demonstrated an association between cyclin B expression 
and the proliferation of cervical and breast cancer cells which were inhibited by the 
downregulation of cyclin B.350 In the following year, Aaltonen and co-workers reported a study 
correlating cyclin B expression and breast cancer proliferation.351 In 2010, Kim and co-workers 
reported that the highest level of cyclin B expression is observed in the G2/Mitosis transition.354 
As compound 3.6 downregulated the expression of cyclin B in MDA-MB-231 cells, it is possible 
that 3.6 may block cell cycle progression into the M-phase, thus causing G2 cell cycle arrest. 
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In summary, the preliminary gene expression experiments carried out in this project using the 
RT-PCR technique suggested that compound 3.6 could down-regulate the hTERT and cyclin 
B expression in treated cell lines.  
3B.6 Electrophoretic Mobility Shift Assay 
An electrophoretic mobility shift assay (EMSA, or gel shift assay) is an affinity electrophoresis 
method that is used to study protein/DNA and protein/RNA interactions. Although this assay 
is normally used to determine the capability of a protein or mixture of proteins to bind to a DNA 
or RNA sequence, the EMSA can also be applied to the study of the interaction of small 
molecules with DNA, RNA or DNA/RNA hybrid complexes. However, there are no previously 
published examples of its use to study the interaction of small molecules with DNA/RNA hybrid 
duplexes.  
According to the electrophoretic mobility shift assay (EMSA) principle, it has been confirmed 
that the protein retards the mobility of the DNA fragments to which it binds; thus, the free DNA 
migrates faster through the gel than does the DNA-protein complex.355 Similarly, this method 
has been used by different research group to study drug/DNA binding with the idea of DNA 
migration with/without drug.  
In our study, the gel showed a very slight retardation of the band after treatment with 3.6 and 
3.8 at a 2.5 M ligand concentration compared with the control DNA ladder (without ligand) 
(Figure 3B.31), which suggests the binding of ligand to the treated DNA strand. This result 
recommends that future experiments could focus on studying higher concentrations of ligands 
to establish whether greater shifts can be obtained. 
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Figure 3B.31: Electrophoretic mobility shift assay using 4% agarose gel. Control Oligo-DRH 
(lane 1), Oligo-DRH with compound 3.6 (2.5 M) (in lane 2), Oligo-DRH with compound 3.8 
(2.5 M) (in lane 3). 
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Chapter 4: Conclusion and Future Work 
After careful modification of the NCI library molecule NSC 273829, a total of 49 molecules with 
varied lengths and flexibilities of methylene spacer and with seven types of terminal building 
blocks were synthesized using a general HOBt/DIC-mediated amide coupling reaction. Most 
of the target molecules were achieved in good yield and purity using established medicinal 
chemistry protocols. Several spectroscopic techniques such as 1H NMR, 13C NMR, IR, LC-MS 
and HRMS were employed to confirm the structures of the synthesized molecules. The initial 
lead molecule was modified with the help of molecular modelling studies to design the first 
library.  
Compounds 3.2-3.10 (library-1) were synthesized by varying the linker length (methylene 
spacer) as well as by inserting a rigid-planar structure of phenyls and biphenyls in place of the 
flexible methylene spacer. Preliminary FRET melting assays on dual labelled telomeric 
DNA/RNA hybrid (DRH) duplex sequences, control DNA duplex (cDRH) and telomeric G-
quadruplex sequences (F21T) were carried out to assess the ability of the library members to 
stabilize the DRH sequence and to understand their selectivity.  
Compounds 3.4 (six methylene spacer), 3.6 (eight methylene spacer) and 3.8 (ten methylene 
spacer) showed promising selectivity, 11.5-, 9.0- and 7.6-fold, respectively toward the DRH 
sequence compared with the control duplex sequence (cDRH).  
Further molecular dynamics studies also confirmed that the molecules with an even number 
of methylene spacers (for example, six, eight, ten) were more selective toward the DRH 
sequence compared with the compounds with an odd number of methylene spacers. It was 
also shown that in their lowest possible energy conformations, compounds 3.6 and 3.8 can 
stabilize the DRH sequence by a dual mode of action, bis-intercalation into the nucleobases 
and hybrophobic interactions with the minor groove of the DRH sequence, whereas compound 
3.4 could mono-intercalate into the nucleobases, with the second benzimidazole pointing out 
from the DNA bases. In addition, MD studies confirmed that the single methylene spacer unit 
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between the phenylene and benzimidazole moieties is responsible for forming a kink and 
allows the benzimidazole moiety to intercalate.  
CD spectroscopic analysis also showed notable shifting in the positive signal upon gradual 
addition of ligands (compounds 3.6 and 3.8) compared with the CD signal for the DRH itself. 
There is no published CD study on the telomeric DRH sequence and therefore it was not 
possible to compare the observed changes in CD with other literature molecules.  
Synthesized molecules were assayed for their cytotoxic potential against the breast cancer 
cell line MDA-MB-231. On the basis of the preliminary investigation, sixteen promising 
molecules from libraries -1, -3B and -4 were further evaluated against the cervical cancer cell 
line HeLa and non-small lung cancer cell line NCI H1975, in which compounds 3.6 and 3.8 
gave low micromolar IC50 values for all three cell lines used.  
In addition, RT-PCR assays for hTERT and cyclin B expression were performed with 
compounds 3.6 and 3.8, where both compounds down-regulated hTERT expression at 1 M 
concentration. However, compound 3.8 did not suppress cyclin B expression like compound 
3.6 at 1 M concentration. An electrophoretic mobility shift assay (EMSA) was also performed 
to evaluate the ability of compounds 3.6 and 3.8 to bind to the DRH sequence.  
The result suggested that the compounds could bind to the DRH sequence and thus showed 
differences in distance travelled by the ligand-bound DNA compared with the DRH itself. 
Though a well-established TRAP assay for telomerase inhibition could not be included in this 
thesis due to time constrains, it should be noted that promising compounds will be evaluated 
in the TRAP-LIG assay in the future. Having obtained evidence of ligand-DRH interaction at a 
low micromolar level, it can be hypothesised that such molecules can be used as leads for 
further investigation in terms of binding selectivity, cytotoxicity and drug-like properties which 
could lead to potential therapeutic agents in the oncology area. 
As some of the compounds synthesized have demonstrated significant activity against the 
breast cancer cell line MDA-MB-231, further biological investigations will be carried out to 
establish the mechanism of action. Molecular dynamics studies suggest that the single 
methylene spacer between the phenylene and benzimidazole moieties is responsible for bis-
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intercalation, further SAR studies will involve varying and/or inserting additional methylene 
spacers, as well as utilizing different terminal building blocks. Future work will also focus on 
establishing a detailed mechanism of action of these ligands at the cellular level so that the 
‘lead’ compounds can undergo further modification to generate suitable preclinical candidates. 
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Appendix 1: Experimental, Synthesis and Characterisation 
of Molecules 
A1.1 Synthesis of bis-benzo[d]imidazole type molecules in library-1 
Synthesis of N,N'-(propane-1,3-diyl)bis(4-((1H-benzo[d]imidazol-1-l)methyl)benzamide) (3.2) 
A solution of 4-((1H-benzo[d]imidazol-1-yl)methyl)benzoic acid (HOBt) (50 mg; 0.20 mmol) in 
dimethylformamide (7 mL) was treated with 1-hydroxybenzotriazole (54 mg, 0.40 mmol) and N,N'-
diisopropylcarbodiimide (DIC) (54 L, 0.35 mmol) at room temperature. After 30 minutes, 1,7-
diaminopropane (31 mg, 0.24 mmol) was added and the mixture was stirred for 16 h, then quenched 
with water (70 mL). The product was extracted with ethyl acetate (3x100 mL) and the combined 
organic layer was washed with a saturated aqueous solution of sodium bicarbonate (2x150 mL), 








(400 MHz, DMSO-d6)  8.46-8.42 (m, 4 H), 7.79-7.75 (m, 4 H), 7.68-7.64 
(m, 2 H), 7.49-7.45 (m, 2 H), 7.35 (d, J = 6.6 Hz, 4 H), 7.22-7.17 (m, 4 
H), 5.55 (s, 4 H), 3.29-3.22 (m, 4 H), 1.70 (t, J = 6.3 Hz, 2 H),  
13C NMR 
(100 MHz, DMSO-d6)  166.1, 144.5, 143.8, 142.0, 141.6, 140.1, 134.3, 
133.8, 127.7, 122.7, 119.7, 110.9, 47.5, 37.2, 29.4 
IR (max/cm
-1) 3344, 3074, 1647, 1616, 1570, 1543, 1496, 1377, 1365 
MS Found 543.20 [M+H]
+, Calculated for C33H30N6O2 543.64 [M+H]+ 
HRMS Observed 543.2509 [M+H]
+, Theoretical 543.2503 [C33H30N6O2+H]+ 
Yield 52 mg (29% yield) 
 
Synthesis of N,N'-(pentane-1,5-diyl)bis(4-((1H-benzo[d]imidazol-1-l)methyl)benzamide) (3.3) 
Protocol employed for the preparation of 3.2 was used. Purification was carried out in flash column 
chromatography using dichloromethane/methanol (0-3%). 







(400 MHz, CDCl3)  8.09 (s, 2 H), 7.79 (d, J = 7.3 Hz, 2 H), 7.83 (d, J = 
8.6 Hz, 2 H), 7.72 (d, J = 8.4 Hz, 4 H), 7.36-7.30 (m, 4 H), 7.12 (d, J = 
8.6 Hz, 4 H), 6.50 (t, J = 6.2 Hz, 2 H), 5.38 (s, 4 H), 3.47 (q, J = 6.2 Hz, 
4 H), 1.71-1.65 (m, 4 H), 1.48-1.43 (m, 2 H) 
13C NMR 
(100 MHz, CDCl3)  163.0, 145.4, 143.8, 141.3, 133.9, 130.1 (2 C), 127.9 
(2 C), 127.2, 124.3, 123.8, 120.6, 110.6, 50.2, 39.1, 31.3, 24.5  
IR (max/cm
-1) 3268, 2936, 1638, 1616, 1540, 1504, 1456, 1385, 1364 
MS Found 570.83 [M-H]
+, Calculated for C35H34N6O2 571.68 [M+H]+ 
HRMS Observed 571.2824 [M+H]
+, Theoretical 571.2816 [C35H34N6O2+H]+ 
Yield 26 mg (23% yield) 
 
Synthesis of N,N'-(hexane-1,6-diyl)bis(4-((1H-benzo[d]imidazol-1-yl)methyl)benzamide) (3.4) 






(400 MHz, DMSO-d6)  8.42 (s, 2 H), 8.37 (t, J = 5.7 Hz, 2 H), 7.76 (d, J 
= 8.3 Hz, 4 H), 7.68-7.64 (m, 4 H), 7.35 (d, J = 8.3 Hz, 4 H), 7.20-7.17 
(m, 4 H), 5.55 (s, 4 H), 3.22-3.17 (m, 4 H), 1.46 (br s, 4 H), 1.28 (br s, 4 
H) 
13C NMR 
(100 MHz, DMSO-d6)  166.6, 144.4, 143.2, 141.7, 133.0, 130.2 (2 C), 
127.5 (2 C), 127.2, 122.6, 121.9, 120.4, 110.6, 59.8, 39.7, 29.6, 26.8 
IR (max/cm-1) 3285, 2935, 2359, 1641, 1569, 1540, 1456, 1436, 1363 
MS Found 584.50 [M-H]+, Calculated for C36H36N6O2 585.71 [M+H]+ 
HRMS Observed 585.2964 [M+H]+, Theoretical 585.2973 [C36H36N6O2+H]+ 
Yield 65 mg (52% yield) 
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Synthesis of N,N'-(heptane-1,7-diyl)bis(4-((1H-benzo[d]imidazol-1-l)methyl)benzamide) (3.5) 
Product 3.5 was prepared by following the same protocol used in the synthesis of compound 3.2. 








(400 MHz, CDCl3)  7.95 (s, 2 H), 7.82-7.78 (m, 2 H), 7.75-7.70 (m, 4 H), 
7.23-7.21 (m, 8 H), 7.17 (d, J = 8.0 Hz, 4 H), 4.20 (br s, 4 H), 3.86-3.80 
(m, 2 H), 3.43-3.36 (m, 2 H), 1.56 (t, J = 6.5 Hz, 4 H), 1.34 (br s, 4 H), 
1.21 (d, J = 6.5 Hz, 2 H) 
13C NMR 
(100 MHz, CDCl3)  166.5, 143.5, 142.8, 138.4, 134.5, 133.4, 127.3 (2 
C), 126.7 (2 C), 122.9, 122.1, 120.1, 109.6, 48.1, 30.5, 28.9, 28.2, 26.2 
IR (max/cm-1) 3339, 2966, 1614, 1556, 1494, 1458, 1361 
MS Found 599.03 [M+H]+, Calculated for C37H38N6O2 599.74 [M+H]+ 
HRMS Observed 599.3123 [M+H]+; Theoretical 599.3129 [C37H38N6O2+H]+ 
Yield 99 mg (83% yield) 
 
Synthesis of N,N'-(octane-1,8-diyl)bis(4-((1H-benzo[d]imidazol-1-yl)methyl)benzamide) (3.6) 
Compound 3.6 was obtained as a white solid after 18 h of reaction following the procedure 






(400 MHz, CDCl3)  7.98 (s, 1 H) , 7.84 (d, J = 7.8 Hz, 1 H), 7.72 (d, J = 
8.4 Hz, 2 H), 7.28 (d, J = 2.5 Hz, 1 H), 7.26-7.23 (m, 2 H), 7.21 (d, J = 
8.4 Hz, 2 H), 6.13 (t, J = 5.9 Hz, 1 H), 5.41 (s, 2 H), 4.00 (br s, 2 H), 3.84 
(dd, J = 13.1, 6.6 Hz, 5 H), 3.45-3.39 (m, 2 H), 1.62-1.56 (m, 2 H), 1.34 
(br s, 2 H), 1.16 (m, 15 H) 
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13C NMR 
(100 MHz, CDCl3)  161.0, 148.1, 143.3, 142.8, 138.4, 134.2, 127.3 (2 
C), 126.9 (2 C), 123.1, 122.3, 120.2, 109.6, 48.2, 39.7, 29.2, 28.6, 26.4 
IR  (max/cm
-1) 3328, 2928, 1627, 1562, 1496, 1458, 1383, 1325 
MS Found 613.88 [M+H]
+, Calculated for C38H40N6O2 613.76 [M+H]+ 
HRMS Observed 613.3268 [M+H]
+, Theoretical 613.3286 [C38H40N6O2+H]+ 
Yield 78 mg (74% yield) 
 
Synthesis of N,N'-(nonane-1,9-diyl)bis(4-((1H-benzo[d]imidazol-1-yl)methyl)benzamide) (3.7) 
General method described for the synthesis of compound 3.2 was used. To ensure the completion 







(400 MHz, CDCl3)  7.97 (s, 2 H), 7.84 (d, J = 8.1 Hz, 4 H) 7.72 (d, J = 
8.4 Hz, 4 H) 7.24 (td, J = 2.9, 1.1 Hz, 4 H) 7.21 (d, J = 8.1 Hz, 4 H) 6.20-
6.15 (m, 2 H) 5.41 (s, 4 H) 3.87-3.83 (m, 4 H) 3.45-3.39 (m, 4 H) 1.27 (br 
s, 10 H)  
13C NMR 
(100 MHz, CDCl3)  162.2, 143.9, 142.8, 142.0, 134.1, 127.6, 127.3, 
126.8, 125.5, 122.9, 120.2, 109.6, 76.9, 50.5, 36.1, 31.1, 28.6, 23.2 
IR (max/cm
-1) 3335, 2966, 2360, 2338, 1638, 1556, 1495, 1458, 1384, 1325 
MS Found 626.98 [M+H]
+, Calculated for C39H42N6O2 626.79 [M+H]+ 
HRMS Observed 627.3436 [M+H]
+, Theoretical 627.3442 [C39H42N6O2+H]+ 
 Yield 32 mg (31% yield) 
 
Synthesis of N,N'-(decane-1,10-diyl)bis(4-((1H-benzo[d]imidazol-1-l)methyl)benzamide) (3.8) 
General method described for the synthesis of compound 3.2 was used. Product was collected by 
filtration when ethyl acetate was added. 
 








(400 MHz, DMSO-d6)  8.06 (s, 2 H), 7.86 (d, J = 8.0 Hz, 4 H), 7.68 (d, 
J = 8.3 Hz, 4 H), 7.22 (td, J = 2.9, 1.1 Hz, 4 H), 7.20 (d, J = 8.0 Hz, 4 H), 
6.20-6.15 (m, 2 H), 5.41 (s, 4 H), 3.87-3.83 (m, 4 H), 3.45-3.39 (m, 4 H), 
1.26 (s, 12 H) 
13C NMR 
(100 MHz, DMSO-d6)  166.5, 144.2, 143.4, 141.8, 135.1, 131.2, 128.6, 
127.6, 122.6, 121.9, 120.4, 110.6, 51.5, 41.0, 31.1, 29.2, 28.6, 26.2 
IR (max/cm
-1) 3336, 2924, 2850, 1639, 1616, 1543, 1492, 1438, 1369 
MS Found 641.30 [M-H]
+, Calculated for C40H44N6O2 641.35 [M+H]+ 
HRMS Observed 641.3580 [M+H]
+, Theoretical 641.3599 [C40H44N6O2+H]+ 
Yield 78 mg (70% yield) 
 
Synthesis of N,N'-(1,4-phenylene)bis(4-((1H-benzo[d]imidazol-1-yl)methyl)benzamide) (3.9) 
Compound 3.9 was synthesized by following general amide coupling reaction used in 3.2. 







(400 MHz, DMSO-d6)  10.19 (s, 2 H), 8.46 (s, 2 H), 7.88 (d, J = 8.1 Hz, 
4 H), 7.71-7.64 (m, 6 H), 7.51 (d, J = 8.6 Hz, 2 H), 7.43 (d, J = 8.3 Hz, 4 
H), 7.23-7.17 (m, 4 H), 5.60 (s, 4 H)  
13C NMR 
(100 MHz, DMSO-d6)  164.9, 143.9, 140.4, 134.9, 134.5, 131.8, 128.1 
(2 C), 127.4 (2 C), 123.7 (2 C), 122.5, 121.7, 120.5, 110.7, 59.9 
IR (max/cm
-1) 3286, 3163, 3066, 2947, 1612, 1570, 1492, 1458, 1350 
MS Found 577.00 [M+H]
+, Calculated for C36H28N6O2 577.66 [M+H]+ 
HRMS Observed 577.2371 [M+H]
+; Theoretical 577.2347 [C36H28N6O2+H]+ 
Yield 81 mg (51% yield) 










(400 MHz, DMSO-d6)  10.47 (s, 2 H), 9.69 (s, 2 H), 8.11-8.07 (m, 4 H), 
7.94-7.91 (m, 4 H), 7.90-7.86 (m, 4 H), 7.85-7.82 (m, 4 H), 7.58-7.54 (m, 
4 H), 7.51 (d, J = 8.6 Hz, 4 H), 5.72 (s, 4 H) 
13C NMR 
(100 MHz, DMSO-d6)  164.2, 144.9, 142.2, 139.6, 134.9, 134.3, 133.1, 
132.9, 128.9 (2 C), 128.7 (2 C), 127.1 (2 C), 125.9, 122.6, 122.0, 120.8 
(2 C), 113.4, 51.5 
IR (max/cm
-1) 3105, 3032, 2989, 1597, 1493, 1438, 1415, 1385, 1365 
MS Found 653.10 [M+H]
+, Calculated for C42H32N6O2 653.26 [M+H]+ 
HRMS Observed 653.2670 [M+H]
+; Theoretical 653.2660 [C42H32N6O2+H]+ 
Yield 65 mg (90% yield) 
 
A1.2 Synthesis of bis-quinoline type molecules in library-2A 
Synthesis of N,N'-(propane-1,3-diyl)bis(2-methylquinoline-4-carboxamide) (3.12) 
To a solution of 2-methylquinoline-4-carboxylic acid (82 mg, 0.44 mmol) in dimethylformamide (7 
mL), HOBt (112 mg, 0.83 mmol) and DIC (113 L, 0.73 mmol) were successively added at room 
temperature and the mixture was allowed to stir for 30 minutes. 1,3-Diaminopropane (30 mg, 0.21 
mmol) was added. After 6 h of stirring, reaction was quenched with water (10 mL) and extracted 
with ethyl acetate (3x20 mL). Organics were combined and washed with a saturated aqueous 
solution of sodium bicarbonate (20 mL), dried over magnesium sulphate, filtered and concentrated. 
The desired compound was purified by flash column chromatography using ethyl acetate/methanol 
(0-10%).  







(400 MHz, DMSO-d6)  8.78 (t, J = 5.5 Hz, 2 H), 8.18 (dd, J = 8.1, 0.9 
Hz, 2 H), 7.96 (t, J = 8.1 Hz, 2 H), 7.87 (ddd, J = 8.4, 7.0, 1.3 Hz, 2 H), 
7.76 (ddd, J = 8.4, 7.0, 1.3 Hz, 2 H), 7.69 (s, 2 H), 3.15 (t, J = 6.1 Hz, 4 
H), 2.61 (s, 6 H), 1.78-1.72 (m, 2 H)  
13C NMR 
(100 MHz, DMSO-d6)  167.2, 157.9, 146.6, 142.4, 129.2, 128.8, 126.0, 
125.4, 123.1, 120.1, 39.7, 28.8, 23.2 
IR  (max/cm-1) 3271, 3059, 2936, 1639, 1589, 1435, 1377, 1338 
MS Found 413.00 [M+H]+, Calculated for C25H24N4O2 413.49 [M+H]+ 
HRMS Observed 413.1973 [M+H]+; Theoretical 413.1972 [C25H24N4O2+H]+ 
Yield 51 mg (48% yield) 
 
Synthesis of N,N'-(hexane-1,6-diyl)bis(2-methylquinoline-4-carboxamide) (3.13) 
Method described for the preparation of compound 3.12 was employed, desired product was 






(400 MHz, DMSO-d6)  8.75 (s, 2 H), 8.07-8.03 (m, 2 H), 7.96 (d, J = 8.1 
Hz, 2 H), 7.74 (ddd, J = 8.3, 7.1, 1.3 Hz, 2 H), 7.57 (ddd, J = 8.3, 7.1, 
1.3 Hz, 2 H), 7.42 (s, 2 H), 3.34 (d, J = 4.0 Hz, 4 H), 2.67 (s, 6 H), 1.64-
1.57 (m, 4 H), 1.43 (m, 4 H)  
13C NMR 
(100 MHz, DMSO-d6)  166.7, 158.6, 147.6, 142.6, 129.7, 128.6, 126.3, 
124.5, 122.6, 119.7, 35.2, 29.0, 26.2, 24.2 
IR (max/cm-1) 3256, 3059, 2928, 1658, 1501, 1469, 1408, 1350 
MS Found 455.10 [M+H]+, Calculated for C28H30N4O2 455.57 [M+H]+ 
HRMS Observed 455.2441 [M+H]+; Theoretical 455.2442 [C28H30N4O2+H]+ 
Yield 31 mg (26% yield) 
 
Synthesis of N,N'-(heptane-1,7-diyl)bis(2-methylquinoline-4-carboxamide) (3.14) 
Desired product 3.14 was obtained by using the protocol described in the synthesis of compound 
3.12. Purification was carried out by flash column chromatography with ethyl acetate/methanol (0-
5%).  







(400 MHz, CDCl3)  8.16 (dd, J = 8.4, 0.9 Hz, 2 H), 8.08 (d, J = 8.1 Hz, 
2 H), 7.78 (ddd, J = 8.4, 6.9, 1.5 Hz, 2 H), 7.71 (s, 2H), 7.58 (ddd, J = 
8.4, 6.9, 1.5 Hz, 2 H), 7.01 (t, J = 5.8 Hz, 2 H), 3.65-3.59 (m, 4 H), 2.69 
(m, 6 H), 1.79 (t, J = 6.4 Hz, 4 H), 1.55 (m, 6 H)  
13C NMR 
(100 MHz, CDCl3)  167.4, 158.3, 147.6, 142.6, 123.0, 128.4, 126.6, 
124.9, 122.6, 119.3, 39.8, 29.3, 28.5, 26.6, 24.8 
IR (max/cm-1) 3279, 3071, 2928, 1632, 1589, 1462, 1439, 1408, 1338 
MS Found 468.90 [M+H]
+, Calculated for C29H32N4O2 468.60 [M+H]+ 
HRMS Observed 469.2603 [M+H]
+; Theoretical 469.2598 [C29H32N4O2+H]+ 
 Yield 54 mg (50% yield) 
 
Synthesis of N,N'-(octane-1,8-diyl)bis(2-methylquinoline-4-carboxamide) (3.15) 
Method described for the synthesis of 3.12 was employed. The desired compound 3.15 was 
obtained after purification by flash column chromatography using dichloromethane/isopropyl 






(400 MHz, CDCl3)  8.14-8.10 (m, 2 H), 8.03 (d, J = 8.6 Hz, 2 H), 7.71 
(ddd, J = 8.4, 7.0, 1.5 Hz, 2 H), 7.56-7.50 (m, 2 H), 7.28 (s, 2 H), 6.18 (t, 
J = 5.5 Hz, 2 H), 3.58-3.52 (m, 4 H), 2.72 (s, 6 H), 1.73-1.68 (m, 4 H), 
1.48-1.40 (m, 8 H)  
13C NMR 
(100 MHz, CDCl3)  167.5, 158.5, 148.2, 142.4, 130.0, 129.0, 126.7, 
124.9, 122.7, 119.3, 40.0, 29.5, 28.9, 26.8, 25.3 
IR (max/cm-1) 3302, 2920, 2854, 1635, 1589, 1539, 1334 
MS Found 483.8 [M+H]+, Calculated for C30H34N4O2 483.63 [M+H]+ 
HRMS Observed 483.2741 [M+H]+; Theoretical 483.2755 [C30H34N4O2+H]+ 
Yield 23.8 mg (24% yield) 
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Synthesis of N,N'-(nonane-1,9-diyl)bis(2-methylquinoline-4-carboxamide) (3.16) 
The desired compound 3.16 was prepared following procedure described for the synthesis of 3.12 
and obtained as a tan solid after purification by flash column chromatography using ethyl 







(400 MHz, DMSO-d6)  8.78 (s, 2 H), 7.96 (t, J = 8.1 Hz, 4 H), 7.78 (ddd, 
J = 8.4, 6.9, 1.3 Hz, 2 H), 7.68 (ddd, J = 8.4, 6.9, 1.3 Hz, 2 H), 7.65 (s, 
2 H), 3.14 (t, J = 4.1 Hz, 4 H), 2.58 (s, 6 H), 1.54-1.50 (m, 4 H), 1.27 (m, 
10 H)  
13C NMR 
(100 MHz, DMSO-d6)  165.2, 156.6, 148.2, 143.2, 130.9, 129.7, 126.4, 
124.5, 123.6, 120.0, 37.3, 30.2, 29.4, 26.2, 23.4 
IR (max/cm-1) 3290, 3059, 2924, 1635, 1589, 1466, 1435, 1377 
MS Found 497.10 [M+H]+, Calculated for C31H36N4O2 497.66 [M+H]+ 
HRMS Observed 497.2909 [M+H]+; Theoretical 497.2911 [C31H36N4O2+H]+ 
Yield 80 mg (64% yield) 
 
Synthesis of N,N'-(decane-1,10-diyl)bis(2-methylquinoline-4-carboxamide) (3.17) 






(400 MHz, DMSO-d6 )  8.73 (t, J = 5.5 Hz, 2 H), 8.04 (dd, J = 8.2, 0.9 
Hz, 2 H), 7.96 (d, J = 8.2 Hz, 2 H), 7.74 (ddd, J = 8.3, 6.9, 1.3 Hz, 2 H), 
7.56 (ddd, J = 8.3, 6.9, 1.3 Hz, 2 H), 7.41 (s, 2 H), 3.32 (m, 4 H), 1.61-
1.52 (m, 4 H), 2.67 (s, 6 H), 1.32 (m, 12 H)  
13C NMR 
(100 MHz, DMSO-d6)  166.6, 158.5, 147.6, 142.6, 129.7, 128.6, 126.3, 
125.2, 122.6, 119.6, 40.1, 29.0, 28.9, 28.8, 26.5, 24.8 
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IR (max/cm-1) 3309, 2924, 2854, 1635, 1585, 1473, 1442, 1323 
MS Found 511.00 [M+H]
+, Calculated for C32H38N4O2 511.68 [M+H]+ 
HRMS Observed 511.3068 [M+H]
+; Theoretical 511.3068 [C32H38N4O2+H]+ 
Yield 49 mg (38% yield) 
 
Synthesis of N,N'-(1,4-phenylene)bis(2-methylquinoline-4-carboxamide) (3.18) 







(400 MHz, DMSO-d6)  10.80 (s, 2 H), 8.12-8.09 (m, 2 H), 8.02 (d, J = 
8.1 Hz, 2 H), 7.81 (s, 4 H), 7.80-7.77 (m, 2 H), 7.65 (s, 2 H), 7.62 (ddd, 
J = 8.3, 7.0, 1.1 Hz, 2 H), 2.74 (s, 6 H)  
13C NMR 
(100 MHz, DMSO-d6)  164.9, 158.4, 156.6, 147.5, 138.9, 134.8, 129.6, 
126.4, 122.2, 120.5 (2 C), 120.2, 23.1 
IR (max/cm-1) 3213, 3132, 2970, 2843, 1616, 1500, 1462, 1381 
MS Found 446.9 [M+H]+, Calculated for C28H22N4O2 447.51 [M+H]+ 
HRMS Observed 447.1832 [M+H]+; Theoretical 447.1816 [C28H22N4O2+H]+ 
Yield 69 mg (55% yield) 
A1.3 Synthesis of bis-(6-fluoro-2-methylquinoline) molecules in library-2B 
Synthesis of N,N'-(pentane-1,5-diyl)bis(6-fluoro-2-methylquinoline-4-carboxamide) (3.20) 
To a stirred solution of 6-fluoro-2-methylquinoline-4-carboxylic acid (50 mg, 0.24 mmol) and DIC 
(66 L, 0.43 mmol) in dimethylformamide (5 mL) was added HOBt (66 mg, 0.49 mmol) in one 
portion at room temperature. After 30 min, 1,5-diaminopentane (17 mg, 0.12 mmol) was added and 
the mixture was left to react for 18 h. The reaction was quenched with water (10 mL) and extracted 
with ethyl acetate (3x20 mL). Then the combined organic phase was washed with a saturated 
aqueous solution of sodium bicarbonate (30 mL), dried over magnesium sulphate, filtered and 
concentrated to give the compound 3.20 as pale yellow solid after purification via flash column 
chromatography using methanol/ethyl acetate/dichloromethane 1:2:97 followed by recrystallization 
with diethyl ether and dichloromethane and the desired product 3.20 was obtained as pale yellow 
powder. 








(400 MHz, DMSO-d6)  8.63 (dd, J = 8.6, 5.1 Hz, 2 H), 8.29-8.26 (m, 2 
H), 7.94-7.86 (m, 2 H), 7.69-7.66 (m, 2 H), 7.42-7.34 (m, 2 H), 3.16 (t, J 
= 6.8 Hz, 4 H), 2.46 (s, 6 H), 1.60-1.56 (m, 4 H), 1.32-1.28 (m, 2 H)  
13C NMR 
(100 MHz, DMSO-d6)  166.4, 158.3, 156.9, 145.1, 142.1, 131.6, 126.6, 
123.5, 120.9, 107.2, 40.0, 29.1, 23.5, 23.4 
IR (max/cm-1) 3336, 2931, 2874, 1612, 1558, 1523, 1462, 1385, 1361 
MS Found 477.1 [M+H]
+, Calculated for C27H26F2N4O2 477.2 [M+H]+ 
HRMS Observed 477.2101 [M+H]
+; Theoretical 477.2097 [C27H26F2N4O2+H]+ 
Yield 32 mg (37% yield) 
 
Synthesis of N,N'-(hexane-1,6-diyl)bis(6-fluoro-2-methylquinoline-4-carboxamide) (3.21) 






(400 MHz, DMSO-d6)  8.79-8.77 (m, 2 H), 8.03 (dd, J = 9.1, 5.5 Hz, 2 
H), 7.84-7.76 (m, 2 H), 7.72-7.64 (m, 2 H), 7.51-7.48 (m, 2 H), 3.66-3.60 
(m, 4 H), 2.71 (s, 6 H), 1.60-1.58 (m, 4 H), 1.43-1.39 (m, 4 H) 
13C NMR 
(100 MHz, DMSO-d6)  166.4, 158.3, 156.9, 145.1, 141.7, 131.6, 123.6, 
123.5, 120.9, 108.7, 40.3, 29.1, 26.4, 24.8 
IR (max/cm-1) 3275, 2966, 2943, 2854, 1639, 1593, 1562, 1547, 1288 
MS Found 491.2 [M+H]+, Calculated for C28H28F2N4O2 491.22 [M+H]+ 
HRMS Observed 491.2252 [M+H]+; Theoretical 491.2253 [C28H28F2N4O2+H]+ 
Yield 28 mg (31% yield) 
 
Synthesis of N,N'-(heptane-1,7-diyl)bis(6-fluoro-2-methylquinoline-4-carboxamide) (3.22) 
Protocol used to prepare compound 3.20 was followed.  







(400 MHz, DMSO-d6)  8.93 (dd, J = 9.2, 2.7 Hz, 1 H), 8.89 (dd, J = 9.2, 
2.9 Hz, 1 H), 8.25 (br s, 2 H), 8.08 (dd, J = 5.0 Hz, 2.3 Hz, 2 H), 7.71 (s, 
2 H), 7.42-7.39 (m, 2 H), 3.39-3.36 (m, 4 H), 2.52 (s, 6 H), 1.53-1.49 (m, 
4 H), 1.26-1.23 (m, 6 H)  
13C NMR 
(100 MHz, DMSO-d6)  165.3, 162.9, 158.2, 145.3, 142.1, 132.5, 125.4, 
122.7, 120.1, 109.8, 41.1, 29.7, 29.1, 26.3, 23.2 
IR (max/cm-1) 3282, 2966, 2965, 2858, 1639, 1593, 1549, 1465 
MS Found 505.20 [M+H]+, Calculated for C29H30F2N4O2 505.23 [M+H]+ 
HRMS Observed 505.2410 [M+H]+; Theoretical 505.2410 [C29H30F2N4O2+H]+ 
Yield 23 mg (25% yield) 
 
Synthesis of N,N'-(octane-1,8-diyl)bis(6-fluoro-2-methylquinoline-4-carboxamide) (3.23) 
Compound 3.23 was obtained as white solid by following the general protocol used for 3.20 after 






(400 MHz, DMSO-d6 )  8.78 (d, J = 5.0 Hz, 1 H), 8.03 (dd, J = 9.2, 5.7 
Hz, 1 H), 7.79 (dd, J = 9.2, 5.7 Hz, 1 H), 7.71-7.64 (m, 2 H), 7.52-7.49 
(m, 1 H), 5.48 (d, J = 6.6 Hz, 2 H), 3.67-3.58 (m, 2 H), 3.34-3.31 (m, 6 
H), 2.69-2.66 (m, 2 H), 1.36-1.34 (m, 2 H), 1.02-0.97 (m, 12 H)  
13C NMR 
(100 MHz, DMSO-d6)  166.5, 158.5, 157.2, 145.3, 141.9, 131.8, 123.4, 
121.1, 120.1, 101.5, 39.3, 29.3, 29.1, 26.8, 23.7 
IR (max/cm-1) 3275, 2966, 2851, 1643, 1593, 1547, 1466, 1334 
MS Found 519.10 [M+H]
+, Calculated for C30H32F2N4O2 519.25 [M+H]+ 
HRMS Observed 519.2567 [M+H]
+; Theoretical 519.2566 [C30H32F2N4O2+H]+ 
Yield 58 mg (92% yield) 
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Synthesis of N,N'-(nonane-1,9-diyl)bis(6-fluoro-2-methylquinoline-4-carboxamide) (3.24) 






(400 MHz, DMSO-d6 )  8.77 (t, J = 5.4 Hz, 2 H), 8.04 (dd, J = 9.2, 5.7 
Hz, 2 H), 7.78 (d, J = 2.8 Hz, 1 H), 7.80 (d, J = 2.8 Hz, 1 H), 7.67 (td, J 
= 8.7, 2.9 Hz, 2 H), 7.50 (s, 2 H) 3.32-3.28 (m, 4 H), 2.67 (s, 6 H), 1.60-
1.54 (m, 4 H), 1.34-1.30 (m, 10 H)  
13C NMR 
(100 MHz, DMSO-d6)  166.1, 158.3, 158.1, 144.9, 141.6, 131.5, 123.4, 
123.2, 120.7, 108.7, 38.9, 29.0, 28.9, 28.7, 26.4, 24.6 
IR (max/cm-1) 3298, 2935, 2854, 1639, 1593, 1539, 1466, 1334 
MS Found 533.21 [M+H]
+, Calculated for C31H34F2N4O2 533.26 [M+H]+ 
HRMS Observed 533.2716 [M+H]
+; Theoretical 533.2723 [C31H34F2N4O2+H]+ 
Yield 52 mg (81% yield) 
 
Synthesis of N,N'-(decane-1,10-diyl)bis(6-fluoro-2-methylquinoline-4-carboxamide) (3.25) 






(400 MHz, CDCl3)  8.03 (dd, J = 9.3, 5.3 Hz, 2 H), 7.79 (dd, J = 9.8, 2.8 
Hz, 3 H), 7.67 (d, J = 8.3 Hz, 1 H), 7.47 (ddd, J = 9.3, 7.9, 2.9 Hz, 2 H), 
6.33 (t, J = 5.7 Hz, 2 H), 7.31 (s, 2 H), 3.56-3.51 (m, 3 H), 2.70 (s, 6 H), 
1.70-1.65 (m, 4 H), 1.46-1.39 (m, 5 H), 1.36-1.32 (m, 4 H), 1.26 (s, 2 H)  
13C NMR 
(100 MHz, CDCl3)  175.1, 168.3, 154.1, 144.8, 143.5, 130.0, 128.9, 
120.8, 120.1, 104.4, 40.1, 32.0, 29.4, 28.9, 26.7, 24.8 
IR (max/cm-1) 3271, 2920, 2850, 1643, 1547, 1226, 1161 
MS Found 547.30 [M+H]
+, Calculated for C32H36F2N4O2 547.28 [M+H]+ 
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HRMS Observed 547.2885 [M+H]
+; Theoretical 547.2879 [C32H36F2N4O2+H]+ 
Yield 60 mg (90% yield) 
 
A1.4 Synthesis of bis-indole compounds in library-2C 
Synthesis of N,N'-(propane-1,3-diyl)bis(1H-indole-5-carboxamide) (3.27) 
To a suspension of 1H-indole-5-carboxylic acid (25 mg, 0.16 mmol) in dimethylformamide (5 mL), 
HOBt (42 mg, 0.31 mmol) and DIC (42 l, 0.27 mmol) were added in one portion at room 
temperature. After 30 minutes 1,3-diaminopropane (6 mg, 6 L, 0.08 mmol) was added and the 
reaction mixture was left under stirring for 24 h, quenched with water (5 mL). Phases were 
separated, the organic layer was washed with a saturated aqueous solution of sodium bicarbonate, 
dried over magnesium sulphate, filtered and concentrated. Purification was carried out by flash 








(400 MHz, MeOD)  8.33 (dd, J = 1.6, 0.6 Hz, 2 H), 7.80 (dd, J = 8.6, 
1.8 Hz, 2 H), 7.43-7.39 (m, 2 H), 7.32 (d, J = 3.3 Hz, 2 H), 6.57 (dd, J = 
3.2, 0.9 Hz, 2 H), 3.68-3.64 (m, 4 H), 1.10-1.02 (m, 2 H)  
13C NMR 
(100 MHz, MeOD)  166.2, 140.7, 129.4, 127.6, 125.0, 124.2, 122.7, 
112.2, 104.2, 48.7, 33.2 
IR (max/cm-1) 3352, 2655, 1605, 1578, 1489, 1462, 1435, 1385 
MS Found 361.27 [M+H]+, Calculated for C21H20N4O2 360.42 [M+H]+ 
HRMS Observed 362.1684 [M+H]+, Theoretical 362.1689 [C21H20N4O2+H]+ 
Yield 26 mg (93% yield) 
 
Synthesis of N,N'-(hexane-1,6-diyl)bis(1H-indole-5-carboxamide) (3.28) 
Method described for preparation of 3.27 was employed. Desired compound 3.28 was obtained as 
a tan solid after purification by flash column chromatography using ethyl acetate/methanol (0-2%). 
 
 






(400 MHz, MeOD)  8.31 (dd, J = 1.7, 0.6 Hz, 2 H), 7.81 (dd, J = 8.4, 
1.7 Hz, 2 H), 7.44-7.40 (m, 2 H), 7.15 (d, J = 1.5 Hz, 2H), 6.59 (dd, J = 
3.2, 0.9 Hz, 2 H), 3.48 (t, J = 6.5 Hz, 4 H), 1.66-1.62 (m, 4 H), 1.29-1.27 
(m, 2 H)  
13C NMR 
(100 MHz, MeOD)  168.2, 139.8, 129.5, 126.6, 121.9, 119.2, 112.4, 
110.6, 103.1, 41.2, 29.2, 24.8 
IR (max/cm-1) 3450, 3201, 2952, 2864, 1635, 1601, 1578, 1443, 1431 
MS Found 403.10 [M+H]+, Calculated for C24H26N4O2 403.50 [M+H]+ 
HRMS Observed 403.2119 [M+H]+; Theoretical 403.2129 [C24H26N4O2+H]+ 
Yield 26 mg (92% yield) 
 
Synthesis of N,N'-(heptane-1,7-diyl)bis(1H-indole-5-carboxamide) (3.29) 
Method described for preparation of 3.27 was employed. Desired compound 3.29 obtained as a 







(400 MHz, MeOD)  8.66 (dd, J = 1.6, 0.6 Hz, 2 H), 7.83 (dd, J = 8.5, 
1.7 Hz, 2 H), 7.37 (d, J = 3.3 Hz, 2 H), 7.17 (d, J = 1.4 Hz, 2 H), 6.61 
(dd, J = 3.1, 0.9 Hz, 2 H), 3.41 (t, J = 6.1 Hz, 4 H), 1.62-1.54 (m, 6 H), 
1.26-1.21 (m, 4 H)  
13C NMR 
(100 MHz, MeOD)  166.7, 141.5, 130.3, 127.4, 119.6, 118.7, 111.8, 
109.7, 103.8, 40.4, 30.7, 29.2, 26.4 
IR (max/cm-1) 3202, 2922, 2868, 1601, 1531, 1300 
MS Found 417.10 [M+H]+, Calculated for C25H28N4O2 417.52 [M+H]+ 
HRMS Observed 417.2276 [M+H]+; Theoretical 417.2285 [C25H28N4O2+H]+ 
Yield 21 mg (73% yield) 
 
Synthesis of N,N'-(octane-1,8-diyl)bis(1H-indole-5-carboxamide) (3.30) 
Method described for preparation of 3.27 was employed. Desired compound 3.30 obtained as 
amber oil after purification by flash column chromatography using ethyl acetate/methanol (0-2.5%). 







(400 MHz, MeOD)  8.96 (dd, J = 1.8, 0.8 Hz, 2 H), 8.01 (dd, J = 8.5, 
1.7 Hz, 2 H), 7.82 (d, J = 3.3 Hz, 2 H), 7.14 (d, J = 1.5 Hz, 2 H), 6.58 (d, 
J = 3.1 Hz, 2 H), 3.36 (t, J = 6.2 Hz, 4 H), 1.56 (t, J = 7.6 Hz, 4 H), 1.28-
1.26 (m, 8 H)  
13C NMR 
(100 MHz, MeOD)  164.1, 140.3, 129.4, 126.5, 120.2, 118.7, 112.3, 
110.0, 103.4, 39.9, 30.2, 29.8, 26.7 
IR (max/cm-1) 3250, 2976, 2849, 1605, 1574, 1469, 1392, 1373 
MS Found 431.20 [M+H]
+, Calculated for C26H30N4O2 431.55 [M+H]+ 
HRMS Observed 431.2430 [M+H]
+; Theoretical 431.2442 [C26H30N4O2+H]+ 
Yield 25 mg (94% yield) 
 
Synthesis of N,N'-(nonane-1,9-diyl)bis(1H-indole-5-carboxamide) (3.31) 
Method described for preparation of 3.27 was employed. Desired compound 3.31 obtained as an 






(400 MHz, MeOD)  8.78 (dd, J = 1.8, 0.8 Hz, 2 H), 8.34 (dd, J = 8.5, 
1.7 Hz, 2 H), 7.95 (d, J = 3.3 Hz, 2 H), 7.86 (d, J = 1.5 Hz, 2 H), 6.58 (d, 
J = 3.1 Hz, 2 H) 3.32 (t, J = 6.2 Hz, 4 H) 1.59-1.55 (m, 4 H) 1.29-1.25 
(m, 10 H)  
13C NMR 
(100 MHz, MeOD)  159.9, 139.3, 131.2, 127.0, 121.3, 119.6, 112.6, 
110.2, 102.0, 41.0, 30.5, 29.4 (2 C), 25.9 
IR (max/cm-1) 3252, 2928, 2854, 1624, 1574, 1466, 1388 
MS Found 445.20 [M+H]
+, Calculated for C27H32N4O2 445.58 [M+H]+ 
HRMS Observed 445.2587 [M+H]
+ ; Theoretical 445.2598 [C27H32N4O2+H]+ 
Yield 24 mg (89% yield) 
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A1.5 Synthesis of bis-acridine molecules in library-3A 
Synthesis of N,N'-(hexane-1,6-diyl)bis(7-fluoro-1,2,3,4-tetrahydroacridine-9-carboxamide) 
(3.33) 
To a stirred solution of 7-fluoro-1,2,3,4-tetrahydroacridine-9-carboxylic acid (75 mg, 0.31 mmol) 
and DIC (89 L, 0.57 mmol) in dimethylformamide (8 mL), HOBt (83 mg, 0.61 mmol) was added in 
one portion at room temperature and stirred for 30 minutes. Then 1,8-diaminohexane (22 mg, 0.15 
mmol) was added and allowed to react for 14 h. The reaction was quenched with water and 
extracted with ethyl acetate (3x30 mL), organics were combined and washed with a saturated 
aqueous solution of sodium bicarbonate (30 mL), dried over magnesium sulphate, filtered and 







(400 MHz, DMSO-d6)  8.72 (t, J = 5.5 Hz, 2 H), 7.98 (dd, J = 9.3, 5.5 
Hz, 2 H), 7.60 (td, J = 8.8, 2.8 Hz, 2 H), 7.28 (dd, J = 9.9, 2.9 Hz, 2 H), 
3.40-3.35 (m, 4 H), 3.05-3.00 (m, 4 H), 2.85 (t, J = 6.2 Hz, 4 H), 1.89 (d, 
J = 5.5 Hz, 4 H), 1.85-1.80 (m, 4 H), 1.59 (d, J = 6.0 Hz, 4 H), 1.44 (br 
s, 4 H)  
13C NMR 
(100 MHz, DMSO-d6)  165.8, 158.4 (2 C), 142.9, 141.8, 131.2, 126.9, 
121.1, 117.1, 107.5, 40.6, 33.2, 28.9, 28.2, 22.3, 22.0 (2 C)  
IR (max/cm-1) 3232, 3055, 2947, 2866, 1632, 1555, 1496, 1450 
MS Found 571.2 [M+H]+, Calculated for C34H36F2N4O2 [M+H]+ 571.28 
HRMS Observed 571.2877 [M+H]
+; Theoretical 571.2879 [C34H36F2N4O2+H]+ 
Yield 47 mg (55% yield) 
 
Synthesis of N,N'-(heptane-1,7-diyl)bis(7-fluoro-1,2,3,4-tetrahydroacridine-9-carboxamide) 
(3.34) 
Protocol described in the synthesis of 3.33 was used. Purification was carried out by flash column 
chromatography with ethyl acetate/methanol (0-4%). 
 









(400 MHz, DMSO-d6)  8.73-8.69 (m, 2 H), 7.98 (dd, J = 9.2, 5.7 Hz, 2 
H), 7.60 (td, J = 8.7, 2.5 Hz, 2 H), 7.28 (dd, J = 9.8, 2.5 Hz, 2 H), 3.05-
3.00 (m, 4 H), 2.86-2.82 (m, 4 H), 1.87-1.84 (m, 4 H), 1.85-1.78 (m, 6 
H), 1.61-1.56 (m, 4 H), 1.40-1.38 (m, 8 H)  
13C NMR 
(100 MHz, DMSO-d6)  165.8, 164.4 (2 C), 142.9, 141.8, 131.3, 126.9, 
123.7, 119.0, 107.7, 40.1, 33.2, 28.9, 28.4, 26.5, 26.4, 22.2 (2 C) 
IR (max/cm-1) 3225, 3074, 2928, 2858, 1631, 1558, 1493, 1454, 1431 
MS Found 585.30 [M+H]
+, Calculated for C35H38F2N4O2 585.30 [M+H]+ 
HRMS Observed 585.3028 [M+H]
+; Theoretical 585.3036 [C35H38F2N4O2+H]+  
Yield 34 mg (39% yield) 
 
Synthesis of N,N'-(octane-1,8-diyl)bis(7-fluoro-1,2,3,4-tetrahydroacridine-9-carboxamide) 
(3.35) 
Protocol used in the synthesis of compound 3.33 was employed and desired product was obtained 






(400 MHz, DMSO-d6)  8.70 (t, J = 5.5 Hz, 2 H), 7.98 (dd, J = 9.3, 5.5 
Hz, 2 H), 7.60 (td, J = 8.8, 2.8 Hz, 2 H), 7.27 (dd, J = 9.8, 2.8 Hz, 2 H), 
3.66-3.59 (m, 2 H), 3.40-3.36 (m, 2 H), 3.05-3.00 (m, 4 H), 2.84 (t, J = 
6.4 Hz, 4 H), 1.89 (d, J = 5.0 Hz, 4 H), 1.84-1.79 (m, 4 H), 1.57 (d, J = 
6.8 Hz, 4 H), 1.42-1.37 (m, 8 H)  
13C NMR 
(100 MHz, DMSO-d6)  168.2, 164.4 (2 C), 142.9, 141.3, 131.9, 126.6, 
123.3, 120.0, 105.1, 39.6, 33.8, 31.4, 27.5, 27.1, 26.4, 21.9 (2 C) 
IR IR (max/cm-1) 3336, 3271, 2858, 1628, 1554, 1493, 1454, 1442 
MS Found 599.30 [M+H]
+, Calculated for C36H40F2N4O2 599.31 [M+H]+ 
  238|Appendix 1 
 
HRMS Observed 599.3190 [M+H]
+; Theoretical 599.3192 [C36H40F2N4O2+H]+ 
Yield 52 mg (57% yield) 
 
Synthesis of N,N'-(nonane-1,9-diyl)bis(7-fluoro-1,2,3,4-tetrahydroacridine-9-carboxamide) 
(3.36) 
Compound 3.36 was prepared by following protocol describer in the synthesis of 3.33 and purified 






(400 MHz, CDCl3)  7.89 (dd, J = 9.2, 5.4 Hz, 2 H), 7.35 (td, J = 8.6, 2.6 
Hz, 2 H), 7.27-7.22 (m, 2 H), 6.40 (t, J = 5.7 Hz, 2 H), 3.52 (q, J = 6.6 
Hz, 4 H), 3.02-2.98 (m, 4 H), 2.83 (t, J = 5.2 Hz, 4 H), 1.91-1.85 (m, 4 
H), 1.83-1.77 (m, 4 H), 1.69-1.63 (m, 4 H), 1.45-1.36 (m, 10 H)  
13C NMR 
(100 MHz, CDCl3)  167.6, 165.0 (2 C), 144.1, 139.2, 133.6, 127.3, 
122.9, 121.1, 103.4, 40.6, 32.8, 29.8, 27.1, 26.4, 26.2, 22.2 (2 C) 
IR (max/cm-1) 3336, 2935, 2874, 1612, 1562, 1523, 1462, 1384, 1327 
MS Found 613.30 [M+H]
+, Calculated for C37H42F2N4O2 613.33 [M+H]+ 
HRMS Observed 613.3354 [M+H]
+; Theoretical 613.3349 [C37H42F2N4O2+H]+ 
Yield 70 mg (74% yield) 
 
A1.6 Synthesis of bis- (2-fluoro-7,8,9,10-tetrahydro-6H-cyclohepta[b] quinoline-11-
carboxamide in library-3B 
Synthesis of N,N'-(pentane-1,5-diyl)bis(2-fluoro-7,8,9,10-tetrahydro-6H-cyclohepta[b] 
quinoline-11-carboxamide) (3.38) 
A stirred suspension of 2-fluoro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinoline-11-carboxylic acid 
(124 mg, 0.48 mmol) in dichloromethane (8 mL) was treated with HOBt (129 mg, 0.96 mmol) and 
DIC (130 l, 0.84 mmol) at room temperature. After 30 min, 1,5-diaminopentane (25 mg, 0.20 mmol) 
was added, and left to react for 6 h. Reaction progress was monitored by TLC and additional 49 
mg (0.19 mmol) of acid, 51 µL (0.33 mmol) of DIC and 51 mg (0.38 mmol) of HOBt were added and 
the resulting mixture was stirred for 16 h, then quenched with water (10 mL) and extracted with 
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ethyl acetate (2x30 mL). Organics were combined, washed with a saturated aqueous solution of 
sodium bicarbonate (20 mL), dried over magnesium sulphate, filtered and concentrated. As the 
concentrated product has got some impurities, finally purification was carried out by ‘Catch and 






(400 MHz, CDCl3)  8.01-7.96 (m, 2 H), 7.93 (dd, J = 9.3, 5.3 Hz, 2 H), 
7.36 (dd, J = 9.3, 2.6 Hz, 2 H), 6.05-5.99 (m, 2 H), 3.60 (d, J = 7.3 Hz, 4 
H), 3.24-3.17 (m, 4 H), 2.96-2.88 (m, 4 H), 2.77-2.73 (m, 2 H), 1.92-1.86 
(m, 4 H), 1.80 (d, J = 6.3 Hz, 4 H), 1.25 (d, J = 6.8 Hz, 4 H), 1.18 (d, J = 
6.5 Hz, 2 H), 1.15 (d, J = 6.3 Hz, 2 H).  
13C NMR 
(100 MHz, CDCl3)  168.7, 165.7, 156.7, 142.9, 137.8, 131.9, 128.2, 
126.8, 123.9, 101.2, 46.9, 37.2, 32.5, 30.4 (2 C), 26.6 (2 C), 24.0  
IR (max/cm
-1) 3258, 2925, 2854, 1711, 1626, 1548, 1499, 1385 
MS Found 583.00 [M-H]
+, Calculated for C35H38F2N4O2 584.70 [M+H]+ 
HRMS Observed 584.3114 [M+H]
+, Theoretical 584.3102 [C35H38F2N4O2+H]+ 




Compound 3.39 was prepared with the method described for the synthesis of compound 3.38 using 






(400 MHz, CDCl3) 8.68 (dd, J = 8.3, 0.8 Hz, 2 H), 8.07-8.03 (m, 2 H), 
7.97-7.93 (m, 2 H), 7.70 (td, J = 7.8, 0.8 Hz, 2 H), 3.78 (spt, J = 6.5 Hz, 
4 H), 3.30-3.25 (m, 4 H), 2.84 (dd, J = 6.3, 4.5 Hz, 4 H), 1.89-1.86 (m, 4 
H), 1.85-1.81 (m, 4 H), 1.81-1.75 (m, 4 H), 1.71-1.65 (m, 4 H), 1.52 (br 
s, 4 H)  
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13C NMR 
(100 MHz, CDCl3)  164.6, 162.4, 159.9, 142.9, 136.1, 131.9, 128.2, 
126.8, 123.9, 107.6, 42.6, 32.7, 29.9 (2 C), 27.7, 26.8 (2 C), 23.6 
IR (max/cm
-1) 3337, 2966, 2925, 2850, 1727, 1615, 1566, 1458, 1380 
MS Found 598.82 [M+H]
+, Calculated for C36H40F2N4O2 598.73 [M+H]+ 
HRMS Observed 599.3185 [M+H]
+, Theoretical 599.3192 [C36H40F2N4O2+H]+ 
Yield 24 mg (73% yield) 
 
Synthesis of N,N'-(heptane-1,7-diyl)bis(2-fluoro-7,8,9,10-tetrahydro-6H-cyclohepta[b] 
quinoline-11-carboxamide) (3.40) 
Protocol described in the synthesis of 3.38 was used. Purification was carried out by flash column 







(400 MHz, CDCl3)  7.97 (dd, J = 9.1, 5.6 Hz, 2 H), 7.40-7.36 (m, 2 H), 
7.34-7.32 (m, 2 H), 5.91 (t, J = 6.4 Hz, 2 H), 3.88-3.83 (m, 4 H), 3.63-
3.57 (m, 4 H), 2.97-2.85 (m, 4 H), 1.91-1.85 (m, 4 H), 1.78-1.70 (m, 8 H), 
1.51-1.49 (m, 4 H), 1.16-1.12 (m, 6 H)  
13C NMR 
(100 MHz, CDCl3)  167.7, 164.9, 163.2, 148.7, 147.9, 132.1, 127.3, 
122.6, 119.4, 101.4, 42.6, 36.6, 35.3, 29.2, 27.9, 26.4, 25.2, 24.3, 23.8 
IR (max/cm
-1) 3253, 2927, 2847, 1634, 1550, 1497, 1455, 1385 
MS Found 611.01 [M-H]
+, Calculated for C37H42F2N4O2 612.33 [M+H]+ 
HRMS Observed 613.3268 [M+H]
+, Theoretical 613.3286 [C37H42F2N4O2+H]+ 




Method described for the synthesis of 3.38 was employed. The crude was purified by flash column 
chromatography using n-hexane/ethyl acetate 0-40%) to afford the desired compound as white 
solid.  








(400 MHz, CDCl3)  7.99 (dd, J = 9.1, 5.3 Hz, 2 H), 7.38-7.34 (m, 2 H), 
7.34-7.31 (m, 2 H), 6.14 (t, J = 5.6 Hz, 2 H), 3.57 (q, J = 6.7 Hz, 4 H), 
3.20-3.15 (m, 4 H), 2.92-2.87 (m, 4 H), 1.87 (dt, J = 11.1, 5.8 Hz, 4 H), 
1.75-1.70 (m, 8 H), 1.44 (s, 4 H), 1.13 (d, J = 6.3 Hz, 8 H)  
13C NMR 
(100 MHz, CDCl3)  167.4, 164.2, 158.9, 149.4, 148.0, 130.2, 127.3, 
122.6, 120.1, 107.4, 42.3, 39.8, 37.7, 31.8, 29.5, 28.9, 28.2, 27.4, 26.7 
IR (max/cm
-1) 2927, 2853, 2364, 1624, 1559, 1499, 1458 
MS Found 627.05 [M+H]
+, Calculated for C38H44F2N4O2 627.78 [M+H]+ 
HRMS Observed 627.3490 [M+H]+, Theoretical 627.3505 [C38H44F2N4O2+H]+ 










(400 MHz, CDCl3)  8.03-7.99 (m, 2 H), 7.65 (d, J = 8.3 Hz, 1 H), 7.42-
7.38 (m, 1 H), 7.36-7.31 (m, 2 H), 6.52 (t, J = 5.8 Hz, 2 H), 3.79 (q, J = 
6.4 Hz, 4 H), 3.57 (q, J = 6.4 Hz, 4 H), 3.19-3.14 (m, 2 H), 2.96 (s, 2 H), 
2.88 (s, 2 H), 1.71-1.66 (m, 4 H), 1.13 (m, 20 H)  
13C NMR 
(100 MHz, CDCl3)  169.2, 164.3, 161.9, 157.2, 147.7, 141.9, 136.4, 
126.5, 125.3, 110.4, 41.2, 31.7, 29.3 (2 C), 28.8, 26.7, 26.1 (2 C), 24.1, 
23.4 
IR (max/cm
-1) 3338, 2928, 2966, 2358, 1614, 1497, 1461, 1384 
MS Found 641.17 [M+H]
+, Calculated for C39H46F2N4O2 641.80 [M+H]+ 
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HRMS Observed 641.3639 [M+H]
+, Theoretical 641.3662 [C39H46F2N4O2+H]+ 




Protocol described in the synthesis of 3.38 was used and desired compound was obtained after 







(400 MHz, CDCl3)  7.99 (dd, J = 9.3, 5.5 Hz, 2 H), 7.41 (dd, J = 8.6, 3.3 
Hz, 2 H), 7.34 (dd, J = 9.3, 2.6 Hz, 2 H), 5.91 (t, J = 5.5 Hz, 2 H) 3.57 (q, 
J = 6.7 Hz, 4 H), 3.20 (d, J = 11.4 Hz, 4 H), 2.94-2.89 (m, 4 H), 1.92-1.87 
(m, 4 H), 1.71-1.66 (m, 4 H), 1.41-1.37 (m, 16 H), 1.16 (m, 4 H)  
13C NMR 
(100 MHz, CDCl3)  168.7, 156.8, 155.1, 147.5, 143.5, 133.3, 127.5, 
122.5, 121.8, 115.3, 39.4, 37.1, 34.5, 30.3 (2 C), 29.7, 28.1, 26.8 (2 C), 
24.6 
IR (max/cm
-1) 3254, 2926, 2852, 1636, 1539, 1498, 1458, 1385 
MS Found 655.02 [M+H]
+, Calculated for C40H48F2N4O2 655.83 [M+H]+ 
HRMS Observed 655.3795 [M+H]
+, Theoretical 655.3818 [C40H48F2N4O2+H]+ 
Yield 31 mg (27% yield) 
 
A1.7 Synthesis of bis-benzofuran type molecules in library-4 
[2,2'-Bipyridine]-5,5'-dicarboxylic acid (3.44), [1,1'-biphenyl]-4,4'-dicarboxylic acid (3.45), [2,2'-
bipyridine]-4,4'-dicarboxylic acid (3.46) and 5-nitrobenzofuran-2-carboxylic acid (3.47) were used 
to synthesize this library molecule. Additionally six tertiary amine tails, 3-(dimethylamino)-1-
propylamine (3.48), 1-(3-aminopropyl)pyrrolidine (3.49), N-(3-aminopropyl)piperidine (3.50), N,N-
dimethyl-1,4-butanediamine (3.51), 1-(4-aminobutyl)pyrrolidine (3.52) and 4-piperidin-1-yl-
butylamine (3.53) were used as terminal tail. Final products were prepared in three steps: starting 
with the synthesis of monoamide intermediate, followed by reduction of the nitro group to generate 
the corresponding amine which was used to generate the final bis-amide product. 
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Synthesis of N-(3-(dimethylamino)propyl)-5-nitrobenzofuran-2-carboxamide (3.54) 
To a suspension of 5-nitrobenzofuran-2-carboxylic acid (200 mg, 0.96 mmol) in dichloromethane 
(10 mL), HOBt (186 mg, 1.40 mmol) and DIC (189 l, 1.20 mmol) were added. After 30 minutes, 3-
(dimethylamino)-1-propylamine (86 L, 0.70 mmol) was added and the reaction mixture was left 
under stirring for 5 h at room temperature. The reaction mixture was passed through a SCX-2 






(400 MHz, CDCl3)  8.78 (s, 1 H), 8.32 (d, J = 7.5 Hz, 1 H), 7.86 (d, J = 
7.5 Hz, 1 H), 7.78 (s, 1 H), 7.58 (s, 1 H), 3.32 (t, J = 6.2 Hz, 2 H),  2.52 
(t, J = 6.2 Hz, 2 H), 2.32 (s, 6 H), 2.15-2.13 (m, 2 H)  
13C NMR 
(100 MHz, CDCl3)  163.2, 159.3, 148.2, 144.6, 131.2, 121.3, 114.6, 
110.2, 106.0, 59.1, 47.0 (2 C), 29.4, 25.9 
MS Found 291.24 [M+H]+, Calculated for C14H17N3O4 291.31 [M+H]+ 
Yield 196 mg (98% yield) 
 
Synthesis of 5-nitro-N-(3-(pyrrolidin-1-yl)propyl)benzofuran-2-carboxamide (3.55) 







(400 MHz, CDCl3)  8.48 (s, 1 H), 8.24 (d, J = 7.4 Hz, 1 H), 7.86 (d, J = 
7.5 Hz, 1 H), 7.78 (s, 1 H), 7.58 (s, 1 H), 3.12 (t, J = 6.1 Hz, 2 H),  2.54-
2.52 (m, 4 H), 2.34 (t, J = 6.1 Hz, 2 H), 2.04-2.02 (m, 2 H), 1.76-1.72 (m, 
4 H)  
13C NMR 
(100 MHz, CDCl3)  166.2, 157.3, 150.2, 142.6, 129.2, 121.3, 118.6, 
109.2, 105.8, 56.4 (2 C), 42.3, 28.4, 23.1 (2 C) 
MS Found 317.19 [M+H]+, Calculated for C16H19N3O4 317.35 [M+H]+ 
Yield 215 mg (99% yield) 
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Synthesis of 5-nitro-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide (3.56) 







(400 MHz, CDCl3)  8.46 (s, 1 H), 8.22 (d, J = 7.5 Hz, 1 H), 7.86 (d, J = 
7.5 Hz, 1 H), 7.78 (s, 1 H), 7.58 (s, 1 H), 3.12 (t, J = 6.1 Hz, 2 H), 2.54-
2.52 (m, 4 H), 2.34 (t, J = 6.1 Hz, 2 H), 2.36-2.32 (m, 2 H), 1.46-1.44 (m, 
6 H) 
13C NMR 
(100 MHz, CDCl3)  165.2, 159.3, 150.2, 147.6, 130.5, 119.3, 116.1, 
110.2, 108.0, 57.1 (2 C), 45.3 (2 C), 28.4, 25.6 (2 C), 24.2 
MS Found 331.19 [M+H]+,  Calculated for C17H21N3O4 331.15 [M+H]+ 
Yield 226 mg (99% yield) 
 
Synthesis of N-(4-(dimethylamino)butyl)-5-nitrobenzofuran-2-carboxamide (3.57) 







(400 MHz, CDCl3)  8.77 (s, 1 H), 8.32 (d, J = 7.4 Hz, 1 H), 7.87 (d, J = 
7.4 Hz, 1 H), 7.78 (s, 1 H), 7.58 (s, 1 H), 3.32 (t, J = 6.2 Hz, 2 H),  2.52 
(t, J = 6.2 Hz, 2 H), 2.32 (s, 6 H), 1.78-1.74 (m, 2 H), 1.54-1.52 (m, 2 H) 
13C NMR 
(100 MHz, CDCl3)  164.1, 159.7, 149.5, 144.2, 129.6, 122.1, 117.0, 
109.8, 106.6, 61.2, 47.0, 32.1, 29.4, 25.9 (2 C) 
MS Found 305.29 [M+H]+, Calculated for C15H19N3O4 305.33 [M+H]+ 
Yield 204 mg (97% yield) 
 
Synthesis of 5-nitro-N-(4-(pyrrolidin-1-yl)butyl)benzofuran-2-carboxamide (3.58) 
Compound 3.58 was prepared using protocol described for the synthesis of 3.54. 








(400 MHz, CDCl3)  8.48 (s, 1 H), 8.24 (d, J = 7.4 Hz, 1 H), 7.86 (d, J = 
7.5 Hz, 1 H), 7.78 (s, 1 H), 7.58 (s, 1 H), 3.08 (t, J = 6.1 Hz, 2 H), 3.02 
(t, J = 5.9 Hz, 2 H), 2.54-2.52 (m, 4 H), 1.64-1.62 (m, 2 H), 1.76-1.68 (m, 
6 H)  
13C NMR 
(100 MHz, CDCl3)  163.0, 158.1, 149.2, 145.6, 131.2, 122.1, 113.9, 
109.6, 108.2, 56.8 (2 C), 55.2, 42.3, 27.3, 24.2, 23.5 (2 C) 
MS Found 331.07 [M+H]+, Calculated for C17H21N3O4 331.15 [M+H]+ 
Yield 224 mg (98% yield) 
 
Synthesis of 5-nitro-N-(4-(pyrrolidin-1-yl)butyl)benzofuran-2-carboxamide (3.59) 







(400 MHz, CDCl3)  8.46 (s, 1 H), 8.22 (d, J = 7.5 Hz, 1 H), 7.86 (d, J = 
7.5 Hz, 1 H), 7.78 (s, 1 H), 7.58 (s, 1 H), 3.06 (t, J = 6.1 Hz, 2 H), 2.94 
(t, J = 6.1 Hz, 2 H), 2.44-2.41 (m, 4 H), 2.36-2.32 (m, 2 H), 1.52-1.37 (m, 
8 H) 
13C NMR 
(100 MHz, CDCl3)  167.1, 159.6, 151.1, 146.5, 132.0, 119.3, 113.2, 
110.9, 106.6, 56.8 (2 C), 55.0, 45.3, 29.4, 27.2, 25.2 (2 C), 23.9 
MS Found 345.31 [M+H]+, Calculated for C18H23N3O4 345.40 [M+H]+ 
Yield 236 mg (99% yield) 
 
Synthesis of 5-amino-N-(3-(dimethylamino)propyl)benzofuran-2-carboxamide (3.60) 
For this second step, the monoamide intermediates 3.54 were hydrogenated in a parr hydrogenator 
reactor at 35 – 40 mbar until the H2 uptake was finished (5 h). Up on completion, the reaction 
mixture was filtered through a layer of diatomaceous earth (Celite) and volatiles were removed 
under vacuum to give 3.60 as brown oil. 







(400 MHz, CDCl3)  7.88 (s, 1 H), 7.86 (s, 1 H), 7.58 (s, 1 H), 7.48 (d, J 
= 7.5 Hz, 1 H), 6.58 (d, J = 7.5 Hz, 1 H), 4.59 (s, 2 H), 3.32 (t, J = 6.2 
Hz, 2 H), 2.52 (t, J = 6.2 Hz, 2 H), 2.12-2.08 (m, 2 H), 2.12 (s, 6 H) 
13C NMR 
(100 MHz, CDCl3)  151.2, 149.3, 148.2, 144.6, 131.2, 115.3, 110.6, 
110.2, 106.0, 59.1, 47.0 (2 C), 29.4, 25.9 
MS Found 261.12 [M+H]+, Calculated for C14H19N3O2 261.33 [M+H]+ 
Yield 174 mg (99% yield) 
 
Synthesis of 5-amino-N-(3-(pyrrolidin-1-yl)propyl)benzofuran-2-carboxamide (3.61) 





(400 MHz, CDCl3)  7.81 (s, 1 H), 7.78 (s, 1 H), 7.58 (s, 1 H), 7.48 (d, J 
= 7.5 Hz, 1 H), 6.58 (d, J = 7.5 Hz, 1 H), 4.62 (s, 2 H), 3.12 (t, J = 6.1 
Hz, 2 H), 2.54-2.52 (m, 4 H), 2.34 (t, J = 6.1 Hz, 2 H), 2.04-2.02 (m, 2 
H), 1.76-1.72 (m, 4 H) 
13C NMR 
(100 MHz, CDCl3)  158.6, 149.8, 146.2, 131.2, 116.1, 108.2, 58.1, 43.2, 
30.5, 25.2, 24.9 
MS Found 287.03 [M+H]+,  Calculated for C16H21N3O2 287.36 [M+H]+ 
Yield 190 mg (97% yield) 
 
Synthesis of 5-amino-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide (3.62) 
Hydrogenation protocol employed for the compound 3.60 was used. 
 





(400 MHz, CDCl3)  7.83 (s, 1 H), 7.80 (s, 1 H), 7.62 (s, 1 H), 7.51 (d, J 
= 7.4 Hz, 1 H), 6.57 (d, J = 7.4 Hz, 1 H), 4.61 (s, 2 H), 3.12 (t, J = 6.2 
Hz, 2 H), 2.56-2.53 (m 4 H), 2.45 (t, J = 6.2 Hz, 2 H), 2.36-2.32 (m, 2 H), 
1.48-1.46 (m, 6 H) 
13C NMR 
(100 MHz, CDCl3)  159.3, 150.2, 147.6, 143.4, 130.5, 119.3, 111.4, 
108.7, 108.0, 57.1 (2 C), 45.3 (2 C), 28.4, 25.6 (2 C), 24.2 
MS Found 301.22 [M+H]+,  Calculated for C17H23N3O2 301.39 [M+H]+ 
Yield 200 mg (97% yield) 
 
Synthesis of 5-amino-N-(4-(dimethylamino)butyl)benzofuran-2-carboxamide (3.63) 








(400 MHz, CDCl3)  7.83 (s, 1 H), 7.76 (s, 1 H), 7.62 (s, 1 H), 7.49 (d, J 
= 7.4 Hz, 1 H), 6.56 (d, J = 7.4 Hz, 1 H), 4.63 (s, 2 H), 3.29 (t, J = 6.2 
Hz, 2 H), 2.53 (t, J = 6.2 Hz, 2 H), 2.34 (s, 6 H), 1.78-1.76 (m, 2 H), 1.56-
1.50 (m, 2 H) 
13C NMR 
(100 MHz, CDCl3)  158.7, 151.2, 147.5, 144.2, 129.6, 122.1, 113.0, 
110.8, 108.6, 61.2, 47.0, 32.1, 29.4, 26.0 (2 C) 
MS Found 275.39 [M+H]+, Calculated for C15H21N3O2 275.45 [M+H]+ 
Yield 180 mg (98% yield) 
 
Synthesis of 5-amino-N-(4-(pyrrolidin-1-yl)butyl)benzofuran-2-carboxamide (3.64) 
Hydrogenation protocol employed for the compound 3.60 was used. 
 
 






(400 MHz, CDCl3)  7.82 (s, 1 H), 7.76 (s, 1 H), 7.64 (s, 1 H), 7.50 (d, J 
= 7.4 Hz, 1 H), 6.66 (d, J = 7.4 Hz, 1 H), 4.62 (s, 2 H), 3.12 (t, J = 6.1 
Hz, 2 H), 3.02 (t, J = 5.9 Hz, 2 H), 2.54-2.49 (m, 4 H), 1.64-1.60 (m, 2 
H), 1.76-1.72 (m, 6 H)  
13C NMR 
(100 MHz, CDCl3) 157.9, 152.0, 149.2, 145.6, 131.2, 122.1, 112.3, 
108.6, 108.2, 56.8 (2 C), 55.2, 42.3, 27.3, 24.2, 23.5 (2 C) 
MS Found 301.46 [M+H]+, Calculated for C17H23N3O2 301.39 [M+H]+ 
Yield 200 mg (98% yield) 
 
Synthesis of 5-amino-N-(4-(dimethylamino)butyl)benzofuran-2-carboxamide (3.65) 






(400 MHz, CDCl3)  7.84 (s, 1 H), 7.80 (s, 1 H), 7.63 (s, 1 H), 7.51 (d, J 
= 7.3 Hz, 1 H), 6.59 (d, J = 7.3 Hz, 1 H), 4.60 (s, 2 H), 3.06 (t, J = 6.0 
Hz, 2 H), 2.96 (t, J = 6.0 Hz, 2 H), 2.46-2.42 (m, 4 H), 2.36-2.32 (m, 2 
H), 1.50-1.39 (m, 8 H) 
13C NMR 
(100 MHz, CDCl3)  158.6, 151.4, 146.5, 142.0, 132.1, 119.3, 113.2, 
108.9, 108.6, 56.8 (2 C), 55.0, 45.3, 29.4, 27.2, 25.2 (2 C), 23.9 
MS Found 315.51 [M+H]+, Calculated for C18H25N3O2 315.42 [M+H]+ 




To a stirred solution of [2,2'-bipyridine]-5,5'-dicarboxylic acid (30 mg, 0.12 mmol) in 
dimethylformamide (7 mL) was added, HOBt (67 mg, 0.49 mmol) and DIC (67 L, 0.43 mmol) in 
one portion. After 30 minutes, 3.60 (65 mg, 0.25 mmol) was added and the resulting mixture was 
left to stir at room temperature for 13 h. The reaction was quenched with water (12 mL). Hexane 
(20 mL) was added to the reaction mixture and the resulting precipitate was recovered by filtration 
and washed with hexane (60 mL). The residue obtained was then dissolved in a mixture of 
acetonitrile/water (50/50) (40 mL), filtered to remove the impurities and concentrated to give the 
entitled product as a white solid.  







(400 MHz, DMSO-d6)  10.31 (s, 2 H), 8.92 (t, J = 5.6 Hz, 2 H), 8.62-
8.56 (m, 2 H), 8.24 (d, J = 8.1 Hz, 4 H), 8.09 (d, J = 8.21 Hz, 4 H), 7.83 
(s, 2 H), 7.66 (d, J = 7.5 Hz, 2 H), 3.28 (d, J = 5.3 Hz, 4 H), 2.48-2.46 
(m, 4 H), 2.28 (s, 12 H), 1.69-1.66 (m, 4 H)  
13C NMR 
(100 MHz, DMSO-d6)  165.6, 159.9, 152.2, 150.2, 144.6 (2 C), 132.8, 
131.1, 130.1, 128.0, 117.9 (2 C), 114.2, 112.0, 109.4, 59.2, 48.2, 40.7 
(2 C), 27.3 
IR (max/cm-1) 3332, 3040, 2878, 1643, 1589, 1543, 1469, 1435, 1354 
MS Found 731.10 [M+H]+,  Calculated for C40H42N8O6 730.83 [M+H]+ 
HRMS Observed 731.3287 [M+H]
+, Theoretical 731.3300 [C40H42N8O6+H]+ 




Compound 3.67 was prepared using protocol described for the synthesis of 3.66. 
 






(400 MHz, DMSO-d6)  10.15 (s, 2 H), 8.62 (t, J = 5.6 Hz, 2 H), 8.58-
8.52 (m, 2 H), 8.32 (d, J = 8.1 Hz, 4 H) 8.19 (d, J = 8.2 Hz, 4 H), 7.78-
7.74 (m, 2H), 7.68 (s, 2 H), 7.54 (d, J = 7.5 Hz, 2 H), 3.23 (d, J = 5.3 Hz, 
4 H), 2.36-2.32 (m, 4 H), 2.21 (s, 12 H), 1.67-1.63 (m, 4 H)  
13C NMR 
(100 MHz, DMSO-d6)  164.9, 158.9, 152.3, 150.0, 143.7, 132.2, 131.0, 
130.1 (2 C), 128.5 (2 C), 117.9 (2 C), 115.2, 112.3, 109.6, 59.5, 47.7 (2 
C), 40.4, 26.3 
IR (max/cm-1) 3247, 3073, 2858, 1654, 1546, 1469, 1363 
MS Found 729.50 [M-H]+, Calculated for C42H44N6O6 729.85 [M+H]+ 
HRMS Observed 729.3382 [M+H]
+, Theoretical 729.3395 [C42H44N6O6+H]+ 











(400 MHz, DMSO-d6)  10.20 (s, 2 H), 8.87 (d, J = 5.6 Hz, 2 H), 8.62-
8.56 (m, 2 H), 8.64 (d, J = 8.1 Hz, 4 H), 7.80 (d, J = 8.2 Hz, 2 H), 7.79 
(s, 2 H), 7.74 (d, J = 7.5 Hz, 2H), 7.59 (d, J = 7.5 Hz, 2 H), 3.28 (d, J = 
5.3 Hz, 4 H), 2.46 (m, 4 H), 2.28 (s, 12 H), 1.69-1.66 (m, 4 H)  
13C NMR 
(100 MHz, DMSO-d6)  166.6, 155.8, 150.0, 149.8, 145.8, 132.7, 131.1, 
122.1 (2 C), 118.2, 117.0 (2 C), 111.2, 112.0, 109.4, 58.1, 47.2 (2 C), 
40.3, 26.2 
IR (max/cm-1) 3255, 3063, 2878, 1655, 1547, 1469, 1362 
MS Found 729.5 [M-H]+, Calculated for C40H42N8O6 730.83 [M+H]+ 
HRMS Observed 731.3296 [M+H]
+, Theoretical 731.3300 [C40H42N8O6+H]+ 
Yield  39 mg (44% yield) 











(400 MHz, DMSO-d6) 10.21 (s, 2 H), 8.78 (t, J = 5.6 Hz, 2 H), 8.32-
8.26 (m, 2 H), 8.14 (d, J = 8.2 Hz, 4 H), 8.11 (d, J = 8.2 Hz, 4 H), 7.69 
(s, 2 H), 7.57 (d, J = 7.6 Hz, 2 H), 3.09 (d, J = 5.3 Hz, 4 H), 2.66-2.61 
(m, 4 H), 2.48-2.44 (m, 8 H), 1.78-1.74 (m, 4 H), 1.71-1.69 (m, 8 H)  
13C NMR 
(100 MHz, DMSO-d6)  168.6, 159.9, 155.3, 154.2, 139.6 (2 C), 135.4, 
132.8, 132.0, 128.0, 125.1, 116.9 (2 C), 113.2, 109.5, 58.0 (2 C), 39.8 
(2 C), 27.2, 23.4 (2 C) 
IR (max/cm-1) 3317, 3086, 2974, 2881, 1643, 1589, 1535, 1469, 1350 
MS Found 783.20 [M+H]+, Calculated for C44H46N8O6 783.90 [M+H]+ 
HRMS Observed 783.3600 [M+H]+, Theoretical 783.3613 [C44H46N8O6+H]+ 




Compound 3.70 was prepared using protocol described for the synthesis of 3.66. 
 







(400 MHz, DMSO-d6) 10.34 (s, 2 H), 8.76 (t, J = 5.5 Hz, 2 H), 8.32-
8.27 (m, 2 H), 8.22 (d, J = 8.2 Hz, 4 H), 8.01 (d, J = 8.2 Hz, 2 H), 7.79 
(s, 2 H), 7.66 (d, J = 5.4 Hz, 4 H), 7.57 (d, J = 7.5 Hz, 2 H), 3.19 (d, J = 
5.2 Hz, 4 H), 2.86-2.82 (m, 4 H), 2.59-2.55 (m, 8 H), 1.86-1.82 (m, 4 H), 
1.73-1.69 (m, 8 H)  
13C NMR 
(100 MHz, DMSO-d6)  165.3, 158.2, 152.8, 150.0, 144.5, 134.2, 132.5, 
131.2 (2 C), 128.0 (2 C), 118.4 (2 C), 115.5, 111.5, 109.4, 58.3 (2 C), 
40.0 (2 C), 27.6, 23.6 (2 C) 
IR (max/cm-1) 3290, 3036, 2970, 2881, 1647, 1535, 1469, 1365 
MS Found 781.20 [M+H]+, Calculated for C46H48N6O6 781.93 [M+H]+ 
HRMS Observed 781.3698 [M+H]+, Theoretical 781.3708 [C46H48N6O6+H]+ 




Compound 3.71 was prepared using protocol described for the synthesis of 3.66. 
 






(400 MHz, DMSO-d6) 10.49 (s, 2 H), 8.80 (t, J = 5.5 Hz, 2 H), 8.34-
8.28 (m, 2 H), 8.13 (d, J = 8.3 Hz, 4 H), 8.01 (d, J = 8.3 Hz, 4 H), 7.69 
(s, 2 H), 7.57 (d, J = 7.5 Hz, 2 H), 3.49-3.45 (m, 10 H), 2.51-2.46 (m, 4 
H), 1.90-1.82 (m, 4 H), 1.69-1.62 (m, 4 H), 1.52 (d, J = 4.8 Hz, 10 H)  
13C NMR 
(100 MHz, DMSO-d6)  166.5, 158.8, 154.2, 150.6 (2 C), 139.5, 132.8, 
131.2, 128.0, 126.9, 117.1 (2 C), 115.3, 112.1, 108.5, 57.6 (2 C), 39.8 
(2 C), 26.6, 24.5, 23.3 (2 C) 
IR (max/cm-1) 3231, 3038, 2943, 2861, 1644, 1539, 1472, 1303 
MS Found 811.40 [M+H]+, Calculated for C46H50N8O6 811.96 [M+H]+ 
HRMS Observed 811.3925 [M+H]
+, Theoretical 811.3926 [C46H50N8O6+H]+ 










(400 MHz, DMSO-d6)  10.53 (s, 2 H), 8.84 (t, J = 5.4 Hz, 2 H), 8.38-
8.32 (m, 2 H), 8.23 (d, J = 8.3 Hz, 4 H), 8.06 (d, J = 8.3 Hz, 4 H), 7.78 
(s, 2 H), 7.58 (dd, J = 7.5 Hz, 4 H), 3.53-3.49 (m, 10 H), 2.52-2.47 (m, 4 
H), 1.93-1.85 (m, 4 H), 1.68-1.61 (m, 4 H), 1.54-1.50 (m, 10 H)  
13C NMR 
(100 MHz, DMSO-d6)  169.5, 157.8, 154.2, 150.6, 139.6, 132.8, 130.2, 
128.0 (2 C), 126.9 (2 C), 117.4 (2 C), 112.6, 108.6, 58.2 (2 C), 39.4 (2 
C), 39.5, 27.7, 25.4 (2 C), 24.6 
IR (max/cm-1) 3234, 3041, 2948, 2864, 1649, 1549, 1470, 1301 
MS Found 809.51 [M+H]+, Calculated for C48H52N6O6 809.98 [M+H]+ 
HRMS Observed 809.4027 [M+H]
+, Theoretical 809.4021 [C48H52N6O6+H]+ 
Yield 39 mg (42% yield) 










(400 MHz, DMSO-d6)  10.32 (s, 2 H), 8.80 (t, J = 5.5 Hz, 2 H), 8.34-
8.28 (m, 2 H), 8.13 (d, J = 8.3 Hz, 4 H), 8.01 (d, J = 8.3 Hz, 4 H), 7.69 
(s, 2 H), 7.57 (d, J = 7.5 Hz, 2 H), 3.09 (d, J = 5.3 Hz, 4 H), 2.96-2.94 
(m, 8 H), 2.88-2.84 (m, 4 H), 1.78-1.72 (m, 8 H), 1.69-1.66 (m, 8 H)  
13C NMR 
(100 MHz, DMSO-d6)  168.2, 159.6, 155.3, 154.1 (2 C), 139.5, 133.9, 
132.5, 131.7, 128.0, 124.9, 118.5 (2 C), 112.1, 109.7, 58.6 (2 C), 56.3, 
39.8, 28.6, 27.2, 23.3 (2 C) 
IR (max/cm-1) 3317, 3086, 2947, 2874, 1643, 1589, 1535, 1469, 1350 
MS Found 811.22 [M+H]+, Calculated for C46H50N8O6 811.96 [M+H]+ 
HRMS Observed 811.3909 [M+H]+, Theoretical 811.3926 [C46H50N8O6+H]+ 




Compound 3.74 was prepared using protocol described for the synthesis of 3.66. 
 







(400 MHz, DMSO-d6)  10.25 (s, 2 H), 8.80 (t, J = 5.5 Hz, 2 H), 8.36-
8.30 (m, 2 H), 8.13 (d, J = 8.3 Hz, 4 H), 7.96 (d, J = 8.3 Hz, 4 H), 7.65 
(d, J = 9.1 Hz, 2 H), 7.56 (s, 2 H), 7.47 (d, J = 7.5 Hz, 2 H), 3.29 (d, J = 
5.2 Hz, 4 H), 2.92-2.88 (m, 8 H), 2.84-2.80 (m, 4 H), 1.80-1.76 (m, 8 H), 
1.59-1.55 (m, 8 H)  
13C NMR 
(100 MHz, DMSO-d6)  173.0, 155.8, 149.5, 145.5, 145.2, 134.7, 128.0 
(2 C), 124.9 (2 C), 118.0 (2 C), 116.1, 110.1, 109.2, 108.7, 59.3 (2 C), 
55.0, 48.2, 38.7, 28.2, 22.4 (2 C) 
IR (max/cm-1) 3255, 3039, 2947, 2874, 1647, 1539, 1469, 1308 
MS Found 809.31 [M+H]+, Calculated for C48H52N6O6 809.98 [M+H]+ 
HRMS Observed 809.3999 [M+H]+, Theoretical 809.4021 [C48H52N6O6+H]+ 











(400 MHz, DMSO-d6) 10.19 (s, 2 H), 8.32-8.28 (m, 2 H), 8.01 (d, J = 
8.1 Hz, 2 H), 7.98 (d, J = 7.7 Hz, 2 H), 7.88-7.82 (m, 2 H), 7.82 (s, 2 H), 
7.57 (d, J = 7.5 Hz, 2 H), 3.01-2.98 (m, 8 H), 2.77-2.75 (m, 4 H), 2.09 (s, 
12 H), 1.78-1.74 (m, 4 H), 1.59-1.55 (m, 4 H)  
13C NMR 
(100 MHz, DMSO-d6)  164.2, 160.1, 158.8, 155.4, 153.1, 150.6, 138.7, 
133.4, 131.7, 127.2, 122.9, 119.1 (2 C), 113.0, 109.5, 62.2, 47.4 (2 C), 
39.9, 27.5, 25.4 
IR (max/cm-1) 3321, 3086, 2939, 1643, 1589, 1531, 1469, 1307 
MS Found 759.32 [M+H]+, Calculated for C42H46N8O6 759.88 [M+H]+ 
HRMS Observed 759.3600 [M+H]+, Theoretical 759.3613 [C42H46N8O6+H]+ 
Yield 42 mg (54% yield) 
 










(400 MHz, DMSO-d6)  10.23 (s, 2 H), 8.78-8.72 (m, 2 H), 8.01 (d, J = 
8.3 Hz, 4 H), 7.98 (d, J = 7.7 Hz, 2 H), 7.92 (d, J = 7.2 Hz, 2 H), 7.90 (d, 
J = 7.1 Hz, 4 H), 7.82 (d, J = 7.4 Hz, 2 H), 7.59 (s, 2 H), 3.01-2.99 (m, 4 
H), 2.62-2.58 (m, 4 H), 2.19 (s, 12 H), 1.80-1.76 (m, 4 H), 1.56-1.51 (m, 
4 H)  
13C NMR 
(100 MHz, DMSO-d6)  163.2, 158.8, 152.1, 150.0, 144.5, 133.6, 131.4, 
130.7 (2 C), 128.2 (2 C), 117.9 (2 C), 115.2, 112.0, 109.5, 62.6, 48.3, 
39.1, 28.1, 24.3 (2 C) 
IR  (max/cm-1) 3325, 2939, 2758, 1647, 1589, 1535, 1469, 1312 
MS Found 757.41 [M+H]+, Calculated for C44H48N6O6 756.90 [M+H]+ 
HRMS Observed 757.3690 [M+H]
+, Theoretical 757.3708 [C44H48N6O6+H]+ 




Compound 3.77 was prepared using protocol described for the synthesis of 3.66. 
 








(400 MHz, DMSO-d6)  10.26 (s, 2 H), 8.86 (d, J = 8.3 Hz, 4 H), 8.16 
(dd, J = 8.1 Hz, 4 H), 7.78 (s, 2 H), 7.68 (dd, J = 7.5 Hz, 4 H), 7.62 (s, 2 
H), 3.12 (t, J = 6.8 Hz, 4 H), 3.09 (t, J = 6.4 Hz, 4 H), 2.56-2.50 (m, 4 H), 
2.48-2.40 (m, 8 H), 1.88 (d, J = 5.6 Hz, 4 H), 1.82 (d, J = 4.6 Hz, 4 H), 
1.59-1.53 (m, 2 H) 1.52-1.48 (m, 8 H)  
13C NMR 
(100 MHz, DMSO-d6)  165.2, 159.1, 155.2, 150.0 (2 C), 138.4, 132.2, 
130.6 (2 C), 123.4, 117.3 (2 C), 113.8, 112.4, 109.3, 58.9, 58.6, 39.6, 
28.4 (2 C), 26.1, 25.6 (2 C), 24.2 
IR (max/cm-1) 3327, 2901, 1640, 1591, 1539, 1489, 1309 
MS Found 839.20 [M+H]+, Calculated for C48H54N8O6 839.01 [M+H]+ 
HRMS Observed 839.4230 [M+H]+, Theoretical 839.4239 [C48H54N8O6+H]+ 




Compound 3.78 was prepared using protocol described for the synthesis of 3.66. 
 
 







(400 MHz, DMSO-d6)  10.42 (s, 2 H), 8.38-8.32 (m, 2 H), 8.23 (d, J = 
8.1 Hz, 4 H), 8.06 (dd, J = 8.3 Hz, 4 H), 7.78 (s, 2 H), 7.68 (dd, J = 7.5 
Hz, 4 H), 3.12 (t, J = 6.8 Hz, 4 H), 3.03 (t, J = 6.4 Hz, 4 H), 2.52-2.47 (m, 
4 H), 2.44-2.40 (m, 8 H), 1.82 (d, J = 5.5 Hz, 4 H), 1.78 (d, J = 4.6 Hz, 4 
H), 1.64-1.58 (m, 2 H), 1.54-1.50 (m, 8 H)  
13C NMR 
(100 MHz, DMSO-d6)  165.6, 158.1, 152.2, 150.2, 144.6, 134.2, 131.8, 
130.6 (2 C), 128.3 (2 C), 118.5 (2 C), 114.6, 112.8, 109.3, 59.0 (2 C), 
58.3, 39.5, 28.7, 26.3, 25.4 (2 C), 24.1 
IR (max/cm-1) 3329, 2932, 1647, 1593, 1535, 1469, 1303 
MS Found 837.32 [M+H]+, Calculated for C50H56N6O6 837.03 [M+H]+ 
HRMS Observed 837.4313 [M+H]
+, Theoretical 837.4334 [C50H56N6O6+H]+ 
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Appendix 2: Experimental data and Graphs 
A2.1: FRET Melting Result 
FRET melting curves are given below for the synthesized compounds. To be noted that all 
curves has got two different line diagrams in a single graph, i.e., sigmoidal and parabolic 
shape. Sigmoidal shaped curve represents the FRET melting and parabolic shaped curve 
represents the change of fluorescence intensity over the change of temperature (-dI/dT). 





  260|Appendix 2 
 
            












  262|Appendix 2 
 






















A2.2: UV calibration curves obtained on Circular Dichroism (CD) Studies 
All CD spectrum of tested compounds were carried out for DNA/RNA hybrid duplex and 
telomeric quadruplex sequences. 50 mM Tris-HCl buffer (pH 7.4) was used to carry out the 
analysis with DRH oligonucleotide and 100 mM NaCl was used along with the Tris-HCl buffer 
for F21T sequence. Ligands were used at 0-5 equivalents over the oligonucleotides. In the 
case of CD analysis with DRH sequence 10 mm path length was applied, whereas 5 mm path 
length was applied for telomeric quadruplex sequence. 
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A2.3: IC50 curves observed in Cytotoxicity Studies (MTT Assay) 
A2.3.1: MDA-MB-231 Cell Line (Breast Cancer Cell Line) 
 
 











A2.3.2: HeLa Cell Line (Cervical Cancer Cell Line) 
 
 












A2.3.2: NCI H1975 Cell Line (Non-Small Lung Cancer Cell Line) 
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